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Summary
G protein coupled receptors (GPCRs), as the name suggests, require a coupling 
transducer called a G protein to enable conversion of extracellular stimuli into 
intracellular second messengers. Over 200 GPCRs with the same topological seven 
transmembrane structure have been identified along with their coupling G proteins. 
To understand more about GPCR signalling and particular components required to 
achieve efficient signalling, extensive studies have involved the p2 ~AR signalling 
pathway. Receptor activation and subsequent receptor desensitisation and 
internalisation of the p2 “AR and GPCRs in general have proved a major area of 
interest.
Various types of ligand can bind to a GPCR such as agonist, inverse agonist and 
antagonist. Pharmacologists have struggled to clearly categorise these types of 
ligands. It was the aim of my first chapter to develop the basis for a GPCR ligand 
screen using the pz-AR as a model system. Previously it has been demonstrated that 
a (constitutively active mutant) CAM-P2 -AR becomes up-regulated when treated 
with the inverse agonist, betaxolol for 24 h (MacEwan and Milligan, 1996a,b). In 
this study, a CAM-Pz-AR, C-terminally tagged with GFP was also found to be up- 
regulated by betaxolol. In fact a differential pattern of up-regulation was found to 
occur with a range of p-blockers. The pattern of up-regulation was found to 
correlate with the ability of the ligands to induce production of cAMP, thus acting as 
partial agonists at the CAM-p2 -AR-GFP construct. This developed the basis for a 
rapid screening assay for ligand regulation of this receptor.
Chapter 2 investigated the sequestration of the WT-pi-AR, WT-P2 -AR and their 
GFP-tagged forms. It was shown that the Pi-AR constructs internalised more 
rapidly than the P2 -AR, but 10-20 % less maximal p i-AR receptor was internalised 
compared to the pz-AR. Tagging these receptors with GFP did not alter their
XIX
pharmacology but receptor sequestration was markedly impeded, indicating 
limitations to the use of GFP as a tagging molecule. Down-regulation of the WT-p2 - 
AR-GFP was also smaller than that of the WT-p2 “AR after 24 h treatment of agonist 
stimulation.
Receptor desensitisation and sequestration of the p2~AR requires phosphorylation of 
the receptor by (protein kinase A) PKA and (GPCR kinases) GRKs. As the roles of 
these kinases and their sites of phosphorylation have been debated, a mutant form of 
the p2 "AR lacking all the potential C-terminal GRK phosphorylation sites (BARK”- 
p2 -AR-GFP) was used to investigate this issue. The construct was found to 
internalise in response to isoprenlaine stimulation, this being at a faster rate than 
internalisation of WT-p2 “AR-GFP. Secondly, the PKA inhibitor Rp cAMP had no 
effect on internalisation of this mutant construct, WT-P2 -AR or WT-P2 -AR-GFP. 
These results suggest that PKA is not involved in sequestration of the P2  AR and 
that other phosphorylation sites in the receptor may be responsible for this effect.
XX
Chapter 1
Introduction
1.1 Cellular Signalling
Repeatedly, different cells in the tissues of the body are exposed to a variety of 
stimuli, including neurotransmitters, peptide molecules and ions, which ultimately 
produce many effects. To monitor these events and respond accordingly it is essential 
for the cell to have a direct mechanism for measuring its environment. The expression 
of cell surface receptors within the plasma membrane of the cell is one way of 
achieving the recognition of external stimuli and decoding them into a form 
recognisable to components inside of the cell. This is not merely a "one step" reaction 
but involves a series of separate steps linked together involving receptor, regulatory 
proteins and effectors to generate recognisable intracellular second messengers. The 
second messengers have the ability to bind and regulate certain enzymes within the cell 
leading ultimately to effects on cell growth, differentiation and division.
One of the most studied sub-types of receptor are the p-adrenergic receptors (p-ARs) 
which respond to circulating adrenaline and noradrenaline. As early as 1957 Rail and 
Sutherland observed that hormone bound p-AR allosterically regulated the effector 
molecule, adenylyl cyclase. This observation prompted intense study into the 
molecular mechanisms of this pathway which identified regulatory protein 
components that linked active p-AR to adenylyl cyclase. These components were 
found to have a requirement for GTP, and hence, were named GTP binding proteins 
or G proteins (Rodbell et al., 1971 a and b ; Gilman, 1987). These are heterotrimeric 
proteins with three subunits, a,  p and y. The p and y subunits are tightly associated 
but the a  subunit continually associates and dissociates from the protein complex 
depending on the requirements of the cell. In order to produce an intracellular second 
messenger signal, ligand bound p-AR associates with the a  subunit of a G protein 
which in turn activate adenylyl cyclase to produce the second messenger cAMP. This 
second messenger is an allosteric effector which activates protein kinase A (PKA) to
produce a variety of cellular effects. The py complex may also be involved in certain 
signalling mechanisms but these are rather dated (Stemweis, 1994).
There are a range of cell surface receptors including growth factor receptors, with 
intrinsic tyrosine kinase activity, but by far the largest class are the seven trans­
membrane spanning receptors that function via the heterotrimeric G proteins. The p- 
AR is a sub-family of this family of G protein coupled receptors (GPCRs). This sub­
family consists of four sub-types, pi, P2 , P3 and P4  -ARs. The aim of this chapter is 
to present as clear a picture as possible of what is known about the p-AR family, their 
coupling G proteins and the effector components of their signalling pathways. How 
these pathways are regulated shall be discussed, including the role of these receptors 
and their signalling in disease. An interesting feature of some GPCRs is their ability 
to induce formation of second messenger signals in the absence of agonist stimulation. 
These receptors are termed constitutively active mutant (CAM) GPCRs and their 
significance in the study of receptor activation and development of drug therapies will 
be discussed. The use of certain techniques used to probe these signalling pathways 
to develop insight into potential new therapies will also be presented.
1.2 The P“Adrenergic Receptor Sub-family
a) Introduction
The p-ARs effect their responses via the sympathetic nervous system and control a 
wide range of physiological responses. These include control of vascular tone, 
cardiac function, metabolism and behaviour. Stimulation of sympathetic nerve 
terminals induces a release of endogenous p-agonists, adrenaline and noradrenaline 
which activate p-ARs on postsynaptic sites.
Presently, there are four identified members of the p-AR family, these being sub- 
types Pi, p2 , p3  and p4 . Before these sub-types were identified it was firstly noted 
that some tissues would respond differentially to the known p-agonists (isoprenaline, 
adrenaline and noradrenaline). Therefore, p-ARs were divided into two classes pi 
and p2  -ARs, displaying a different order of potency to p-agonists, p i (isoprenaline > 
noradrenaline > adrenaline) versus p2  (isoprenaline > adrenaline > noradrenaline). A 
third "atypical’ p-AR was subsequently identified now termed the P3 -AR (Emorine et 
al., 1989). This receptor exhibited a distinct pharmacological profile compared to the 
P 1 and p2  -ARs, showing a lower affinity for classical p-agonists with the rank order 
of potency being, noradrenaline > isoprenaline > adrenaline. The Pi and p% -AR 
antagonist CGP12177A acts as an agonist at the P3 -AR and is more potent at the 
human compared to the rat receptor (Liggett, 1992). No P3  selective antagonist has 
been identified which can cause problems when trying to investigate this receptor, 
especially in tissues in which it is co-expressed with other p-ARs. There are some 
non-selective antagonists available, e.g. (-)-bupranolol, ICI 118551 and CGP20712A. 
Recently, a fourth ‘atypical’ P4 -AR was discovered in rat atria by Kaumann and 
Lynham (1997). Kaumann had previously proposed the existence of this receptor in 
mammalian heart (Kaumann, 1989). It has been elegantly demonstrated that 
CGP12177A (a P3 -AR agonist and a Pi and P2  -AR antagonist) causes 
cardiostimulation and binds to cardiac putative P4 -ARS in both WT and P3 -AR 
knockout mice (Kaumann et al., 1998).
b) p-adrenergic receptor cloning
Three distinct mammalian p-AR cDNAs, Pi (Frielle et al., 1987), P2  (Dixon et al., 
1986) and p3  (Emorine et al., 1989) have been isolated. Both the pi and p% -AR 
genes are intronless and therefore, neither sub-type can generate diversity by 
differential mRNA splicing. In humans the P3 -AR gene consists of two exons and a
single intron (Granneman et al., 1992) and therefore, the gene can undergo differential 
splicing of pre-mRNA to generate multiple forms of the pg-AR. In fact there are two 
distinct splice variants of the ps-AR in humans varying only by the presence or 
absence of 6  C-terminal amino acids.
c)P-adrenergic receptor structure
All p-ARs are 7 transmembrane (TM) spanning receptors which couple through G 
proteins to elicit a response within the cell (Figure 1.1a). These 7 TM regions are 
linked by 3 extracellular and 3 intiacellular loops. The protein is lodged in the plasma 
membrane of the cell so that the N-teiminal region of the protein is extracellular and 
the C-terminal region projects into the cell.
High conservation between family members within the 7 TM a  helical regions 
indicated that this area of the GPCR is important for ligand recognition. Each TM 
region has a specific orientation within the plasma membrane to form the ligand 
binding pocket (Figure 1.1b). Site directed mutagenesis studies have been used to 
identify specific residues involved in ligand recognition by GPCRs. Not surprisingly 
the most extensive research has concentrated on the p%-AR. Strader et al., (1988, 
1989) identified AspH3 in TM 3 as vital for both antagonist and agonist binding. The 
latter is also dictated by Ser^^ and Ser205 of TM5. Also important for sterio- 
selectivity of catecholamines is Asn^^ in TM6  of the p%-AR (Wieland et al., 1996; 
Zurmond et al., 1999). From studies on the Pi-AR, TM4 is largely responsible for 
the 1 0  fold increase in affinity of noradrenaline at this receptor compared to the P2 -AR 
(Frielle et al., 1988; Dixon et al., 1989). Isogay a et al (1998, 1999) generated Pi/p2 - 
chimeric receptors to demonstrate that TM2 and TM7 of the p2 ~AR are important in 
the binding of P2 -AR selective agonists, Tyr^^ of TM7 being particularly important. 
As this is a Phe in the Pi-AR only Leiri^^, Thr^^^ and Vari^^ in TM2 of this receptor
were found to dictate binding of ligands. Various ps-AR mutants with residues 
altered in their TM domains have been studied (Gros et al., 1998). These included 
delVLA (deletion of Val, Leu and Ala in TMl), G53F (TMl), D117L (TM3) and 
N312A (TM6 ) P3 -AR mutants. Both TMl mutations did not alter the binding of 
ligands or signalling of the receptor. The TM3 mutant exhibited suppressed ligand 
binding and adenylyl cyclase activation and the TM6  mutation led to alterations in the 
signal transduction pathway of the receptor.
Recently GPCRs have been described as two or even more independent folding units 
(Herbert et al., 1996; Tarasova et al., 1999). To demonstrate this split muscarinic 
receptors have been utilised, where the receptor is broken at the 3rd intracellular loop 
to generate an m3-trunk and an m3-tail (Jakubik and Wess, 1999). When they were 
co-expressed in COS-7 cells both m3 fragments specifically interacted and the 
presence of muscarinic ligands enhanced the association. This was a receptor specific 
interaction since fragments from other co-expressed receptor constructs did not 
associate with the m3 fragments. Three conserved proline residues located in TM5, 6  
and 7 were identified as being essential for proper fragment association again 
indicating the importance of the TM domains in receptor structure conformations. A 
study on the lutenising hormone (LH) receptor demonstrated that co-expression of 
receptor units in HEK293 cells partially reconstituted ligand-induced signal generation 
(Osuga et al., 1997). An important role of TMl was discovered in signalling of the 
LH receptor. The use of antagonist peptides to receptor TM regions has also proved 
useful to demonstrate the importance of TM association in the functioning of GPCRs. 
A peptide derived from TM6  of the P2 -AR, when co-expressed with P2 -ARS inhibited 
receptor activation and dimérisation (Herbert et al., 1996). This method has also been 
utilised by Tarasova et al., (1999) to identify regions important for functioning of the 
CCXR4 and CCR5 chemokine receptors.
Figure 1.1
a) Topological representation of a typical G protein coupled receptor
G protein coupled receptors (GPCRs) have 7 a  helices forming the 7 transmembrane 
(TM) regions (blue), linked by 3 intracellular (IC) and 3 extracellular (EC) loops 
(orange). The N-terminal region (green) contains the sites for glycosylation and the 
C-terminal tail (grey) contains the site for palmitoylation.
b) Position of the 7 TM a  helices in the cell plasma membrane and the specific 
residues important for ligand binding and signalling.
The view is from the intracellular side of the membrane. The residues found to be 
important for ligand binding and functioning of the receptor are indicated by colour, 
Pa-AR (green), pg-AR (black), pi- and P2- AR (blue). TM5 is important in selective 
noradrenaline binding at the pi-AR (pink).
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It is not only the TM domains that are important for regulation of receptor functions. 
The intracellular loops and the C-terminal tail are also important regions. These are 
the regions of the GPCR that are facing into the cell and are a prime target for 
intracellular signalling molecules. In the case of GPCRs these are firstly the G 
proteins. Two main areas of the p%-AR have been identified as being important in 
coupling to G proteins (Gg or possibly Gi). These are the 3rd intracellular loop and 
the C-terminal tail also found to be targets for phosphorylation by cAMP dependent 
protein kinase (PKA) and G protein coupled receptor kinases (GRKs) (Benovic et al., 
1985; Fredericks et al., 1996). These kinases assist in switching off of the signalling 
cascade by uncoupling the receptor from G protein. Intracellular loop 2 has also been 
identified as a regulatory region in this process (Jockers et al., 1996). Once 
desensitised the receptor can undergo down-regulation or resensitisation. For 
resensitisation to occur the receptor is internalised and dephosphorylated. Intracellular 
loops 1 and 2 and the C-terminal tail of the p2"AR were found to regulate this process 
(Jockers et al., 1996). Also present in the C-terminal tail of the p2 -AR is a site for 
dynamic palmitoylation which regulates the ability of the receptor to be desensitised. 
A palmitoylation minus (C341G) mutant of the P2 -AR displayes increased basal 
phosphorylation and a decreased rate of agonist-promoted desensitisation (Moffett et 
al., 1993 and Section 1.6f).
d)^-adrenergic receptor function and signalling
The (3-ARs are co-expressed in many tissues througout the human body but usually in 
a specific tissue one receptor type will predominate. In cardiac tissue the pi-AR is 
predominantly expressed but the P2 -AR also plays important functional roles. The 
P2-AR is predominantly expressed in respiratory airways and lung to control 
bronchial relaxation. The P3 -AR has important functions in adipose tissue and
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lypolysis regulating many metabolic processes. The P2 -AR again has a role to play in 
this area of bcxiy metabolism (see Sections 1.7 a-e).
All three subtypes are coupled to adenylyl cyclase through the stimulatoi-y G protein 
Gg to stimulate the generation of the second messenger cAMP, and this has been 
documented in Section 1.4. In heart the P2 -AR also regulates L-type Ca^+ channels 
possibly through Gi and stimulates phospholipase A2  mediated by arachadonic acid 
(Skeberdis et al., 1997; Pavoine et al., 1999) (see Section 1.7b for details).
1.3 Guanine Nucleotide Binding Proteins (G proteins)
a) Introduction
In 1971 Rodbell et al., discovered that hormone activated receptor linked signal 
transduction had a requirement for GTP. Study of these GTP dependent processes 
has revealed a protein component which binds and hydrolyses GTP (G proteins) to 
link ligand/hormone bound receptor to effectors which generate recognisable 
intracellular signals. These activate the appropriate cellular processes to achieve a 
specific cellular response. G proteins are therefore, signal transducers and those that 
couple to GPCRs consist of an u-subunit (39-52 kDa), which contains the guanine 
nucleotide binding site and intrinsic GTPase activity, and two tightly associated p 
(35-36 kDa) and y (6-10 kDa) subunits forming a Py subunit complex (Gilman, 
1987).
Figure 1.2
G protein a  subunit amino acid identity
The relationship among mammalian G a  subunits is displayed. The a  subunits are 
grouped by amino acid sequence identity and define four distinct classes o f Get 
subunits. The splice variants of Gga are not shown (Simon et al., 1991).
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b) G protein subunits
More than 20 different G protein a  subunits have been identified corresponding to 16 
gene products divided into four functionally different classes termed Gg, Gi, Gq and 
G 12 (Figure 1.2). All a  subunits share sequence homology to a greater or lesser 
degree which reflects the similar function of these proteins. The Gg family includes 
Gga and Goifcx, and mediates the hormonal stimulation of adenylyl cyclase and 
closing of Ca^+ channels. The Gia family include Gia (an , a{2, « 13), (Jones and 
Reed, 1987), Gta («t and cxt2) (Lochrie et a l, 1985; Tanabe et a l, 1985; Yatsunami 
and Khorana, 1985; Medinski et a l, 1985), Go« («oA» «oB) (Hsu et al., 1990; van 
Dongen et al., 1988), Ggugta and G%a. Gia is generally involved in the inhibition of 
adenylyl cyclase and opening of K+ channels, Gt«, the rod outer segment G protein 
mediates the stimulation of cGMP phosphodiesterase and Go«, mediates Ca^+ 
channel closure and inhibition of phosphoinositide (PI) turnover. It is unclear which 
effectors are mediated by Ggustot but it is involved in recognition of taste, and G%a 
has no clear function as yet but may inhibit type I and V adenylyl cyclases (Taussig 
and Gilman, 1995). The Gq family includes Gqa, G n a , G^^cc, G isa and Gj^ot 
(Strathmann and Simon, 1990; Simon et a l, 1991;Wilkie et a l, 1991) and are 
predominantly coupled to the stimulation of PI turnover. The last class contains G 12a  
and G iaa as members (Strathman and Simon, 1990).
In addition to the diversity among a  chains, there are also multiple genes encoding at 
least 6 Gp and 12 Gy subunits. Five of the Gp subunits share around 80% amino 
acid homology with the differences spread throughout their '-340 amino acid length 
(Simon et a l, 1991; Watson et a l, 1996). Gps has only 53 % amino acid identity 
with other Gp subunits. The 12 Gy subunits share little sequence identity (Ray et a l, 
1996). These subunits tightly associate as a dimer complex which is thought of as a 
single functional monomer because the two subunits cannot be dissociated except 
with dénaturants. If the known Gp and Gy subunits could combine to form Gpy
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dimers, there would be 72 potential combinations (Neer, 1997). However, Gp and 
Gy subunits show certain allowed associations in cells (Schmidt et al., 1992; Pronin 
et a l, 1992; Muller et a l, 1993; Yan et a l, 1996).
c) Structural features o f G proteins
This super family of GTP hydiolases share a common structural core exemplified by a 
particular G protein p21*^ (Ras). At the core of every G protein is the guanine 
nucleotide-binding site which binds and hydrolyses GTP to GDP. Both substrate and 
product stably bind the G protein. It is the a  sub-unit of the G protein which contains 
this catalytic core able to hydrolyse GTP to GDP. It consists of 5 a  helices 
surrounding a 6 -stranded p-sheet and contains the consensus sequences involved in 
GTP binding. These bind the phosphate group and guanine ring of GTP. Also 
present in the core is a binding consensus site for Mg^+, essential for catalysis 
(Sprang, 1997). The p subunit has an N-terminal helix followed by a repeating 
module of seven similar p-sheets, each with four antiparallel strands, that form the 
blades of a p-propeller structure. The y subunit contains two helices and no inherent 
tertiary structure. The N-terminal helix of the y subunit forms a coiled-coil with the 
N-terminal helix of the p subunit, whereas the remainder of this subunit interacts 
extensively with the p-propeller (Lambright et a l, 1996; Sondek et a l, 1996). The 
py complex acts as an inhibitor of GDP to GTP exchange at the a  subunit and 
interaction occurs at two distinct interfaces. However, upon receptor activation by 
agonist ligand a conformational change occurs in the a  subunit reducing its a  helical 
content, as demonstrated for the Gia subunit (Tanaka et a l, 1998). Lambright et a l, 
(1996) firstly demonstrated this conformational change in a refined 2.0 Â crystal 
structure of the G^a subunit at two switch regions (I and II) but not in its py 
counterpart. Figure 1.3 demonstrates the switching on and off of G protein in the G 
protein cycle.
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Figure 1,3
The G protein cycle
The GTPase cycle o f trimeric G proteins. The 'tum-on' step begins when the 
activated receptor (R*) associates with the trimer (aGDPPy), causing dissociation of 
GDP. Then GTP binds to the complex of R* with the trimer in its 'empty' state 
(aepv)» the resulting GTP-induced conformational change causes aGTP to 
dissociate from R* and form Py- After the 'turn-off step (hydrolysis of bound GTP 
to GDP and inorganic phosphate Pi), oGDP reassociates with py (from liri et al., 
1998).
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In order for G protein to couple to receptor it needs to be anchored to the membrane in 
some way. This is achieved by lipid modification with either myristate and/or 
palmitate (Casey, 1994, 1995; Milligan et al., 1995b; Ross, 1995). Only some G 
protein a  subunits are co-translationaliy myristoylated (eg, Gia and Goa). It has 
been debated whether this is merely an anchoring lipid or if it has a different 
regulatory role to play as has been proposed for the post-translational modification of 
palmitoylation. Palmitoylation occurs on all G protein a  subunits (except at). As it is 
dynamic and appears to have a regulatory role in p^-AR signalling it may also play a 
regulatoiy role at the level of the G protein.
d) Activation o f Gga
As this study is concerned with p-AR signalling and its effects on adenylyl cyclase 
regulation, this section will concentrate on coupling of p-ARs to the stimulatory G 
protein Gga, which regulates the effector molecule adenylyl cyclase. However the py 
subunit can induce certain effects acting synergistically with some forms of adenylyl 
cyclase. Most cells express two forms or splice variants of Gga, these being the long 
and the short forms (GgaL and Ggas), with molecular weights of 45 and 42 kDa on 
SDS-PAGE gels, respectively. They differ by a 15 amino acid insert between the 
Ras-like domain and the a-helical domain and there is an exchange of Glu for Asp at 
position 72 of the polypeptide (Bray et al., 1986; Robishaw et al., 1986). Studies 
have been performed to determine if the long and short forms differentially interact 
with either receptors or adenylyl cyclase. Y agami, (1995) showed that a p-AR 
agonist/receptor complex catalysed the exchange from GDP to GTP on GgaL but not 
on Ggag. It was also demonstrated that the glucagon receptor in rat liver shared GgUL 
with the p-AR but also coupled to Ggas (Yagami, 1995). As the guanine nucleotide 
site is between these two domains this change in the linker size may have an influence 
on the kinetics of these two splice variants. This indeed was found to be the case for
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the P2 -AR signalling through these splice variant forms (Seifert et al., 1998). Fusion 
proteins between the P2 -AR and either GgWL or Ggas were used to study GPCR/G 
protein coupling in a oneione ratio. It was observed that the p2 -AR-Gg(%L form 
exhibited properties of a constitutively active GPCR.
e) G-protein stoichiometry
The IP prostanoid receptor is another GPCR which also stimulates production of 
second messenger cAMP. From studies on this receptor endogenously expressed in 
NG108-15 cells Kim et al., (1994) estimated the copies per cell of each member or the 
IP receptor/Gga/adeny 1 yl cyclase signalling cascade to measure the stoichiometrical 
ratio of these proteins. Kim et al., (1994) found that for 100 000 copies of receptor 
per cell there were at least 10 times more GgCt molecules (1 250 000) but only 17 500 
copies of adenylyl cyclase per cell. Therefore, adenylyl cyclase appears to be a 
limiting factor in the Ggoc/adenylyl cyclase cascade.
/) Gia , Gfiy and other ejfector pathways
The p2 “AR is not exclusively coupled to Gga but can also couple to the inhibitory G 
protein to induce effects on other effector pathways. Daaka et al., (1997) presented a 
model for P2 -AR-mediated G protein switching to activate MAP kinase. Once P2 -AR 
stimulation induces activation of PKA, a negative feedback occurs where PKA 
phosphorylates the P2 -AR and uncouples it from Gga. The receptor is then able to 
couple to Gia, releasing Py subunits which then activate MAP kinase (Crespo et al., 
1995; Daaka et al., 1997). A similar mechanism occurs in heart for PLA2  activation 
where PKA activated by both Pi and p2  -ARs phosphorylates and uncouples the P2 - 
AR from Gga. Activation of PLA2  can then occur (Pavoine et al., 1999). The P2 -AR
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can also activate L-type Ca^+ channels but there is debate as to whether the channel is 
activated by PKA phosphorylation (Skeverdis et al., 1997) or is regulated through 
Gia (Xiao et al., 1995). Other reports demonstrate the regulation of the P2 -AR by 
Gia (Kuschel et al., 1999; Zou et al., 1999).
1.4 A denylyl C yclase
a) General overview
The second messenger cyclic 3', 5' adenosine monophosphate (cAMP) has played a 
central role in hormone signalling since the late 1950s when it was discovered by 
Sutherland et al., (1957). The adenylyl cyclases are the family of enzymes that 
convert intracellular ATP to cAMP. This is a multi-gene family (Table 1.1 modified 
from Houslay and Milligan, 1^7) of which there are at least 9 isoforms (Taussig and 
Gilman, 1995), some of which have splice variant forms. The first adenylyl cyclase 
isoform (AC I) was purified from bovine brain using a forskolin affinity resin by 
Krupinski et al., (1989). Forskolin is a diterpene molecule that directly binds and 
activates all adenylyl cyclase isoforms except type IX (Yan et al., 1998). Six 
additional full length isoforms (ACs II - VI and VIII) were identified by application of 
low stringency hybridisation and PCR techniques (Feinstein et al., 1991; Bakalyar et 
al., 1990; Gao and Gilman, 1991; Katsushika et al., 1992; Premont et al., 1992; 
Yoshimura et al., 1992; Cali et al., 1994). Type VII adenylyl cyclase, identified by 
Krupinski et al., (1992), is a partial sequence of novel isoforms. All adenylyl cyclase 
isoforms have molecular weights of --120 000 Da. Varied activation of adenylyl 
cyclases by both a  and py subunits of G proteins occurs upon agonist stimulation of 
GPCRs. Following generation of cAMP, activation of protein kinase A (PKA) 
occurs. This enzyme phosphorylates many cellular substrates to cause the onset of a
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variety of molecular pathways to produce the desired physiological or biochemical 
responses within the cell.
b) Structure o f adenylyl cyclases
All nine isoforms of adenylyl cyclase share a common structure of two transmembrane 
regions Mi and M2 , and two cytoplasmic regions Ci and C2  (Krupinski et al 1989 
Taussig and Gilman, 1995; Hurley, 1999). The transmembrane domains are each 
composed of 6  spanning a  helices to form a common double motif. Mi and M2  are 
linked by the Ci region and the C-terminal tail of the protein contains the C2  region 
(Figure 1.4a from Houslay and Milligan, 1997). Unlike the GPCR family, it is the 
intracellular regions of adenylyl cyclases, Ci and C2 , that show high homology 
between family members. In the GPCR family it is the transmembrane regions that 
are highly conserved between family members. The cytoplasmic regions provide the 
active site(s) and catalytic activity of the protein. Unlike Ci, the C2  region of adenylyl 
cyclase exhibits catalytic activity but this is enhanced in the presence of C 1. It appears 
that the Cl and C2  regions form a heterodimer to form the active site(s) (Figure 1.4b). 
Two intensely hydrophobic pockets are formed at the end of each binding pocket 
when forskolin binds, acting as a glue to join together the two cytosolic subunits. The 
endogenous cellular substrate for this enzyme is ATP and this molecule has been 
shown to bind in this cleft by mutagenesis studies (Liu et al., 1997; Tang et al., 1995; 
Yan et al., 1997; Tucker et al., 1998; Sunahara et al., 1998). The ATP binding 
pocket is lined by hydrophobic residues of C2 , which pack around the purine ring, 
and charged residues of Ci which interact with phosphate groups of ATP. Mg^+ is 
essential for this interaction and conversion of ATP to cAMP (Pieroni et al., 1995; 
Zimmermannetal., 1998).
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Figure 1.4
a) A general topographical representation of adenylyl cyclases
The putative structure of adenylyl cyclase has been deduced from sequence analysis, 
implying 12 transmembrane helices, and from functional studies that locate the 
catalytic and various regulatory sites to the intracellular cytosolic-located regions of 
the molecule (adapted from Houslay and Milligan, 1997).
b) The active site of adenylyl cyclases
Regions Cia and C2a of adenylyl cyclases bind to form the active site for catalysis 
and binding of the regulators Fsk (forskolin) or ATP.
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c) Activation by G-protein subunits
Agonist activation of GPCRs induces activation of G proteins which in turn cause 
dissociation of Py subunits from G TP bound ot subunits. G T P-G ga binds to and 
regulates all adenylyl cyclase isoforms at a crevice on the outside of C2  and the N 
terminus of Cj. This binding can be similar to the "glue-like" mechanism of 
forskolin, but G TP-G ga also appears to bind and regulate adenylyl cyclase by another 
mechanism involving a conformational change in the protein to allosterically regulate it 
(Yan et al., 1997; Tesmer et al,, 1997). Gia selectively inhibits adenylyl cyclase 
types V and VI and it may bind in a groove pseudo symmetrically related to the Gga 
binding groove (Yan et al., 1997; Tesmer et al., 1997). The GPy subunit 
conditionally regulate several adenylyl cyclases including the type II isoform. Its 
binding site does not overlap with the Gga binding site, consistent with the 
obseiwation that GPy activates type II adenylyl cyclase when G ga is bound (Chen et 
al., 1995).
d) Other regulatory mechanisms o f adenylyl cyclases
The effects of Ca^’*' on adenylyl cyclase isoforms are varied depending on which 
isoform is being targeted and what concentration of Ca^+ is being used. Types I, VIII 
and to some extent type III are markedly stimulated by nM concentrations of 
Ca2+/calmodulin. The other isoforms (II, IV , V and VI) are insensitive to 
calmodulin. However, high concentrations of Ca^+ (100-1000 pM) result in 
inhibition of adenylyl cyclase isoforms due to competition for Mg^+ which is essential 
for catalysis (Taussig and Gilman, 1995).
Phosphorylation is a mechanism of regulation commonly exhibited by an extensive 
range of moleculai' signalling pathways. Adenylyl cyclases are indirectly regulated by
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the phosphorylation of stimulated GPCRs by the second messenger activated and 
agonist-dependent kinases that phosphorylate these receptors during desensitisation 
(detailed in Section 1.6 b and c). The possibility of PICA phosphorylation of adenylyl 
cyclases as a negative feedback inhibition has been investigated but to little avail 
(Premont et al., 1992). PKC phosphorylation of adenylyl cyclases has been studied 
in more detail. Apparently PKC activates the enzymatic activity of type II and V 
adenylyl cyclases (Jacobowitz et al,, 1993; Yoshimura et al, 1993; Lustig et al., 1993; 
Kawabe et al., 1994).
1.5 Receptor Activation Models
a) Constitutively active mutant receptors
It is well documented and accepted that agonist bound GPCR has a conformation or 
structure which is in an activated state, able to couple to its cognate G protein and 
induce activation of effector and second messenger production. For the last two 
decades it has been debated whether agonist binding induces a change in receptor 
conformation (Okuma et al., 1992) or if agonist binds to an already active receptor 
conformation (Leff, 1995). In favour of the theory proposed by Leff is the finding 
that certain GPCRs can couple to G proteins and induce second messenger production 
in the absence of agonist. These are termed constitutively active mutant (CAM) 
GPCRs. The agonist-independent activity of these GPCRs can be lowered by 
addition of inverse agonists indicating that these receptors are precoupled to G protein 
in the absence of agonist. They can also be further stimulated by addition of agonist. 
Therefore, GPCRs must exist together as inactive and active forms. Studies on these 
CAM GPCRs has led to better understanding of mechanisms by which GPCRs 
function. Secondly, various activated conformations for one GPCR may occur to
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induce differential effector outputs (Kenakin, 1995; Leff et al., 1997). Several 
theories of receptor activation have been proposed and are summarised.
b) Two state receptor theory
This receptor theory has developed from consideration of ion channel states. The 
active state of the channel is one that allows the flow of ions and the inactive state is 
the closed channel. Therefore, it is predicted that all GPCRs exist as an equilibrium 
between two receptor conformations, i.e. an inactive form (R) and an active form (R*) 
(Leff, 1995). In a resting system the equilibrium between R and R^ defines the basal 
activity of the effector cascade. Effective activation of G protein only occurs through 
R*. The position of the equilibrium between R and R* varies with individual receptors 
and is altered by the presence of receptor ligands (Figure 1.5 modified from Milligan 
et ai., 1995). Agonists possess increased affinity for R* and, therefore, bind and 
stabilise this form to activate G protein and effector. Inverse agonists have the 
opposing property of binding and stabilising the R form to often reduce basal effector 
output. Antagonists bind GPCRs, but do not preferentially stabilise either form of the 
receptor. Figure 1.6a shows the two-state scheme of receptor activation by Chidiac et 
al., (1994). The influence of any auxiliary proteins is not directly considered in this 
model.
c) Ternary complex model
Unlike the two-state receptor theory, the ternary complex model takes into 
consideration the role of the coupling G protein in receptor activation. The receptor is 
also considered as a flexible entity since it is capable of producing more than one 
effect within the cell (DeLean et al., 1980; Costa et al., 1992). Figure 1.6b shows
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that the receptor itself or agonist bound receptor can form complexes with G protein. 
The resulting agonist/receptor/G protein complex is the ternary complex. This model 
was revised to take into account the two-state receptor theory (Samama et al., 1993). 
In this model GPCRs still resonate between R and R* conformations and agonists do 
not directly drive the inactive receptor to assume the active conformation. In addition 
a transient R^-G complex occurs, whose formation is promoted by the binding of 
agonists to form a ternary complex of HR*-G where H represents agonist/hormone 
(Figure 1.6c). In this circumstance the GPCR is an allosterically regulated enzyme. 
The action of agonist increases the affinity of the receptor for the G protein and 
inverse agonists inhibit the formation of these complexes. Gardner, ( 1995) has 
described the flexibility of this model to demonstrate that agonists affect the affinity of 
the receptor for the G protein rather than the proportion of the receptors distributed 
between R and R^.
d) Three-state receptor model and the cubic ternary complex model
Study of GPCRs has indicated that they can exhibit altered pharmacology and can 
undergo differential coupling to multiple effector pathways. An agonist can act 
strongly through one arm of a signalling pathway but act as an inverse agonist in the 
other. Leff et al., (1997) have revised their two-state receptor model and propose a 
three-state receptor model in which two active conformations of the receptor exist, 
each being able to couple to a different G protein and effector pathway. They argue 
that in the two-state model of receptor activation, if the receptor is able to activate two 
different G proteins this would not allow for the altered pharmacology of receptors 
through different pathways. Therefore, in order for receptor promiscuity to result in 
altered agonist pharmacology it is necessary to propose more than one active receptor 
state. The three-state receptor model is shown in Figure 1.7a and a full explanation 
and derivation of the model is presented by Leff et a l, (1997).
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Figure 1^
Ligands that bind to GPCRs
The diagram shows the position of the equilibrium between an inactive state R and 
an active state R* which varies with individual receptors and is altered by the 
presence o f receptor ligands. Agonists function by stabilising R* while inverse 
agonists preferentially stabilise R. A continuum of ligands between full agonists and 
full inverse agonists is expected to exist, with antagonists being able to bind to 
receptor but having no preference for R or R*, or effect on equilibrium between 
these two forms.
24
Figure 1.5
full inverse 
agonist
m
partial
inverse
agonist
kL
antagonist P^i^l 
agonis!i
full
agonist
m
R -R*
Figure 1.6
a) The two sate receptor theory
This depicts a system wherein a receptor spontaneously assumes either an inactive 
state (R) or and active state (R*), with the equilibrium between these being described 
by a unimolecular constant Ks ([R*]/[R]). A given ligand (H) binds to R and R*, to 
yield the association constants K h (ie [HR]/[H][R]) and aKji (ie [HR*]/[H][R*]), 
respectively; H is assumed to have no other effect on either R or R*. If a  > 1, then 
H binds with greater affinity to the active form of the receptor and increases the 
number of receptors in the active state (ie [R*] + [HR*]), thereby stimulating the 
activity of the receptor (ie H is an agonist). If a  < 1, the number of receptors in the 
inactive state is increased by H (ie H has a negative intrinsic activity). The influence 
of any auxiliary proteins is not directly considered.
b) The ternary complex model
This model takes into account the role o f the coupling G protein in receptor 
activation as the presence o f guanine nucleotide appears to convert the receptor from 
a high to low affinity state. The receptor is considered as a flexible entity since it is 
capable of producing more than one effect within the cell. The scheme shows M as 
the affinity of R (receptor) for G (G protein), a  as the efficacy of the ligand and K 
the receptor affinity o f the ligand. K = [HR]/[H][R], M = [RG]/[R][G], a  = 
[HRG][R]/[HR][RG].
c) The revised ternary complex model
This shows the extended or allosteric ternary complex model. This model introduces 
an explicit isomérisation step regulating the formation of the state o f the receptor 
from R to R*, which is capable o f binding to the G protein. J represents an 
equilibrium constant in receptor isomérisation. J = [R*]/[R], K = [HR]/[H][R], M = 
[R*G]/[R*][G], a =  [HR*G][R*]/[HR*][R*G], [HR*][R]/[HR][R*].
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In fact it has been proposed that a GPCR may have several active receptor states 
coupling to different G proteins (Kenakin, 1995). Kenakin proposed the theory of 
“agonist trafficking” in which each agonist may be able to select or activate its own 
specific active receptor state. These receptor states may possess differential ability to 
activate subsequent signalling pathways. Evidence for this idea comes from studies 
on the « 1B-AR, in which a single point mutation with the 2 0  different amino acids 
was carried out. All 20 mutant constructs were found to have different degrees of 
constitutive activity, the wild-type construct being quiescent (Kjelsberg et al., 1992). 
This indicated that the receptor could form many active states and that only one state is 
quiescent (ie the wild-type).
The three-state receptor model has been developed further to accommodate for 
coupling of different receptor conformations to different G proteins and effector 
pathways (Zuscik et al., 1998). This was derived from studies on the Pa-AR, which 
is routinely classed as a receptor which couples to Ggoc and downstream cAMP 
production. Studies now indicate that the p%-AR activates Na**'/H+ exchange. A 
Cl 16F mutant of the P2 -AR was engineered that exhibited the ability to constitutively 
activate Na+/H+ exchange while only maintaining competent coupling to cAMP. This 
indicated that this receptor could form multiple activation states that are G protein 
specific. A revised cubic ternary complex model was devised to explain the coupling 
of two distinct active receptor states coupling to two different G proteins (Figure 1.7b 
from Zuscik et al., 1998).
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Figure 1.7
a) The three state receptor theory
It is hypothesised that the receptor exists in three states, an inactive or resting 
conformation, R, an active conformation, R*, which interacts with G protein, G l, 
and another active conformation, R**, which interacts with G protein, 02. In the 
absence of agonist/hormone H, the distribution of the receptors into the three states 
is governed by the equilibrium constants L = [R]/[R*] and M = [R]/[R**]. The 
activity of agonist is governed by the equilibrium dissociation constants K h  -  
[H][R]/[HR], K h * = [H][R*]/[HR*] and K h ** = [H][R**]/[HR**], which determine 
its affinity for R, R* and R** respectively. The receptor is distributed amongst the 
three unoccupied and three occupied states, so that total receptor concentration is; 
Rtot =  [R] + [R*] + [R**] + [HR] + [HR*] + [HR**].
b) The cubic ternary complex model
A single receptor can form two distinct activated conformations that selectively 
interact with different G proteins. A = agonist, R = receptor and G = G protein.
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e)The CAM-^2-^renergicreceptor
The most studied CAM GPCR is a form of the human P2 -AR in which a short 
segment of the third intracellular loop was replaced with the corresponding region 
from the aiB-AR (Samama et al., 1993; Samama et al., 1994). This work has 
stemmed from findings that the reciprocal mutation in the hamster a  ib-AR (part of the 
3rd intracellular loop replaced by the corresponding region in the P2 -AR) produced a 
CAM form of this receptor (Cotecchia et al., 1990; Kjelsberg et al., 1992). As this 
receptor displays elevated basal adenylyl cyclase and GTPase activity, it has been 
investigated what properties determine the receptor’s constitutive activity. From 
analysis on the structure of this CAM protein it was found that the same Cys which 
moves upon agonist binding to WT-P2 -AR is found closer to the ligand binding 
pocket than in the ligand-unoccupied WT receptor (Javitch et al., 1997).
Certain inverse agonists such as betaxolol and sotalol but not other p-blockers have 
been shown to reduce basal levels of CAM-P2 -AR induced cyclase activity. After 
long-term treatment of CAM-P2 -AR expressing cells with inverse agonists, an up- 
regulation of the receptor was detected and again this was not exhibited by other p- 
blockers (MacEwan and Milligan 1996a,b). As inverse agonists uniquely displayed 
these properties it was proposed that these ligands could potentially be put to 
therapeutic use in disease states.
1.6 R eceptor D esensitisation  M echanism s
a) Introduction
Sustained exposure of cells expressing GPCRs to agonist ligands frequently results in 
a waning of response to the ligand. This effect is termed desensitisation and can be
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viewed as a negative feed back loop mechanism, its role being to regulate the 
sensitivity of the receptor to the initial stimulus. For GPCRs desensitisation is a 
multi-step phenomenon (Lohse, 1993; Bohm et al., 1997). First, uncoupling of the 
receptor from the G protein occurs causing the receptor function to be desensitised. 
Sequestration of the receptor into an intracellular compartment then occurs followed 
by possible down-regulation, if the stimulation is chronically persistent. Down- 
regulation may involve a loss of receptor number due to degradation of the receptor 
protein and reduction of steady state mRNA. Desensitisation has been categorised as 
either homologous (agonist-specific) or heterologous (agonist-non specific).
b) Homologous Desensitisation
This phenomenon occurs only at receptors which have been stimulated by agonist 
(agonist specific) and consequently desensitises the subsequent response of the same 
receptor only. The proteins primarily found to be involved in homologous 
desensitisation are the G protein coupled receptor kinases (GRKs), of which there are 
currently six full length cDNAs encoding the members of the emerging GRK sub­
family of Ser/Thr protein kinases (Table 1.2, Pitcher et al, 1998; Strader et al., 1995). 
The first GRK isolated was rhodopsin kinase (RK or GRKl). This GRK has limited 
tissue distribution being found in the retina of the eye. pARICl (GRK2) and pARK2 
(GRK3) are the p-adrenergic receptor kinases, originally given this name due to their 
initial characterisation as kinases able to phosphorylate and desensitise the P2 -AR 
(Fredericks et al., 1996) and the Pi~AR (Freedman et al., 1995). pARKs are not 
exclusive to the pAR system since they have also been reported to phosphorylate the 
muscarinic receptor (Kameyama, et al., 1993), the type lA angiotensin receptor 
(Oppermann et al., 1996) and many other GPCRs. GRK4 has been reported to be 
found predominantly in the testis. Like GRKs 2 and 3, GRKs 5 and 6  are 
ubiquitously expressed. GRK5 has been reported to phosphorylate the P2  and pi-
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Table 1.2 Molecular properties of G protein coupled receptor kinases (GRKs)
Family
name
Common
name
Membrane
association
Tissue
distribution
Chromosome
Mapping
Features/
Regulation
GRKl RK* Famesylation Retina 13q34 Autophospho-
lylation
GRK2 pARKl GjSy, acidic PL Ubiquitous llq l3 PH domain, 
PKC,
calmodulin
GRK3 PARK2 Gpy acidic PL Ubiquitous 2 2 q ll PH domain
GRK4 lT-11 Palmitoylation Testis 4ql6.3 Four splice 
variants
GRK5 PL binding Ubiquitous 10q24-qter Autophospho­
rylation
GRK6 Palmitoylation Ubiquitous 5q35 Calmodulin
*RK, rhodopsin kinase; PL, phospholipid; PH, plekstrin homology.
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adrenergic receptors in vitro and in vivo (Fredericks et al. 1996; Rockman et al., 
1996; Oppermann et al., 1996).
Structurally, GRKs contain a catalytic domain of 263 - 266 amino acids, flanked by a 
large N-terminal domain (- 185 amino acids) with structural homology between GRK 
sub-types. The flanking C-terminal domain varies substantially between GRK sub- 
types. An interesting feature of GRKs 2 and 3 (pARKs) is their possession of a 
carboxy-terminal py binding domain (Inglese, et al., 1993). Other GRKs (RK and 
GRKs 4, 5 and 6 ) do not possess such a domain. Table 1.2 summarises the family of 
GRKs, their distribution and membrane association. The py binding domain recruits 
the kinase to the membrane through interactions with the Py sub-units situated on the 
inner surface of the plasma membrane. Recent reports have shown this remarkable 
function of Py sub-units to intimately link receptor activation to pARIC-mediated 
desensitisation (Pitcher et al,, 1992; Koch et al., 1994; Chen et al., 1995; Koch et al., 
1993). Fushman et al., (1998) have examined this region and identified it as a 
pleckstrin homology (PH) domain, conferring binding specificity to py proteins, 
assisting recruitment of the protein to the plasma membrane. The solution structure 
and dynamics of the PH domain of GRK2 (pARK 1) show that it is capable of 
protein/protein interactions with Py sub-units (Fushman et al., 1998). On binding of 
agonist, the receptor adopts the appropriate conformation releasing py subunits from 
the a  subunit, both these factors in combination facilitate recruitment of the pARK 
and phosphorylation of the receptor. Since only the agonist-occupied or stimulated 
receptor has the appropriate confonnation for the GRK to bind, this creates an agonist 
specific mechanism.
In the case of rhodopsin kinase, this protein has been shown to be unique in that it is 
the only GRK thus far reported to be isoprenylated (farnesylated) which facilitates 
anchorage of the kinase to the plasma membrane. Isoprenyl moieties are present on 
py subunits also, the y subunit containing the geranyl-geranyl type of moiety. Studies
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have reported that distinct p and y subunit isoforms are present in G-proteins that may 
show a certain specificity for different GRKs (Schmidt et al., 1992; Pronin et al., 
1992; Muller et al., 1993; Y an et al., 1996). This may be a possible means of 
directing different enzyme isoforms to different receptors although this has not been 
conclusively proved. GRK5 carries out its phosphorylation of the p-AR involving 
recruitment to the plasma-membrane through its phospholipid (PL) binding domain. 
The sites of phosphorylation in the p-AR by both GRK2 and GRK5 have been 
investigated extensively over the past decade and as yet there is still debate as to 
whether the sites identified in vitro are the sites of in vivo phosphorylation. It has 
even been postulated that additional or new sites of phosphorylation could be present 
in this receptor. Location of GRK2 and GRK5 phosphorylation sites within the 
extreme C-terminal tail (last 40 residues) of the p^-AR have revealed that all are either 
Ser or Thr residues (Fredericks et al., 1996). However, from in vivo studies these 
residues do not appear to be important for desensitisation (Seilbold et al., 1998). It 
has been suggested that four other residues in the C-terminal tail out with the last 40 
amino acid residues investigated may be targets for in vivo phosphorylation. 
Hausdorff et al, (1991) have studied a mutant p%-AR only containing mutations at 
these four amino acids (Ser 355, 356, 364 and Thr 360), and found that the in vivo 
sites of GRK phosphorylation could be among these.
GRK phosphorylation in isolation results in minimal desensitisation (Hausdorff et al., 
1989) but proteins which assist in this desensitisation by binding to the 
phosphorylated receptor have been discovered. These are the functional co-factor 
arrestin proteins. Two arrestins, S arrestin (or arrestin) and cone arrestin are found in 
retina and are similar in substrate specificity (i.e. rhodopsin) (Craft et al., 1994). p- 
arrestin- 1  and p-arrestin 2  were discovered following the revelation that the ability of 
pARKl to desensitise the p%-AR is reduced during purification. This indicated a loss 
of a co-factor required for efficient desensitisation and subsequently p-arrestin 1 and 
P-arrestin 2 were identified in a variety of tissues (Parruti et al., 1993). Binding of
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these arretins to phosphorylated receptors in a 1 :1  ratio disrupts the interaction of 
receptor with G protein and therefore, promotes homologous desensitisation (Lohse et 
al., 1993). In the P2 -AR system, p-arrestin increases pARKl mediated 
desensitisation by -10 fold (Pippig et al., 1993). It has also been reported that p- 
arrestins promote desensitisation of the pi-AR (Freedman et al., 1995). In the basal 
state p-arrestin 1 is phosphorylated but undergoes a dephosphorylation when binding 
to agonist bound receptor (Lin et al., 1997). It is not clear whether this 
phosphorylation precedes or follows receptor binding. Once bound the arrestin 
protein acts as a clathrin adapter to induce internalisation of the protein (see Section 
1 .6 g on receptor sequestration).
c) Heterologous Desensitisation
In common with homologous desensitisation, heterologous desensitisation also 
involves a phosphorylation mechanism but, by different kinases i.e. the agonist non­
specific, or second messenger activated kinases, PKA and PKC (Chaung et al., 
1996). Heterologous desensitisation, unlike homologous desensitisation, is a process 
whereby activation of one type of receptor causes desensitisation of other types of 
receptors also. For example, in the murine neuroblastoma x embryonic Chinese 
hamster brain NCB20 cells, transfected with the P2 -AR, stimulation with isoprenaline 
(a p-AR agonist) resulted in heterologous desensitisation of the endogenously 
expressed IP prostanoid receptor (Mullaney et al., 1995). In contrast exposure of 
cells to similar doses of iloprost (IP receptor agonist) did not result in any 
heterologous desensitisation of the P2 -AR. Therefore, not all GPCRs undergo 
heterologous desensitisation.
Distinct phosphorylation sites for second messenger activated kinases (PKA/PKC) 
have been investigated. Two consensus sites for PICA mediated phosphorylation
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have been identified in the p2 -AR (Benovic et aL, 1985; Hausdorf et aL, 1989; Clark 
et al., 1989; Yuan et al., 1994). Firstly in the 3rd intracellular loop of the receptor (at 
serines 261 and 262) which is essential for Gg/receptor coupling and is the preferred 
site for PKA mediated phosphorylation. The second and less preferred site is in the 
N-terminal part of the C terminus (at serines 345 and 346), thought to play a part in 
receptor/Gs coupling. In fact PKC can phosphorylate these sites also. It appears that 
the number of consensus PKA phosphorylation sites present is correlated with the 
extent of heterologous desensitisation. The Pl~ and Pg-AR have two, one and no 
phosphorylation sites, respectively. p^-ARs undergo little or no heterologous 
desensitisation whereas, the pi-AR (Freedman et al., 1995) is intermediate and the 
p2 "AR undergoes extensive heterologous desensitisation. In this respect Ps-ARs can 
continue to respond to p-AR ligands if other co-expressed p-ARs are desensitised on 
stimulation by agonist.
e) Heterologous Regulation o f Homologous Desensitisation
Previously it was considered that both homologous and heterologous desensitisation 
were completely separate events. This was shown in experiments on the PKA 
defective kin" S49 murine lymphoma cell line, which expresses the P2 -AR. Both 
wild type and kin" S49 cells express similar profiles of p-AR desensitisation of cAMP 
production and P2 -AR loss (Clark et al., 1988). The ability of the cAMP analogue 8 - 
Br-cAMP to mimic the effect of adrenaline in decreasing p-AR agonist-induced 
adenylyl cyclase activity in membranes prepared from treated cells indicated that, 
along with the previous result, PKA is not involved in homologous desensitisation. 
However, Post et al., (1996) have demonstrated an important regulatory role for 
PKA in homologous desensitisation. By using a novel pH] forskolin binding assay 
which provides a direct means of measuring hormone-stimulated Gg/adenylyl cyclase 
interactions in both wild type and kin" S49 cells under desensitising conditions, it was
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demonstrated that P2 ~AR induced pH] forskolin binding decreased reflecting 
functional desensitisation of the P2 -AR pathway. The difference in the extent of 
desensitisation between the two cell types demonstrated a key role for PKA in 
homologous desensitisation.
The second messenger activated kinase, PKC, appears to regulate GRK expression in 
T cells but this appears to be a selective regulation among GRKs (De Blasi et al., 
1995). Certain GRKs (GRK2) are phosphorylated by PKC which increases the 
activity of the GRK promoting increased desensitisation. Plekstrin homology 
domains may be the site of interaction between the GRK and PKC . Conversely, P- 
arrestin 1 expression is regulated by PKA through cellular levels of cAMP (Inglese et 
al., 1993; Chaung et al., 1996). Therefore, it can be concluded that second 
messenger activated kinases have various important regulatory roles to play in 
homologous desensitisation.
f)  Involvement o f Palmitoylation in Desensitisation
The importance of fatty acyl chains on signalling molecules has already been 
discussed when considering palmitoylation, a lipid modification of G proteins. This 
is a dynamic post-translational modification (Magee, 1990; Casey, 1994; Casey,
1995) and therefore, has the potential to be regulated. Most GPCRs are palmitoylated 
on Cys residues located in the proximal section of their C-terminal tail. This anchors 
the N-terminal portion of the cytoplasmic tail to the plasma membrane creating a 
fourth intracellular loop. Agonist exposure of the P2 -AR and the D1 dopaminergic 
receptor (Ng et al., 1994) alters this palmitoylated state and there is evidence that 
palmitoylation may effect the desensitisation of the receptor. One site of PICA 
phosphorylation is very close to the palmitoylated Cys, C341, on the P2-AR and it 
has been proposed that depalmitoylation of the receptor may expose this site for
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phosphorylation causing resultant desensitisation. In fact it has been demonstrated 
that the palmitoylated Cys 341 modulates phosphorylation of the p2 -AR by PKA 
(Moffett et al., 1996). This was indicated on finding that a C341G p2 -AR mutant 
which is not palmitoylated displays an elevated level of basal phosphorylation and a 
decreased rate of agonist-promoted desensitisation (Moffett et al., 1993). Therefore, 
it was proposed that concerted interactions between palmitoylation and 
phosphorylation could play an important role in regulation of P2 -AR function.
As documented earlier in this chapter (Section 1.3c) palmitoylation also plays a role in 
desensitisation at the level of the G protein Ga subunit (Milligan, 1993). All Ga 
subunits are palmitoylated and some have a requirement to be myristoylated. 
Palmitoylation of G a subunits is also a dynamic process and therefore a site of 
regulation (Milligan et al., 1995b). After formation of the active a^-GTP complex, 
depalmitoylation of the G^a occurs releasing as from the membrane which may 
contribute to desensitisation of G protein signals.
A more recent report demonstrates that activation of a p2 “AR-Gsa chimera leads to 
rapid depalmitoylation and inhibition of repalmitoylation of both receptor and G 
protein (Loisel et al., 1999). By using a P2 ~AR-Gsa chimera the receptor was 
permanently linked to Gga and was therefore, in the active state (as if agonist bound) 
and could not be desensitised, internalised or down-regulated. Upon agonist 
activation both the receptor and GgU portions of the chimera were depalmitoylated. 
However, forskolin activation of adenylyl cyclase did not induce depalmitoylation of 
the construct. Therefore, depalmitoylation is not regulated by second messenger 
production but by agonist activation. Repalmitoylation was therefore proposed not to 
occur at the active receptor/Gga complex but at a later event in the pathway.
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g) Receptor Sequestration
Once phosphorylated and uncoupled from G protein the p2 ~AR receptor is found to 
internalise by a clathrin/dynamin mediated pathway assisted by j3-arrestins which are 
clathrin adapters (Zhang et al., 1996, Lin et a l, 1997). Originally, sequestration of 
GPCRs was thought to be a desensitisation mechanism since Gg was not found to be 
associated with receptors in the light membrane fractions and therefore, G 
protein/receptor coupling could not occur (Waldo et a l, 1983). Evidence exists to 
disagree with this. Firstly, in most systems receptor sequestration is too slow 
compared to the rapid phosphorylation of receptor and uncoupling of G protein, and, 
hence, sequestered receptors will already have an impaired function (Roth et a l, 
1991). Secondly, in the majority of cell systems receptor sequestration is too limited 
to account for the extent of desensitisation observed (Lohse et a l ,  1990). In fact 
there has been an accumulation of evidence to indicate that sequestration is a 
mechanism for resensitisation of the receptor. This has been observed for the P2 -AR 
system where an agonist-induced internalisation of the receptor occurs (Yu et al., 
1993; von Zastrow et a l, 1994; Pippig et al., 1995). Removal of agonist or addition 
of antagonist causes redistribution of receptors to the cell surface indicating that the 
mechanism is agonist dependent. Following internalisation into endosomes/vesicles 
dephosphorylation of the P2 -AR by a vesicular membrane-associated form of the 
phosphatase PP-A2 occurs. This event only occurs under acidic pH and can be 
inhibited by NH4 CI (Kreuger et a l, 1997). The Pi-AR is also thought to internalise 
via a clathrin/dynamin dependent pathway but a recent study by Tang et a l, (1999) 
have revealed a novel machanism for internalisation of this receptor. There is a 24 
amino acid polyproline rich motif within the 3rd intracellular domain of the Pi-AR, 
and such motifs are known to mediate protein-protein interactions such as with Src 
homology (SH) 3 domains. An SH3 protein p4 was found to bind to the pi-AR. 
These proteins also function sequentially in endocytic clthrin-coated vesicle formation 
and may act as an adapter protein by directing the Pi-AR to the endocytic machinery.
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SH3/p4 has also been found to bind to dynamin in vivo. Therefore, the Pi-AR may 
be regulated by a different mechanism from the p2 -AR.
In parallel with the extent of heterologous desensitisation, the P2 -AR shows maiked 
sequestration, whereas the Pi- and p3 ~subtypes do not. These agonist regulated 
receptors may share or utilise the same endocytic machinery that mediates the 
constitutive endocytosis of a variety of receptors. How these receptors are targeted 
into the cell has been suggested by the finding of a conserved NPXXY motif present 
in many GPCRs which is homologous to constitutive endocytosis signals.
h) Down-regulation
Following chronic, long term exposure of cells to agonist, a ligand-dependent 
reduction of total receptor number may occur. This phenomenon is termed down- 
regulation and has been investigated quite rigorously over the past decade (Hadcock 
and Malbon, 1988a,b; Molenaar et al., 1990; Kompa et al., 1992; Gagnon et al., 
1998; Jockers et al., 1999 and references therein). These studies have concentrated 
mainly on the p2 -AR system which have revealed that down-regulation involves at 
least two pathways. The first is the reduction in receptor mRNA steady-state level 
resulting from de stabilisation of the transcript (Hadcock and Malbon, 1988; Bouvier 
et al., 1 ^9 ; Nantel et al., 1994; Danner et al., 1998).
The second pathway has been demonstrated through studies on the p-AR. This 
receptor was found to display a 40 to 50% down-regulation when hamster vas 
deferens DDT 1 MF-2 cells were treated for 1 h with isoprenaline, and this reduction in 
receptor level was maintained for 16 h as assessed by intact-cell [I25i] 
iodocyanopindolol binding (Hadcock and Malbona, 1988a,b). The rapid initial phase 
of agonist-specific down-regulation of the p-AR was predicted to either be caused by
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a change in conformation of the receptor such that it could no longer bind and respond 
to agonist, or to be due to sequestration of the receptor away from the plasma 
membrane. Indeed, p-AR sequestration has been linked to down-regulation in a 
number of reports (Mahn et al., 1985; Gagnon et al., 1998; Kallal et al., 1998), 
claiming that internalised receptors are sent to lysosomes and degraded. However, 
there are contradictory views to this, stating that receptor sequestration is not linked to 
receptor down-regulation (Valiquette et al., 1990, Hausdorff et al., 1991, Campbell et 
al., 1991, Green et al., 1994, Barak et al., 1994; Jockers et al., 1999). From studies 
on L cells stably expressing a p^-AR construct, a novel model of receptor down- 
regulation was presented by Jockers et al., (1999). As down-regulation of the P2 -AR 
still occurred in response to isoprenaline despite blockade of receptor endocytosis they 
postulated that a primary inactivation step may occur at the plasma membrane. The 
two contradictory models of P2 -AR down-regulation are presented in Figure 1.8.
Despite the ambiguities in the above process it is routinely agreed that the p2 -AR 
undergoes extensive (40 to 50 %) down-regulation following long-term agonist 
exposure. Studies on the Pi and P3  sub-types of p-AR are less well established. 
IjDng-term exposure of animals to p-AR agonists cause a loss of Pi- and p2 - ARs 
(Summers et al., 1997 and references therein). It has been reported that isoprenaline 
leads to preferential down-regulation of the P2 -AR (Summers et al., 1997). 
However, noradrenaline affects both Pi- and p2 - AR levels but not levels of ps-AR 
when administered to hamsters (Carpene et al., 1993). It is generally accepted that the 
p2 "AR undergoes extensive down-regulation, whereas the P3 -AR undergoes very 
little down-regulation (Chambers et al., 1994), and the Pi-AR is intermediary 
between the two.
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Figure 1.8
Models of GPCR down-regulation
Model 1: predicts that agonist binds to receptor and it is sequestered into early 
endosomes where it can be recycled. If the stimulation is chronically persistent the 
receptor is sent to lysosomes where it is degraded.
Model 2: predicts that the receptor is destabilised by agonist binding at the plasma 
membrane before it is sequestered. Following sequestration it is then degraded.
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1.7 p-A drenergic R eceptors in Disease
a) Introduction
The sub-family of p-ARs are expressed in many tissues throughout the human body 
and are key targets within the autonomic nervous system, regulating a wide variety of 
physiological processes. The three types, pi, p% and p3 are differentially expressed 
and aie each primarily important in the regulation of biological processes of specific 
organs. It is generally accepted that the Pi-AR is predominantly expressed in heart, 
the p2 "AR is predominantly expressed in lung and the pg-AR is predominantly 
expressed in adipose tissue. All sub-types are linked to the production of the second 
messenger cAMP, a molecule which can activate and regulate many different 
signalling pathways in cells ultimately inducing an effect on a variety of physiological 
processes. In addition to adenylyl cyclase activation, the P2 -AR in cardiac cells can 
regulate other effectors, including voltage-sensitive calcium channels and sodium 
channels (Reiter, 1988; Skeberdis et al., 1997). In disease it is often these signalling 
pathways that can malfunction and endless efforts have been made to find the exact 
mechanisms involved to cause disease. This section will concentrate on some main 
areas of disease and the roles p-ARs play in these. These will include the involvement 
of the p i and P2  -AR and to some extent the P3 -AR in heart failure, the contributory 
factors of asthma involving the P2 -AR, and the regulation of lipolysis by the P3 -AR, 
and associated problems to causing obesity and diabetes. The role the P2 -AR has to 
play in obesity and diabetes will also be discussed along with the regulation of blood 
pressure.
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b) Cardiac Disease
Stimulation of p-ARs by sympathetic neuronal activation, by circulating 
catecholamines, or by adrenergic agonists increases heart rate (chronotropism), force 
of cardiac contraction (ionotropism), rate of cardiac relaxation (lusitropism) and 
automaticity (Post et al., 1999; Dzimiri, 1999). A common clinical condition is 
congestive heart failure (CHF) in which there is the loss of ability of the cardiac 
muscle to pump blood to tissues of the body. The severity of the condition is 
correlated with a rise in plasma catecholamines, but it is found that p-AR mediated 
responsiveness decreases in patients with CHF. Therapies are now being directed to 
the p-AR signalling pathway by firstly using disease induced animal models. It is 
unclear, however, how real these models are compared to the actual disease processes 
in human patients.
The mammalian heart primarily expresses the pi-AR (75 - 85%) but these only 
mediate about 60% of ventricular contractility. A substantial number of P2 -AR can 
also be detected in cardiac tissue (Bristow et al., 1989). It has been reported that 
cardiac tissue also expresses both P3 - and P4 - ARs but their physiological relevance is 
unclear (Kaumann and Lynham, 1997; Kaumann et al., 1998). The P3 -AR apparently 
has a negative inotropic effect in cardiac tissue and this may be through activation of 
Gia (Gauthier et al., 1996). At the end-stage of CHF the pi-AR appears to be down- 
regulated with no decrease in P2 -AR levels, however it was found to be uncoupled 
from G protein. It is thought that this down-regulation is a way of protecting the heart 
from the rise in circulating catecholamine levels which occurs in CHF. It is at this 
stage that the P2 -AR response becomes predominant over that of the Pj-AR, in 
particular at low adrenaline concentrations. Therefore, the potential role for the p%-AR 
to improve cardiac performance has been investigated. In healthy human heart both 
Pi and p2  -ARs are coupled to adenylyl cyclase regulating cAMP levels. However, 
during CHF pi-ARs are down-regulated and the P2 -AR does not couple efficiently to
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this effector, although, the positive inotropic effects of adrenaline and noradrenaline is 
increased >50% (Pavoine et al., 1999). It has now been identified that the P2 -AR can 
also regulate other signal transduction pathways in the heart. Pavoine et al., (1999) 
found that cAMP is the messenger of pi~AR responses, but cell responses to P2 -AR 
stimulation are mediated by arachadonic acid release via phospholipase A2  under 
cAMP control. Therefore, this p2 "AR signalling pathway through PLA2  is regulated 
by the Pi-AR. The P2 -AR also controls the activation of L-type Ca^+ channels in 
cardiac myocytes through phosphorylation of the channel by PKA activated by second 
messenger cAMP (Skeverdis et al,, 1997). However, this is contradictory to 
experiments by Xiao et al., (1995). They showed that activation of L-type Ca^+ 
channels through the P2 -AR was enhanced by pertussis toxin treatment indicating the 
role of a pertussis toxin sensitive G protein (possibly Gi) here, indicating a cAMP 
independent mechanism.
Polymorphisms of both the Pi-AR and P2 -AR have been identified. Green et ai., 
(1993, 1994) have identified and pharmacologically characterised 4 polymorphic 
forms of the P2 -AR at positions 16, 27, 34 and 164. The Ilel64 (T164I) variant was 
found in heart to be substantially uncoupled from Gg in both the non-agonist and 
agonist occupied forms. As the P2 -AR is also markedly uncoupled from Gg in CHF, 
individuals harbouring this receptor with heart failure may exhibit marked 
decompensation. Turki et al., (1996) have demonstrated that the He 164 variant form 
when expressed in a transgenic model revealed a substantial impairment imposed by 
this polymoiphism in cellular as well as intact heart function. Liggett et al., (1998) 
have extended this study to indicate that the He 164 polymorphism of the p2 “AR can 
adversely affect the outcome of CHF. These findings prompted studies into 
identification of Pi-AR polymorphisms. Mason et al., (1999) have identified a 
G389R switch within a region of the Pi-AR important for receptor/G protein 
coupling, the resulting variant having enhanced receptor-Gg interaction with enhanced
43
activation of adenylyl cyclase. This may in some way have an influence on CHF and 
the extent of the disease.
Treatment of heart failure involves the use of |3-blockers which function to inhibit the 
effects of high levels of circulating catecholamines which are continually stimulating 
Pi- and p2 - ARs to lead to CHF (reviewed by Doughty and Sharpe, 1997). The use 
of p-blockers in treatment have indicated an increase in ejection of blood from the left 
ventricle of the heart and an increase in left ventriclar volume. Studies which do not 
show this have been criticised for their short period of study. Metoprolol and 
carvedilol are two p-blockers which have been extensively studied but only carvedilol 
has been shown to be beneficial in survival rates (Doughty and Sharpe, 1997).
c) Asthma
Extensive studies on p2 "AR polymorphisms (at positions 16, 27, 36 and 164) and 
their involvement in asthma have been performed over the recent years due to high 
expression of this receptor in the lung. Endogenous catecholamines and administered 
P2 -agonists exert their primary effect on the p2 -AR of bronchial smooth muscle, 
resulting in relaxation and bronchial dilation. During asthma there is thought to be a 
malfunction of the P2 -AR signalling pathway since a substantial bronchial constriction 
occurs in this disease. Two of the P2 -AR polymorphisms have been studied in detail 
Glyl6  (R16G) and Glul7 (Q27E). In 1995 Turki et al., identified a down-regulation 
of the P2 -AR at night in patients with nocturnal asthma. They found an over 
representation of a G lyl6  allele of the p2 ~AR in these patients. Therefore, it was 
concluded that the Glyl6  polymorphism may play a role as an important genetic factor 
in asthma. However, when an asthmatic population as a whole was considered no 
role of this allele or the Glu27 or Ilel64 alleles were identified as being the primary 
cause of asthma (Liggett, 1997).
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When studying the response of these polymorphic forms of the P2 -AR to prolonged 
exposure to agonist it was found that the Glyl6  variant underwent enhanced agonist- 
promoted down-regulation compared to WT-P2 -AR, whereas the Glu27 form was 
resistant to down-regulation (Green et ai., 1994). Investigation into the roles of the 
Glu27 allele have indicated that this variant form of the P2 -AR provides a protective 
role against bronchial hyperactivity (the most common physiological abnormality 
found in asthmatic patients) (Hall et al., 1995). One way of treating this asthmatic 
response is to administer p2 ~AR agonists since they enhance bronchial relaxation 
although there is debate as to the therapeutic benefits of these drugs.
d) Obesity and Diabetes
Obesity and non-insulin-dependent diabetes mellitus are two of the most common 
metabolic diseases and it appears that the pg-AR may be linked to both. This receptor 
is the main receptor involved in the regulation of thermogenesis and lipolysis in brown 
and white adipose tissues in rodents (and possibly larger animals), so it is not 
surprising that it might have a role to play in these diseases (Strosberg et al., 1997a).
In Ps-AR-deficient mice, a modest increase in body fat occurs which conesponds to 
reduced levels of pg-AR mRNA in genetically modified obtob mice and fa!fa Zucker 
rats (Susulic et al., 1995; Charon et al., 1995). An Arg64 (W64R) polymorphism in 
the Pg-AR has been identified associated with obesity in Pima Indians and Japanese.
In fact this mutation is observed in all populations of the world, but only a weak 
association, mostly in women, of the presence of the Arg64 variant with a number of 
symptoms related to the metabolic syndrome was detected. This polymorphism has 
also been associated with the early onset of non-insulin-dependent diabetes mellitus in 
a Finnish population, the Pima Indians, Mexican Americans and Japanese (Strosberg,
1997b). This single polymorphism in the Pg-AR is unlikely to be solely responsible 
for the onset of morbid obesity. Leptin is the product of the gene altered in ob/ob
]
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mice and may play a role in regulating energy metabolism (Halaas et al., 1995). It is 
thought to activate the JAK-STAT signalling pathway in the hypothalamus to release 
noradrenaline, which would activate the pg-AR. Agonists for the pg-AR reduce 
mRNA levels of leptin and increase of leptin correlates with reduced pg-AR activity. 
A negative feedback loop appears to operate here. However, very few defects in 
leptin or its receptor have been found in human populations. Large etal., (1997) have 
extended studies to investigate the role of the P2 -AR and its polymorphisms in 
obesity. The Glu27 variant in the homozygous form was found to be associated with 
increased body fat and enlarged fat cells, whereas the G lyl6  variant improved 
adipocyte P2 -AR function. Mori et al., (1999) have also investigated the role of the 
Glu27 polymorphism in obesity in Japanese men. This variant of the P2 -AR was 
found to be significantly more frequent in the obese subgroup than the nonobese 
subgroup and was associated with weight gain in the subcutaneous fat area. 
Therefore, genetic variability in the human P2 -AR gene may be of importance in 
obesity.
e)Hypertension
Adrenergic neurotransmitters are important in the regulation of blood pressure and the 
P-AR functions to cause vessel relaxation and decreased resistance. p-ARs are 
known to contribute to the regulation of blood pressure through effects at several 
target sites, including the central nervous system, adrenergic nerve terminals, blood 
vessels, heart and kidney. Alterations in the sympathetic nervous system contributes 
to the development of systemic hypertension. The use of p-blockers appears to lower 
blood pressure in patients with hypertensive symptoms. The precise mechanisms by 
which this occurs has not been resolved.
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1.8 Green Fluorescent Protein
Green fluorescent protein (GFP) is a 27 kDa polypeptide phosphoprotein from 
Aequorea victoria that emits green light with emission maximum of 509 nm upon 
fluorescent excitation at 488 nm. Its crystal sturucture has been reported by Oemo et 
al., (1996). Prior to its use as a bioluminescent reporter the study of cellular 
dynamics of GPCRs was limited to two main strategies.
a) Before GFP
The first strategy was the use of fluorescent labelling of GPCR ligands. There are 
obvious advantages of fluorescence over radioactivity measurements, however, there 
are also some disadvantages of this method. The pharmacological specificity and 
potency (if possible) of the fluorescently labelled ligand should be preserved but, 
unfortunately, the most appropriate ligands for this are antagonists. Atlas et al., 
(1976, 1978) have developed fluorescently labelled forms of the p-antagonist 
propranolol and a BIODIPY-CGP 12177 derivative has been developed by Heithier et 
al., (1994), which is also an antagonist at pi- and p%- ARs. Therefore, there are 
limited studies on agonist stimulations at GPCRs (in particular p-ARs) and their 
subsequent cellular trafficking. Quantitation and visualisation of specific ligand- 
receptor complexes in intact cells by fluorescence measurements have also been 
compormised by a too weak signal, high levels of tissue autofluorescence, and a lack 
of fluorescent staining specificity. Sometimes the cell can be swamped with 
flourescent ligand and thorough washing of the cells can be required if there is little 
change in fluorescence intensity upon binding of ligand to the GPCR. Some of these 
problems are being overcome and in time this method may be used for studying 
populations of receptors and their cycling within intact live tissue (McGrath et al.,
1996).
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Immunochemical detection of GPCRs is an alternative approach. This involves use of 
an antisera to certain peptide sequences within the GPCR or to a peptide tagging 
sequence engineered onto the N or C terminus of the protein. Many tags are available 
eg, HA, FLAG™, c-myc and VSV. Generally these tags do not alter the properties of 
the receptor. One disadvantage of this strategy is that fixed cells which have been 
permeabilised (to allow antibody access to potentially internalised GPCR) need to be 
used and, hence, this limits use of real time, dynamic, cell imaging (Milligan, 1999).
b) Studies using GFP as a bioluminescent reporter
The use of GFP as a bioluminescent reporter has overcome the dificulty in monitoring 
GPCR trafficking within living cells in real time. Several studies using GPCR-GFP 
fusion proteins has allowed time optical measurement of GPCR trafficking in 
response to agonist stimulation in live cells stably expressing the construct. These 
GPCRs include the p2 “AR (Barak et al., 1997; Kallal et al., 1998; McLean and 
Milligan, 1999) and a CAM-P2 -AR (McLean et al, 1999), the cholecystokinin type A 
receptor (Tarasova et al., 1997), the thyrotropin releasing hormone receptor (TRHR- 
1) (Milligan, 1998;Drmotaetal., 1998, 1999), the oia-A R (Hirasawa et al., 1997), 
the aiB-AR (Hirisawa et al., 1997; Awaji et al., 1998), the vasopressin V2 receptor 
(Schulein et al., 1998), the parathyroid hormone receptor (Conway et al., 1999), the 
CXCR-1 chemokine receptor (Barlic et al., 1999) and the Ca^+-sensing receptor 
(Gama and Breitwieser, 1998).
Colocalisation experiments of some of these GFP-tagged receptors have been carried 
out with markers known to enter cells. For example, transferrin which enters cells via 
the constitutive endocytic pathway, has been labeled with various markers, which 
fluoresce red, (eg, rhodamine, Cys3, Texas red or Alexa^95) to look at its 
colocalisation with various receptors. This is to determine if the receptor being
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studied enters the cell through the same pathway as the known pathway of transferrin 
receptor cell entry. Merging of the red (transferrin) and green (receptor) images 
produces a yellow image if the two proteins colocalise (Tarasova et al., 1997; Drmota 
et al., 1998; Kallal et al., 1998; Awaji et al., 1998). A second protein used for 
determining the fate of receptors is fluorescently labelled dextran which is 
preferentially sorted to late endosomes or lysosomes (Kallal et al., 1998).
Other colocalisation studies have been performed using GFP-tagged j3-arrestin 
proteins. These are the proteins which assist GRKs in thier ability to phosphorylate 
and desensitise GPCRs in an agonist-dependent manner. This type of experiment was 
initiated by studies invoving a p-arrestin 2-GFP colocalising with the p2 ~AR at the 
plasma membrane following agonist treatment of HEK293 cells transiently expressing 
the two constructs (Barak et al, 1997). The gonadotrophin releasing hormone 
(GnRH) receptor is resistant to short-term desensitisation. Following agonist 
stimulation at this receptor a p-arrestin 1-GFP construct was not redistributed to the 
plasma membrane (Vrecl et al., 1998). However, stimulation of the TRHR-1 
receptor stably expressed in HEK293 cells did result in redistribution of a transiently 
expressed p-arrestin 1-GFP construct (Milligan et al., 1998; Vrecl et al., 1998; 
Groarke et al., 1999). Groarke et al., (1999) have also demonstrated that p-arrestin 
1-GFP stably expressed in HEK293 cells is again redistributed when a transiently 
expressed TRHR-i receptor is stimulated with TRH. Several other studies on 
GPCRs interacting with p-arrestins have been performed (Dery etal., 1999; Mhaouty- 
Kodjaetal., 1999; Zhang etal., 1999).
c) Studies using GFP pairs
Until recently, it was not possible to label more than one protein at a time using GFP 
since there were no suitable variants of the protein that fluoresced at different
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wavelengths. Therefore, the immunofluorescence studies in fixed cells, already 
outlined, would be the only option to study 2  proteins or more at any one time in a 
cell. However, there are now several GFP mutant forms available which emit 
different wavelengths of light giving different colours in addition to green light, eg. 
blue, cyan (Heim et al., 1994), yellow and red. Table 1.3 diplays the GFP variants 
used in double labelling experiments so far. W7/ECFP and lOC/EYFP have been 
used as double label pairs to label 2 distinct proteins in NRK cells. It was shown that 
a GFP variant lOC-labelled nuclear envelope marker, lamin B receptor (LBR-IOC) 
could be detected in the same cell as a golgi complex marker, galactosyltransferase 
fused with the W7 variant of GFP. Cells were also imaged expressing LBR-IOC and 
the chromatin marker, histone 2B fused to ECFP (H2B-ECFP) (Ellenberg et al, 1998; 
Ellenberg et al., 1999). GFP pairs have also been used for FRET (fluorescence 
resonance energy transfer) experiments in which fluorescent indicators for Ca^+ 
termed ‘caméléons’ were constructed. These consisted of tandem fusions of blue or 
cyan-emiting GFP, calmodulin, the calmodulin-binding peptide M13 and enhanced 
green or yellow-emiting GFP. Binding of Ca^+ caused calmodulin to wrap around 
M13 increasing FRET between the flanking GFPs (Miyawaki et al., 1997). 
Therefore, this development has opened up an exciting avenue for monitoring the 
interaction of proteins within living cell systems.
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Table 1.3 Some GFP variants used in double labelling and their nomenclature^.
Variant
name
Colour Ëx/eiîi Amino acid changes Commercial
availability
p 4-3 blue 381/445 Y6 6 H, Y145F No
BFPsg50/
BFP
blue 387/450 F64L, Y6 6 H, V163A Q
EBFP blue 380/440 F64L, S65T, Y6 6 H, Y145F"''' c
W2 cyan 432/480 Y6 6 W, I123V, Y145H, H148R, 
M153T,V163N, N212K
No
W7 cyan 434/474 Y6 6 W, N146I, M153T, V163A, 
N212K’’
No
ECFP cyan 434/474 K26R, F64L, S65T, Y6 6 W, 
N146I, M153T, V163A, 
N164H, N212K‘’'‘*
C
S65T green 489/511 S65T C
GFPsg25/
rsGFP
green 473.509 F64L, S65C, I167T, K238N Q
EGFP green 488/507 F64L, S 6 5 r’“ c
IOC yellow 514/527 S65G, V6 8 L, S72A, T203Y No
EYFP yellow 514/527 S65G, V6 8 L, S72A, T203Y'"’ C
‘^ Abbreviations: Ex, excitation peak; Em, emission peak; GFP, green luorescent
protein. Suppliers: C, Clontech Inc., Palo Alto, CA, USA; Q, Quantum 
Biotechnologies, Montreal, Canada.
’’Has the Q80R mutation that does not change the spectrum.
‘’Variant has one valine residue inserted at position 2, which is not counted. 
‘’Variant has the H231L mutation that does not affect the spectral properties. 
(Table adapted fiom Ellenberg et al., 1999)
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Chapter 2
Methods
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2.1 Materials
All reagents employed were of the highest grade possible and were obtained from the 
following suppliers.
a) General reagents, enzymes and kits
Alexis Corporation San Diego. CA, USA 
[DL-Dithiothreitol] DTT
Bio-Rad Laboratories Ltd., Hemel Hempstead, Hertfordshire, UK 
Ammonium persulphate (APS)
Calbiochem, CN Biosciences UK, Nottinsham. UK 
H89, 0418, Rp cAMP.
Fisher Scientific, Loushboroueh, Leicestershire. UK
Sucrose, EDTA, glacial acetic acid, sodium chloride, calcium chloride, concentrated 
HCl, glucose, potassium di-hydrogen orthophosphate, magnesium sulphate, calcium 
chloride, HEPES, DMSO, sodium dodecyl sulphate, glycine, methanol, ethanol, 
sodium hydroxide, trichloro acetic acid.
ICN Pharmaceuticals Ltd., Basinsstoke, Hants, UK 
Betaxolol
Merck Ltd.. Poole, Dorset, UK
Glycerol, potassium chloride, di-sodium hydrogen orthophosphate, bacto-agar, bacto- 
tryptone, bacto-yeast extract.
Promesa UK Ltd,, Southampton, UK
T4 ligase, pfu, CIAP, restriction enzymes, SV mini-prep kit, Wizard™ maxi-prep kit. 
Ouiasen, Crawley, West Sussex 
Gel purification kit.
RBI, Natick, MA., USA 
CGP12177
Roche Molecular BiochemicalslBoehrinsr Mannheim, Mannheim, Germany
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DNA molecular weight marker X, Tris, restriction enzymes 
Sisma-Aldrich Comvam Ltd.. Poole, Dorset, UK
Agarose, bromophenol blue, forskolin, manganese chloride, ethidium bromide, 
DMEM (powder), poly-D-lysine, trypsin, Triton X-100, TEMED, acrylamide, 
bisacrylamide. Tween 20, isoprenaline, alprenolol, propranolol, labetolol, 
dihydroalprenolol, ÏCI118551, imidazole, cAMP, ATP, MOPS, rubidium chloride, 
Dowex, alumina. Ponceau S, bovine serum albumin, mineral oil, sodium tartrate, 
parpformaldehyde, phenol red, AEBSF [4-(2-Aminoethyi)benzenesulfonyi fluoride], 
apoprotinin, pepstatin A, leupeptin.
Whatman international Ltd., Maidstone, UK 
GF/C Glass fibre filters.
b) Tissue culture plastic ware
Costar, Cambridse, MA., USA
75 cm^ tissue culture flasks, 25 cm^ tissue culture flasks, 6  cm and 1 0  cm tissue 
culture plates, 6 , 12, 24 and 96 well plates, biofreeze vials,
Merck Ltd., Poole, Dorset, UK 
Coverslips
c) Tissue culture reagents
GIBCO BRL, Life Technolosies Ltd., Paisley, UK
New bom calf serum, OPTIMEM, glutamine (200 mM), Lipofectamine transfection 
reagent.
Roche Molecular Biochemicals/Boehrinser Mannheim. Mannheim, Germany 
Dotap transfection reagent.
Sisma-Aldrich company Ltd., Poole, Dorset, UK
Dulbecco’s modification of Eagle’s medium (1 x), minimal essential medium (1 x).
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d) Radiochemicals
Ny corned Amer sham pic.. Little Chalfont. Buckinehamshire, UK
1) pH] DHA (64 Ci/mmol)
( l-[propyl-2,3-^H\ Dihydroalprenolol)
2) (-)-pH]CGP-12177 (44 Ci/mmol)
[(-)-4-(3-t-butylaminO"2-hydroxypropoxy)-[5,7-3H] Benzimidazol-2-one].
3) [2-3H]Adenine (23 Ci/mmol, 1 mCi/ml)
e) Antisera
Clontech. Palo Alto. CA 94303-4230, USA
Anti-GFP - rabbit polyclonal IGg (Img/ml), recognises GFP and various mutant 
forms.
New England Biolabs, Inc., Beverly, MA 01915-5599, USA 
PhosphoPlus CREB (Serl33) Antibody kit 
Ny corned Amer sham pic.. Little Chalfont, Buckinghamshire, UK 
Anti rabbit IgG (horse radish peroxidase)
Santa Cruz Biotechnology, Inc., Santa Cruz, California 95060, USA
Anti-pi-AR (A-20) - rabbit polyclonal IgG (200 |ig/ml), mapping to the C terminus of
the human Pi-AR.
Anti-P2-AR (H-20) - rabbit polyclonal IgG (200 pg/ml), mapping to the C terminus of 
the human P2 -AR. Cross reacts with pg-ARs.
f) Oligonucleotides
Oswel DNA Service, Bolderwood, Southampton, UK
All oligonucleotides used to synthesise receptor-GFP constructs were diluted to a 
stock concentration of 100 pmol/mg and stored at -20 °C
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2.2 Buffers and Reagents
a) Reagents for molecular biology 
Gel loading buffer (6x)
For 10 mi:
Bromophenol Blue (2%) 1.25 ml
Sucrose 4 g
Dissolve in sterile H2 O and store at 4 °C 
TAE buffer (50x)
Tris-acetate (40 mM) 242 g Tris
EDTA (1 mM) 100 ml of 0.01 M (pH 8 )
glacial acetic acid 57.1  ml
Dilute to a final volume of 1 litre. This stock was diluted to a Ix solution when 
required.
Liquid broth (LB)
For 1 litre:
Bacto-tryptone 10 g
Bacto-yeast extract 5 g
NaCl 10 g
Dissolve in deionised water and pH to 7.0. Sterilise by autoclaving at 126 °C.
b) Assay buffers
Phosphate buffered saline (10 x)
137 mM NaCl 80 g
2.7 mMKCl 2 g
1.5 mM KH2PO4  2 g
8  mM Na2 HP0 4  11.4 g
Make up to 1 L in H2 O, pH 7.4. Dilute 1:10 to make a 1 x solution.
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Binding wash buffer (TE)
75 mM Tris 45.4 g
ImMEDTA 1.86 g
Make up to 5 L, pH 7.4 with concentrated HCl.
Binding assay buffer (TEM)
75 mM Tris 45.4 g
ImMEDTA 1.86 g
12.5mMMgCl2 12.7 g
Make up to 5 L, pH 7.4 with concentrated HCl
Krebs-Ringer-HEPES buffer
130 mM NaCl 7.0 g
5 mMKCl 0.37 g
1.2 mM MgS0 4 0.3 g
1.2 mM CaCl2 0.26 g
20 mM HEPES 4.76 g
1.2 mM Na2HP0 4 0.17 g
10 mM glucose 0.9 g
0.1 % (w/v) BSA 0.5 g
Make up to 500 ml in H2 O, pH 7.4,
Cyclase assay medium 
(for 1 0 0  ml in H2 O)
DMEM 1.34 g
HEPES 0.48 g
glutamine (0.292 g/L) 1.00 ml 
IBMX(lOOmM) 1.00 ml
pH to 7.4 with 5 M KOH
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Cyclase stop solution
(for 250 ml in H2 O)
TCA 12.5 g
cAMP 8 8  mg
ATP 137.5 mg
2.3 Molecular Biology
a) LB ampicillin agar plates
This has the same composition as LB but with bacto-agar (1.5% w/v) added. After 
autoclaving, it was left to cool before ampicillin was added to a final concentration of 
50 pg/ml. The liquid LB agar was poured into 10 cm diameter petri dishes, and 
allowed to solidify before storing at 4 ®C. LB ampicillin agar plates can be stored for 
up to 3 weeks without any loss of antibiotic activity.
b) Preparation of competent bacteria
The strain of E. coli used for transformation is DH5a, which can take up and express 
the vector pcDNA3 containing a particular cDNA. Multiple copies of this are 
produced by the bacteria which can be purified from cultures. For the DH5a to take 
up the DNA it has to be made competent. To make E. coli receptive or competent for 
foreign DNA entry the cells are treated with the following chemicals.
Solution 1 (for 100 ml)
1 M Potassium acetate 3.00 ml
IMRbCla 1 . 0 0  ml
IM C aC b 1 .0 0  ml
lM M nCl2  5.00 ml
80% (w/v) glycerol 18.75 ml
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The final volume was made up to 100 ml with deionised water and pH adjusted to 5.8 
with 100 mM acetic acid. The solution was filter-sterilised and stored at 4°C. 
Solution 2 (for 40 ml)
100 mM MOPS pH 6.5 4.00 ml
IM C aC h 3.00 ml
IM RbCla 0.40 ml
80% (w/v) glycerol 7.50 ml
The final volume was made up to 40 ml with deionised water and pH adjusted to 6.5 
with cone HCl. The solution was filter-sterilised and stored at 4 °C .
DH5a cells were streaked out on an agar plate with no antibiotics and grown 
overnight at 37 °C. A single colony was grown in 5 ml of L broth overnight at 37 °C, 
and this was subed into 100 ml of L broth and grown until the optical density at 550 
nm was 0.48. After chilling on ice for 5 min the cells were spun at 2-3 K for 10 min 
at 4 °C in 50 ml sterile falcon tubes. Each pellet was resuspended in 20 ml of solution 
1 by pipetting, then chilled on ice for 5 min and spun as before. Each pellet was then 
resuspended in 2 ml of buffer 2 by pipetting and chilled on ice for a further 15 min. 
Cells were aliquoted and stored at -80 °C.
c) Transformation of competent cells with plasmid DNA
Between 10-100 ng of DNA was incubated with 50 pi of competent cells on ice for 15 
min. The cells were then heated for 90 seconds at 42 °C and returned to ice for 2 min 
prior to addition of 800 pi of L broth. Cells were then allowed to recover by 
incubation at 37 ®C for 1 h in a shaking incubator. After spinning at 13K for 5 min 
the cell pellet was resuspended in 200 pi of L broth and 50-200 pi was spread on an 
agar plate containing 50 pg/pl ampicillin. Plates were incubated overnight at 37 °C 
and transformed colonies selected and grown up overnight in 5 ml of L broth 
containing 50 pg/pl ampicillin.
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d) Preparation of plasmid DNA
i) miniprep
Plasmid cDNA was prepared using the Promega™ Wizard Plus SV miniprep 
purification system. Briefly transformed bacterial cells from a 5 ml culture were spun 
and the pellet resuspended in resuspension solution [50 mM Tris-HCl, (pH7.5), 10 
mM EDTA, 100 pg/ml RNase A], followed by cell lysis with lysis solution (0.2 M 
NaOH, 1 % SDS). The resulting lysate was then neutralised with neutralisation 
solution (4.09 M guanidine hydrochloride, 0.759 M potassium acetate, 2.12 M glacial 
acetic acid, pH4.2) to precipitate out unwanted chromosomal DNA. This was 
removed by centrifugation and the resulting supernatant was loaded onto a DNA 
purification column. Washing was performed with ethanol column wash (60 mM 
potassium acetate, 10 mM Tris-HCl, pH 7.5, 60 % ethanol) followed by elution with 
sterile water (100 pi at a concentration of 0.1-0.5 pg/pl)
ii) maxiprep
A similar method of purification was achieved but on a larger scale using the 
Promega"^" maxiprep system. Plasmid cDNA was purified from a 500 ml culture to 
yield approximately 1 ml of DNA at a concentration between 0.5-2.0 pg/pl.
e) Quantitation of DNA
The concentration of DNA in a given sample was determined by measuring the 
absorbance at 260 nm (A2 6 0 ) of a 1:200 dilution of the sample in sterile H2 O, 
assuming 1 absorbance unit was equivalent to 50 pg/ml of double stranded DNA. 
The purity of DNA was assessed by measuring the A2 8O in parallel and calculating the 
A260-A280 ratio. A ratio of approximately 1.8 for DNA was considered to be 
sufficiently pure for use.
f) Digestion of plasmid DNA with restriction endonucleases
Plasmid DNA, generally 1 or 10 pg was digested in a volume of 10 or 50 pi 
respectively using buffer conditions recommended by the manufacturers instructions
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and with 4-10 units of appropriate restriction enzymes at 37 °C for 4 hours to 
overnight. Specific digestions used in this study to make constructs are detailed in 
Section 2.4.
g) Separation of digested plasmid DNA by electrophoresis
Digested DNA was routinely analysed by agarose gel electrophoresis. Samples were 
prepared by addition of 6 x loading buffer to a Ix final concentration. Samples 
between 0.5 and 5 kb were electrophoresed through 1 % (w/v) agarose gels 
containing 1 x TAE buffer and 2.5 mg/ml ethidium bromide. Electrophoresis was 
carried out towards the anode at 75-100 mA at room temperature in a horizontal 
electrophoresis tank containing 1 x TAE buffer. Ethidium bromide stained DNA 
fragments were visualised under UV light and photographed. Size was assessed by 
comparison with a 1 kb ladder. To isolate fragments for gel purification a sterile 
scalpel blade was used to excise the fragment from the gel.
h) Purification of DNA from agarose gels
To purify agarose gel fragments between 70 bp and 10 kb a Quiagen QIAquick gel 
purification kit was used. This involved melting of the gel fragment in QIAquick 
buffer (QG) followed by addition of isopropanol. The solution was loaded onto a 
purification column and washed with an ethanol based wash solution (PE). Elution of 
the DNA fragment was performed in sterile H^O.
i) Phoshphatase treatment of DNA fragments
For one-site cloning procedures it was necessary to phosphatase treat the cut cloning 
vector so that it cannot recircularise. Removal of the 5’ phosphate group was 
achieved by using calf intestinal alkaline phosphatase (CIAP from Promega). CIAP 
treatment was performed using 2.0 units of enzyme in a buffer (50 mM Tris-HCl, pH
9.3,1 mM MgCl2 , 0.1 mM ZnCl2 , 1 mM spermidine) at 37 °C for 2 h. The reaction 
mixture was ran on a 1 % agarose gel and the vector isolated by gel purification.
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j) Ligation of DNA fragments
Ligation of vector DNA was routinely carried out overnight at 4 in a reaction 
volume of 20 p,l containing Ix ligation buffer (30 mM Tris-HCl, pH 7.8, 10 mM 
MgCl2 , 10 mM DDT, 1 mM ATP), 3 units of T4 DNA ligase plus vector and insert 
DNA fragments. Reactions were performed using ratios of vector:insert of 1:1, 1:3 
and 1:6. Ligated DNA was transfonned as described in 2.3d.
k) Polymerase chain reaction
Amplifications were routinely performed in a reaction volume of 50 pi containing 20 
ng of DNA template, dNTPs (0.2 mM each dATP, dCTP, dGTP and dTTP), 25 
pmoles each of sense and anti sense oligonucleotide primers, Ix thermophilic buffer 
(20 mM Tris-HCl, pH 8.2, 10 mM KCl, 6  mM (NH4 )2S0 4 , 2 mM MgCh, 0.1 % 
Triton X-100, 10 pg/ml BSA). Samples were overlaid with light mineral oil to 
prevent evaporation, and the reaction was carried out on a Hybaid Omnigene thermal 
cycler. Pfu DNA polymerase (3 units) was added after the reaction mixture had been 
heated to 95 for 5 min. PCR conditions in preparation of receptor-GFP fusion 
constructs (Section 2.4) are outlined in Table 2.1.
2.4 Construction of GPCR-GFP fusion constructs
a) WT-P2 -AR-GFP
A MrttflII-Signal-FLAG-P2 -AR-GFP-jEc<?RI construct was a kind gift from Glaxo 
Wellcome, Stevenage.
b) CAM-P2 -A R-G FP
Human wild-type p2 "AR in pcDNA3 was amplified by PCR using a Hmt/IH-FLAG 
forward primer, 5’-AAAAAAAAGCTTGCCACCATGGACTACAAGGACGACGA- 
TGATAAGGGGCAACCCGGGAACGGC-3’, and a Barnm reverse primer, 5’-AA-
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Table 2.1 PCR Conditions for construction of Receptor-GFP fusions
Template Step 1 
(1 cycle)
Step 2 
(20 cycles)
Step 3 
(I cycle)
WT-pî-AR 95 T ,  5 min 95 °C, 1 min 
60 °C, 1 mill 
72 “C, 2  min
72 T ,  10 min
CAM-Pz-AR
BARK-p2-AR
95 ‘‘C, 5 min 95 ”C, 1 min 
55 T ,  1 min 
72 T , 2 min
72 T ,  10 min
GFP 95 T ,  5 min 95 °C, 1 min 
60 °C, 1 min 
72 °C, 4 min
72 °C, 10 min
AU PCRs were performed using pfu DNA polymerase, in a final volume of 50pl. 
Reactions contained, 20 ng of DNA template, 25 pmoles of each primer, 0.2 mM 
dNTPs and 10 % DMSO.
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AAAGGATCCTCCCGCCAGCAGTGAGTCATTTGTA-3’. This removed the stop 
codon and the initiating methionine (start codon) of the P2 -AR, with an initiator ATG 
being present in the N-terminally added FLAG epitope tag (ATG GAC TAG AAG 
GAC GAC GAT GAT AAG). The PCR product was digested with HindlW and 
BamWl and the resulting fragment ligated into pcDNA3. The sequence encoding 
amino acids 172 to 291 was restricted from this construct using KpnVHpal and 
replaced by the equivalent region of the CAM-P2 -AR (Samama et al., 1993, 1994). A 
modified form of GFP (Zernicka-Goetz et al., 1997) was also amplified by PCR 
using aRawHI forward primer, 5’-AAAAAGGATCCAGTAAAGGAGAAGAACTT- 
TTC-3’, and an Xbal reverse primer, 5’-TGCTCTAGATTATTTGTATAGTTCATC- 
CATGCCATG-3 ’. This removed the initiating methionine of GFP, and the resulting 
PCR product was digested with BamYQ. and Xbal and linked in frame to generate the 
CAM- P2 -AR construct.
c) W T -P i-A R -G F P
Human WT-pi-AR in pcDNA3 was amplified by PCR using a M/ztflll-FLAG 
forward primer, 5’-AAAAAAAAGCTTGCCACCATGGACTACAAGGACGACGA- 
TGATAAGGGCGCGGGGGTGCTC-3’ and a BarrMl reverse primer 5’-AAAAAG- 
GATCCTCCCGCCCACCTTGGATTCCGAGGC-3% This removed the stop codon 
and the initiating methionine (start codon) of the Pi-AR, with an initiator ATG being 
present in the N-terminally added FLAG epitope tag (ATG GAC TAC AAG GAC 
GAC GAT GAT AAG). The PCR product was digested with Hindlll and BaniYll 
and the resulting fragment ligated into pcDNA3. The BarriYlllXbal GFP fragment 
generated previously was linked in frame to generate the WT-pi-AR-GFP.
d) BARK “-p2“A R -G FP
Human BARK"-p2 -AR in pcDNAS was amplified by PCR using a Mndlll-FLAG 
forward primer, 5’-AAAAAAAAGCTTGCCACCATGGACTACAAGGACGACGA- 
TGATAAGGGGCAACCCGGGAACGGC-3’, and a BamYil reverse primer, 5’-AA-
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AAAGGATCCTCCCGCCAGCAGTGCGTCATTTGC. This removed the stop 
codon and the initiating methionine (start codon) of the BARK"-P2 “AR, with an 
initiator ATG being present in the N-teiminally added FLAG epitope tag (ATG GAC 
TAC AAG GAC GAC GAT GAT AAG). The PCR product was digested with 
Hindlll and BanMl and the resulting fragment ligated into pcDNAS. The 
BamirnXbal GFP fragment generated previously was linked in frame to generate the 
BARK-P2 -AR-GFP.
All constructs were sent to the Department of Genetics, University of Glasgow, UK 
for sequencing.
2.5 Routine Cell Culture
a) Cell growth
The parental cell line used for this study was Human Embryonic Kidney (HEK293) 
cells. It was grown in 75 cm^ tissue culture flasks in Minimal Essential Medium 
(MEM) supplemented with 0.292 g/L L-glutamine and 10% Newborn Calf Serum 
(NBCS). Cells were incubated in cell culture incubators with a humidified 
atmosphere of 5 % C02/95 % air at 37 °C.
b) Cell subculture
Confluent cells were passaged using a sterile trypsin solution (0.1% w/v trypsin, 
0.025% w/v EDTA, and 10 mM glucose). Growth media was removed from the cells 
and 2 ml of trypsin solution added. When the cells had detached from the surface of 
the flask, trypsinisation was stopped by the addition of 8  ml of growth medium. This 
cell suspension was mixed gently and split into fresh flasks or dishes as required.
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c) Coating of plates with poly-D-lysine
50 mg of poiy-D“lysine was diluted in 50 ml of sterile H2 O to make a 1 mg/ml 
solution which was stored at 4 ®C. To coat tissue culture plates or coverslips the 
required amount was diluted 1:10. This resulting 0.1 mg/ml solution was left on 
plates or coverslips for 1 0  min then removed and the plates rinsed with sterile H2 O.
d) Transient transfections
Transient transfections of DNA into HEK293 cells were achieved using 
Lipofectamine™ reagent (Gibco Life Technologies) according to the manufacturers 
instructions.
i) Transfection of cells in 10 cm dishes
Briefly, cells were split into a required amount of 10 cm dishes and grown to 60-80% 
confluency. For each dish 10 pg of DNA was used. 0.1 mg/ml DNA stock solutions 
were made up in sterile water.
For a hypothetical transfection DNA mixes are as follows:
Transfection Mock
pcDNAS
(plasmid) 25 pi 1 0 0  pi
DNA 75 pi -
Optimem 500 pi 500 pi
TOTAL 600 pi 600 pi
A Lipofectamine™/optimem mix was also made up in a ratio of 10:190. 600 pi of this 
was used for each transfection. The 600 DNA mix was incubated with the 600 pi 
of Lipofectamine™ mix for 30 min at room temperature. Once the cells were washed 
with optimem, 4.8 ml of optimem was added to each incubation and the resulting 
mixture added gently to the plate. After 5 h incubation in a cell culture incubator, 6  ml
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of DMEM containing 20 % NBCS was added to the dish, and left overnight in the 
incubator. On the following morning, the DNA/Lipofectamine™ mixture was 
removed and replaced with about 10 ml of growth medium. The cells were incubated 
for a further 24 to 48 h before they were harvested or assayed.
ii) Transfection of cells on cover slips in 6 well plates
One pg of DNA was transfected into each well. A 0.1 mg/ml stock solution of DNA
was prepared in sterile H2 O. For 1 cover slip the following mixes were prepared:
DNA mix Lipid mix 
DNA (1 mg/ml) 15 pi
Lipofectamine^^ - 5
Optimem 35 pi 95 pi
TOTAL 50 pi 100 pi
These two solutions were combined and incubated at room temperature for 30 min. 
To stop the incubation 850 pi of optimem was added to the mixture and the resulting 1 
ml added to the appropriate well after it had been washed with optimem. After 5 h, 2 
ml of 10% NBCS/MEM was added to the well and left overnight. On the following 
morning the DNA/Lipofectamine mixture was removed and replaced with 3 ml of 
growth medium. The cells were left for a further 24 h before viewing on a fluorescent 
or confocal microscope.
e) Génération and maintenance of stable cell lines
Generation of stable cell lines involves selecting isolated colonies of cells which have 
incorporated the transfected DNA into their chromosomes. This is achieved using a 
selection antibiotic that kills all cells except those that have resistance conferred to 
them from the antibiotic resistance gene present in the plasmid carrying the cDNA to 
be expressed.
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The transfection protocol for stable transfection is the same for that of transient 
transfection into 10 cm dishes except that 10 % NBCS/DMEM was used instead of 
optimem. After 24 h the medium was changed to normal cell culture medium (10% 
NBCS/MEM). After a further 24 h the stable transfections were split 1:4 into new 10 
cm dishes in medium containing 1 mg/ml G418 sulphate. This medium was renewed 
every 3 days to maintain selection in order to obtain resistant clones. A plate of 
parental HEK293 cells of similar confluency to the transfected plates was used as a 
negative control to determine the rate of cell death. After 7 to 10 days, when all 
untransfected HEK293 cells in the control dish were dead, isolated clones of cells in 
the transfected dishes were picked. Approximately 50 clones for each transfection 
were picked by scraping with sterile blue tips and drawing up 0.5 ml of medium. The 
clones were transferred to a 24 well plate in 1 ml of G418 medium (1 mg/ml) per well. 
Medium again was renewed every 3 days.
Once the clones were confluent they were transferred to one well of a 6  well dish then 
to a 25 cm2 flask and eventually into 2 x 75 cm2 flasks. In the case of the GFP 
tagged constructs, clones from 24 well plates were split into one well of a 6  well plate 
and one well of a 6  well plate containing a poly-D-lysine coated cover slip. Each 
cover slip was examined in a fluorescent microscope and those clones which 
fluoresced expanded into a 25 cm2 flask and eventually into a 75 cm2 flask. For the 
non GFP-tagged constructs, one 75 cm2 flask was harvested for assaying receptor 
levels and the other was expanded. Once the desired clones were obtained frozen cell 
stocks were made.
f) Preservation of cell lines
Stable cell lines were preserved in the earliest passage possible. Cells in 75 cm2 
flasks were grown to confluency before trypsinisation as in Section 2.5b. After 
addition of 8  ml of cell culture medium to the detached cells the resulting mixture was 
collected in a 10 ml falcon tube and centrifuged at 800 x g for 5 min. The cell pellet
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was suspended in 1 ml of NBCS with 7.5 % DMSO (as a cryo-protectant). The cell 
suspension was transferred into a 1.5 mi cryovial. This was frozen overnight packed 
in cotton wool at -80 and then transferred the following day to liquid nitrogen.
Cells to be resurrected were thawed at room temperature and resuspended in 10 ml of 
growth medium. After centrifugation at 800 x g for 5 min to remove traces of DMSO, 
the cell pellet was resuspended in 1 ml of growth medium and transferred to a new 75 
cm^ flask containing 1 0  ml of fresh growth medium.
g) Cell harvesting
Cells were harvested firstly by removing the growth medium and rinsing once in ice 
cold PBS buffer. In the case of cells having undergone long term drug treatments 
cells were washed 3 times. Using a disposable cell scraper, the cells were scraped 
off the base of the flask or 10 cm dish in 5 ml of PBS buffer. The cell suspension 
was collected into a 10 ml or 50 ml falcon tube along with a further 5 ml wash from 
the flask or plate. The tubes were centrifuged at 800 x g at 4 ®C for 5 min. The cell 
pellets were stored at -80 °C until required for membrane preparation.
2.6 Protein Biochemistry
a) Production of crude plasma membranes
Frozen cell pellets were thawed and suspended in 5 volumes of ice-cold TE buffer, 
then homogenised with 50 strokes of a ground glass on teflon homogeniser to rupture 
the cells. Unbroken cells and nuclei were removed by centrifugation at low speed 
(1200 rpm) in a refrigerated microcentrifuge. The supernatant fraction was then 
centrifuged at 75 000 rpm for 30 min in a Beckman Optima TLX Ultracentrifuge (Palo 
Alto, CA) with a TLA 100.2 rotor. The pellets were resuspended in TE and passed
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through a syringe attached to a 25 gauge needle. Membranes were diluted to a final 
concentiation of 1-5 mg/ml and stored at -80 until required.
b) Protein determination by BCA assay
To determine protein concentration of purified membrane preparations a method using 
bincinchoninic acid (BCA) and copper sulphate was used. Proteins reduce alkaline 
Cu(II) to Cu(I) in a concentration-dependent manner. Bicinchoninic acid is a highly 
specific chromogenic reagent for Cu(I), forming a purple complex with an absorbance 
maximum at 562 nm. The absorbance is directly proportional to the protein 
concentration. Known concentrations of bovine serum albumin (BSA) were used as 
standards (0 .1-2 . 0  mg/ml).
REAGENTA
1 % (w/v) BCA 10 g
2  % (w/v) Na^COg 2 0  g
0.16 % (w/v) sodium tartrate L6 g
0.4 % NaOH 4 g
0.95 % NaHCOg 9.5 g
Make up to one litre with H2 O, pHl 1.25 with 50 % NaOH.
REAGENT B 
4 % CUSO4
Mix 49 parts A with 1 part B and add 200 pi to each well of a 96 well plate containing 
10 pi of protein sample or standard. After incubation at 37 °C for 30 min, the 
absorbance was read.
c) Sample preparation for SDS-PAGE gel electrophoresis
i) Membrane protein samples were diluted to a final concentration of 2 mg/ml in TE 
buffer. This protein sample was then diluted in Laemmli buffer (5 M urea, 0.17 M
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SDS, 0.4 M dithiothreitol, 50 mM Tris-HCl, pH 8.0 and 0.01 % bromophenol blue) 
to a final concentration of 1 mg/ml. After boiling the sample for 5-10 min 10 to 20 pg 
of protein was loaded into each well of a SDS-PAGE protein gel.
ii) Cell lysate samples were prepared as follows. Cells from a 6  cm dish were 
washed in PBS after the appropriate drug treatment. Cells were lysed in 500 pi of ice 
cold lysis buffer (25 mM HEPES, pH 7.4, 5 mM EDTA, 50 mM NaCl, 30 mM 
sodium pyrophosphate, 50 mM NaP, 1 % (v/v) TX-lOO, 10 % (v/v) glycerol) 
containing protease inhibitors (final concentrations of 1 mM sodium vanadate, 1 mM 
AEBSF, 2 pg/ml apoprotinin, 2 pg/ml pepstatin A, 2 pg/ml leupeptin). For a further 
20 min the extract was lysed in an Eppendorf tube while spinning on a rotating wheel 
at 4 °C. The sample was then centrifuged at 4 °C for 10 minutes at 13 K and 150 pi 
of the supernatant was added to 50 pi of 4x sample buffer (0.25 M Tris, 8  % (w/v) 
SDS, 50 % (v/v) glycerol, 0.4 M DTT, 0.02 % phenol red, pH 6 .8 ). After boiling 
the samples for 1 0  min, 2 0  pi was loaded on the gel.
d) SDS-PAGE gel electrophoresis
Resolving polyacrylamide gel: 10 % (v/v) acrylamide, 0.27% (v/v) bisacrylamide, 
with 0.75 M Tris (pH8 .8 ), 0.1 % (w/v) SDS, 0.01 % (w/v) ammonium persulphate 
and 0.001 % (v/v) TMED.
Stacking gel: 5 % (v/v) acrylamide, 0.13 % (v/v) bisacrylamide, with 0.25 M Tris 
(pH 6 .8 ), 0.1 % (w/v) SDS, 0.01 % (w/v) ammonium persulphate and 0.001 % (v/v) 
TMED.
Running buffer: 25 mM Tris (pH 8.5), 0.192 M glycine and 0.1 % (w/v) SDS. 
Samples were ran at 200 V using a Mini Protean II gel kit (Bio-Rad, Richmond, CA).
e) Western blotting
Following SDS-polyacrylamide gel electrophoresis, proteins were electrophoretically 
transferred onto nitrocellulose at -100 V and 400 mA in transfer buffer (0.2 M 
glycine, 0.025 M Tris and 20 % (v/v) methanol). The membrane was then blocked
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for 1 h in 3 % fat-free milk in PBS-T buffer (PBS containing 0.1 % (v/v) Tween 20). 
After a brief wash in PBS-T buffer, the membrane was incubated overnight at 4 
with an appropriate primary antibody (anti-pi-AR, anti-P2 -AR or anti-GFP) diluted at 
1:2000 in PBS-T buffer containing 1 % fat-free milk. The primary antibody was then 
removed, and the blot was washed extensively in PBS-T buffer. Subsequent 
incubation with secondary antibody (donkey anti-rabbit IgG conjugated with 
horseradish peroxidase) diluted at 1:10 000 in PBS-T buffer containing 1 % fat-free 
milk, was performed for 2 h at room temperature. Following extensive washing in 
PBS-T buffer, the blot was visualised by enhance chemiluminescence. Exposure onto 
photosensitive film was performed. For immunodetection using the phosphoCREB 
antibody in Chapter 5, BSA was used instead of non-fat milk as specified by the 
PhosphoPlus CREB (Ser 133) Antibody Kit (New England Biolabs Inc.).
f) Sucrose-density gradient experiments
CAM-p2 ~AR-GFP cells were collected by low speed centrifugation and washed in ice 
cold PBS. They were then resuspended in 2 ml of ice cold hypotonic lysis buffer (20 
mM Tris-HCl, pH 7.5, 3 mM MgCl2 , 1 mM EDTA) and homogenised for 5 min on 
ice in a Potter-Elvehjem (Teflon-glass) homogeniser. The resulting homogenate was 
adjusted to a final volume of about 7.5 ml with lysis buffer and centrifuged at 600 g 
for 5 min to remove nuclei and cell debris. A portion (7 ml) of this homogenate, 
containing approximately 2 0  mg of protein, was layered on to the top of a 
discontinuous sucrose-density gradient [5 ml each of 19 %, 23 %, 27 %, 31 %, 35% 
and 43 % (w/v) sucrose in hypotonic lysis buffer]. The gradient was centrifuged at 
27 000 rev/min for 60 min in a Beckman SW 28 rotor at 4 °C. Seven 5 ml fractions 
were subsequently collected manually from the top of the gradient. The pellet was 
resuspended in 5 ml of lysis buffer and designated fraction 8 . The fractions were 
stored at -80 ®C until used.
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Distribution of protein and marker-enzyme activities in this type of sucrose-density 
gradient has been described in detail previously (Svoboda et al., 1996; Svoboda et al., 
1992). The first fraction (the first 5 ml from the top of the preformed sucrose 
gradient) represents the soluble cytosolic fraction, the second and third fractions are 
enriched in low-density membranes (light vesicles) and fractions 6  and 7 are 
preferentially enriched in plasma membranes.
g) Electrophoresis and immunoblot analysis
The proteins contained in the fractions were precipitated by incubation with 6  % (w/v) 
trichloroacetic acid on ice for 1 h. The precipitates were dissolved in a small volume 
of buffer B [1 M Tris (base), 0.5 M boric acid, 0,01 M EDTA] and then solubilised in 
an equal volume of Laemmli buffer. In order to resolve CAM-P2 -AR-GFP, a borate- 
based electrophoresis buffer system (Poduslo, 1981) was used, with modifications. 
Briefly, the resolving polyacrylamide gel was made with 10 % (w/v) acrylamide, 
0.0625 % (w/v) bisacrylamide, 0.1 M Tris/0.1 M boric acid (pH 8.5), 0.0025 EDTA, 
0.1 % (w/v) SDS, 0.005 % (w/v) TMED and 0.1 % (w/v) ammonium persulphate. 
The stacking gel was of the same composition, except that it contained 4 % (w/v) 
aciylamide. The borate electrophoresis running buffer was: 0.1 M Tris/0.1 M boric 
acid, 0.0025 EDTA, 0.1 % (w/v) SDS, pH 8.5. Electrophoresis was carried out at 
150 V for 1 h using a Mini Protean II gel kit (Bio-Rad). After SDS-PAGE, proteins 
were electrophoretically transferred onto nitrocellulose at -100 V and 400 mA in 
transfer buffer (0.2 M glycine, 0.025 M Tris and 20 % (v/v) methanol). The 
membrane was then blocked for 1 h in 3 % fat-free milk in PBS-T buffer (PBS 
containing 0.1 % (v/v) Tween 20). After a brief wash in PBS-T buffer, the 
membrane was incubated overnight at 4 with an appropriate primary antibody 
(anti-GFP) diluted at 1:2000 in PBS-T buffer containing 1 % fat-free milk. The 
primary antibody was then removed, and the blot was washed extensively in PBS-T 
buffer. Subsequent incubation with secondary antibody (donkey anti-rabbit IgG 
conjugated with horseradish peroxidase) diluted at 1:10 000 in PBS-T buffer
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containing 1 % fat-free milk, was peifomred for 2  h at room temperature. Following 
extensive washing in PBS-T buffer, the blot was visualised by enhance 
chemiluminescence. Exposure onto photosensitive film was performed.
2.7 Assays
a) Membrane radioligand binding with [^H] DHA
The expression of p-AR constructs in stable cell lines and transiently transfected cells 
were assessed by pH] DHA binding studies. These were performed in borosillicate 
glass tubes in triplicates, containing the following mix:
Membrane Protein ( 1 mg/ml) 20 pi
Assay buffer (TEM) 60 pi
pH] DHA (-20 nM) 10 pi
Propranolol (p2). betaxolol (Pl) (10"4 M) or H2 O 10 pi
Total Volume: 100 pi
Reactions were incubated for 45 min at 30 °C. Binding was stopped by vacuum 
filtration through GF/C filters. The filters were washed 3 times in ice-cold wash 
buffer to remove free radioligand from the membrane. Filters were inserted into vials 
containing 5 ml of liquid scintillant. After leaving the filters to soak the vials were 
counted in a Beckman LS6500 scintillation counter using the [^H] counting channel. 
Specific binding was determined by subtracting the counts performed in the presence 
of propranolol or betaxolol (non-specific counts) from that with out (total counts). 
Receptor expression level (fmol/mg) was calculated by taking into consideration the 
specific activity of pH] DHA (64 Ci/mmol) and the amount of membrane protein used 
per tube.
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The maximal binding (Bmax) and the equilibrium dissociation constant (K4 ) for DHA 
at the various p-AR constructs were assessed using increasing concentrations of pH] 
DHA (0.1-10 nM) with or without a single concentration of propranolol or betaxolol 
(10-5 M final) to measure non-specific binding. The binding affinity of the receptors 
for various p-drugs (isoprenaline, alprenolol and betaxolol) were assayed, using a 
single concentration of pH] DHA close to the Kd (-0.5-1.0 nM) and increasing 
concentrations of unlabelled dmg (10-15 to 10-5 M).
b) Intact cell radoligand binding with pH ] CGP 12177 and p H ] DHA 
(in tubes)
To measure the receptor number within the plasma membrane of stably transfected 
intact cells the hydrophobic ligand pH] CGP 12177 was used. These were 
performed in borscillicate glass tubes in triplicates, containing the following mix:
50 000-200 000 intact cells in KRH 80 pi
pH] CGP 12177 (-100 nM) 10 pi
Propranolol (pa), betaxolol (p 1) ( 10“^  M) or H2 O 10 pi
Totai Volume: 1 0 0  pi
Reactions were incubated for 2.5 h at 14 °C (adapted from Gagnon et al., 1998). 
Binding was stopped as for pH] DHA membrane binding and the specific binding 
determined as previously. Receptor number was calculated by taking into account the 
number of cells per assay tube, and the specific activity of pH] CGP 12177 (44 
Ci/mmol). The fmoles of receptor per cell was converted to the number of receptors 
per cell by using Avagadro's number Na-
The hydrophilic ligand pH] DHA was used to determine total cell membrane receptor. 
Incubations were set up as follows:
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50 000-200 000 intact cells in ICRH 80 pi
pH] DHA (-20 nM) 10 pi
Propranolol (P2 ), betaxolol (pi) (10^ M) or H2 O 10 pi
Total Volume: 100 pi
Incubations were performed as for pH] DHA membrane binding and the calculations 
as above.
c) Intact cell radioligand binding with f^H] CGP 12177 or pH ] DHA 
(on 24 well plates)
Stably transfected cells were plated out into 24 well plates the day before the binding 
assay unless long term drug treatments were to be performed prior to binding. After 
the appropriate drug stimulations the cells were washed twice with ice cold PBS 
followed by addition of 2 0 0  pi of binding mix.
Binding mix (final concentrations);
10-5 ]y[ propranolol (P2 ) or betaxolol (p 1) (or water-for total binding)
10 nM pH] CGP 12177 or 2 nM pH] DHA 
in KRH buffer
pH] CGP 12177 bindings were performed on ice for 90 min and pH] DHA bindings 
in a 30 °C incubator for 45 min. Following incubation the binding medium was 
discarded and cells were washed once with ice cold PBS to wash excess pH] away. 
Addition of 0.5 ml of 0.5 mM EDTA/PBS helped detach the labelled cells from the 
plate. These were collected and put into vials containing 5 ml of scintillant along with 
a further 0.5 ml of PBS wash from each well. After capping and vortexing, the vials 
were counted in a Beckman LS6500 scintillation counter using the pH] counting 
channel. For each assay unlabelled cells were counted in a hemocytometer to calculate 
the receptor number for each clone.
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All short term drug treatments were applied in KRH buffer in a 37 incubator/oven. 
Cell washes were performed in PBS . Over night drug treatments were performed in 
normal cell culture medium in a 37 «C incubator with 5% CO2 .
d) Intact cell adenylyl cyclase assay 
This method has been taken from Wong, 1994.
i) Column preparation
Dowex; To prepare 100 columns, 200 g of Dowex (50WX 4-400) was washed once 
in 1 L of 1 M HCi, once in 1 L of 1 M NaOH and then several times in distilled H2 O 
until the residual wash was neutral pH 7. The washed Dowex was then made up to a 
volume of 200 ml and 2 ml of this solution was added to 100 glass wool stoppered 
columns pre-washed with distilled H2 O. Prior to use the columns were washed with 
4 ml of HCI then with 14 ml of H2 O. Columns were stored at room temperature in 
H2O.
Alumina: To prepare alumina cloumns 1 gof dry neutral alumina was added to glass 
wool stoppered columns and the columns washed with 12 ml of 1 M imidazole buffer 
(pH 7.3), followed by 15 ml of 0.1 M imidazole (pH 7.3) and then stored at room 
temperature in H2 O. On the day of use, each column was washed with 8 ml of 0.1 M 
imidazole (pH7.3). After use columns were washed with 6 ml of 0.1 M imidazole 
and then stored in H2 O.
ii) Assay conditions
Transiently or stably transfected cells were seeded into poly-D-lysine coated 24 well 
plates and were allowed to reattach overnight. Cells were then incubated in medium 
containing pH] adenine (1.0 pCi/well) for 16 to 24 h. On the day of assay the cell 
culture medium was removed and 2 ml of HEPES buffered DMEM added to wash 
away excess pH] adenine. Cells were then treated with 0.5 ml of agonist or 50 pM 
forskolin (positive control) in assay medium for 10 or 30 minutes at 37 °C. On
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removal of agonist ice cold stop solution was added to stop the reaction and lyse the 
cells. After 30 minutes cells were scraped into the stop solution and the resulting mix 
transferred to Eppendorf tubes and spun for 5 min at 4 ®C. The supernatant was 
applied to pre-washed Dowex columns over scintillation vials containing 4 ml of 
scintillant. 3 ml of H2 O was applied to the column to wash pH] ADP and ATP into 
these vials. The Dowex columns were then placed onto the Alumina columns, over a 
waste basin and 10 ml of H2 O applied. pH] cAMP was then eluted with 6 ml of 0.1 
M imidazole, from the alumina columns over scintillation vials containing 8 ml of 
scintillant.
2.8 Confocal Laser Scanning Microscopy
Cells were observed using a laser scanning confocal microscope (Zeiss Axiovert 100: 
Zeiss Oberkochen, Germany) with Zeiss Plan-Apo 63 x 1.40 NA oil immersion 
objective, pinhole of 20, and electronic zoom 2 or 3. The GPP was excited using a 
488-nm argon/krypton laser and detected with a 515- to 540-nm band pass filter. The 
images were manipulated with Universal Imaging MetaMoiph software.
a) Fixed cell work
Cells grown on glass coverslips were washed with PBS and fixed for 20 min at room 
temperature using filter sterilised 4 % paraformaldehyde in PBS/5 % sucrose, pH 7.2. 
After one wash with PBS, the coveislips were mounted on microscope slides with 40 
% glycerol in PBS.
b) Live cell work
When examining live cells, cells grown on a glass coverslip were maintained in 
Krebs-Ringer-HEPES buffer (KRH) and the temperature was maintained at 37 ®C.
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For time-course experiments the agonist isoprenaline was applied in KRH buffer at 
the appropriate concentration.
c) Spectrofluorlmeter assay
Cells were seeded into black Costar view plates on the day before the experiment. On 
the day of the experiment, the media was removed from the cells and drug was added 
to the well in a final volume of 100 pi. The experiments were performed in phenol 
red-free F12 media containing 10 % fetal calf serum. A Spectrafluor Plus fluorimeter 
was used to read the plates, reading from the bottom at a gain of 100. A blank plate 
was initially read on the fluorimeter, and then the plates of cells were read at time 0 
and after a 22 h incubation at 37 ®C with drug. Results were calculated by subtracting 
the blank plate from the fluorescence values obtained to control for plate 
autofluorescence.
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Chapter 3
Visualising Ligand Regulation of a 
Constitutively Active Mutant Pa-Adrenergic 
Receptor-Green Fluorescent Protein Fusion
Protein
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Chapter 3
3.1 Introduction
Binding of agonist to a G protein coupled receptor (GPCR) induces an allosteric 
transition within the receptor structure to produce a conformation of the receptor 
which is able to activate its cognate G protein and thus regulate the activity of down­
stream effector enzymes. In the case of the p2"^drenergic receptor (P2 -AR) for 
example, binding of agonist to the wild type receptor causes a structural modification 
in which movement of transmembrane helix 6  occurs, as measured by the position of 
Cys285 (Gether et al., 1997a). This phenomenon of agonist-induced formation of an 
active receptor conformation has led to acceptance of a modified ternary complex 
model where the active receptor (R*) and inactive receptor (R) are in equilibrium. In 
this model agonists preferentially bind to and stabilise R* shifting the equilibrium 
towards this form (Bond et al., 1995; Leff, 1995; Leff et al., 1997; Zuscik et al., 
1998 and Chapter 1, Section 1.7).
In endogenous receptor systems, in the absence of agonist there is always a small 
quantity of R* present which is able to couple to G protein generating a basal effector 
output. Receptor mutations have been studied which induce an agonist-independent 
shift in isomérisation equilibrium towards an R^-like conformation (Lefkowitz et al., 
1993; Bond et al., 1995; Scheer and Cotecchia, 1997; Leurs et al. 1998). These 
receptors are termed constitutively active mutant (CAM) receptors and can generate 
agonist-independent signalling. Perhaps the most studied CAMGPCR is a form of the 
human P2 -AR in which a short segment of the third intracellular loop was replaced 
with the corresponding region from the aig-AR (Samama et al., 1993; Samama et al., 
1994) (Figure 3.1). This work had stemmed from findings that the reciprocal 
mutation in the hamster ctig-AR (part of the 3rd intracellular loop replaced by the
81
Figure 3.1
Structural model of the constitutively active mutant (CAM) 
adrenergic receptor.
Substitution of a short segment of the third intracellular loop of the P2 -AR with the 
corresponding region from the aiB-AR renders the receptor constitutively active, 
resulting in stimulation of adenylyl cyclase in the absence of agonist-induced 
receptor activation. Solid circles represent the amino acids (in single letter code) of 
the WT-p2 “AR that were mutated. The amino acid residues mutated are shown to 
the right (Leu266Ser, Lys267Arg, His269Lys, and Leu272Ala).
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corresponding region in P2 -AR) generated a constitutively active mutant (Cotecchia et 
al., 1990; Kjelsberg et al., 1992).
TheCAM-P2 -AR has been used to help clarify structural alterations upon binding and 
subsequent activation at the WT-p2 ~AR. In the CAM form of this receptor the same 
Cys which moves upon agonist binding to WT-j3 2 -AR is found closer to the ligand 
binding pocket than in the ligand-unoccupied WT receptor (Javitch et al., 1997). 
Previous studies have found that overexpressed CAM-p2 -AR in mammalian cells 
displays increased agonist affinity, elevated basal adenylyl cyclase and GTPase 
activity and higher maximal agonist-stimulated adenylyl cyclase and GTPase activity 
than for WT-p2 "AR (Lefkowitz et al., 1993; Scheer and Cotecchia, 1997; Leurs et al, 
1998). This has also been reported using the Sf9 insect cell expression system 
(Gether et al., 1997). Secondy, when conserved residue Asp-130 in TM3 of the p2 ~ 
AR was mutated to asparagine (D130N) a constitutively active receptor was formed. 
It was suggested from this that Asp-130 is an important part of the molecular switch 
that controls transition of the receptor between its active and inactive state. As TM6  is 
rearranged in the D130N mutant, the molecular switch. Asp-130, may govern the 
spatial disposition of TMs 3 and 6  (Rasmussen et al., 1999).
Of particular interest to my study are obseiwations that sustained treatment of cells 
expressing the CAM-P2 -AR with certain "p-blockers", including betaxolol results in 
the subsequent detection of higher levels of pH] P2 -AR antagonist binding sites in 
membranes prepared from these cells (Pei et a l, 1994; MacEwan and Milligan, 1996 
a,b). Betaxolol has the characteristics of an inverse agonist (Pei et a l, 1994; Samama 
et al., 1994; MacEwan and Milligan, 1996a,b)., i.e. a ligand that suppresses the basal 
signalling capacity of a GPCR. This effect appeared to be selective, because certain 
other p-blockers, including alprenolol, did not mimic these effects. Furthermore, the 
effects of the inverse agonist on CAM-P2 -AR levels were not related to their capacity
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to suppress the GPCR-mediated activation of basal adenylyl cyclase activity 
(MacEwan and Milligan, 1996b).
In contrast to the effects on cellular levels of CAM-p2 -AR, it was noted that equivalent 
treatment with betaxolol had a much less dramatic effect on cellular levels of the wild 
type human-p2 “AR when it too was expressed in NG108-15 cells (MacEwan and 
Milligan 1996a). Because betaxolol treatment of CAM-p2 -AR-expressing cells had 
little effect on the levels of mRNA encoding this receptor (MacEwan and Milligan, 
1996a), inverse agonists of the CAM-P2 -AR may function to stabilise an inherently 
unstable protein and thus decrease its rate of degradation. In the face of an apparently 
unchanged rate of synthesis, then, the inverse agonist causes an increase in steady- 
state levels of the GPCR. Kobilka and colleagues have gone further, indicating that 
any appropriate receptor ligand, whether agonist, neutral antagonist, or inverse 
agonist, may act to stabilise the structure of the purified CAM-p2 -AR and slow its 
dénaturation (Gether et al., 1997 a,b).
In this chapter I set out to investigate whether ligand-induced up-regulation of the 
CAM-p2 -AR is restricted to compounds that display inverse agonism as reported by 
MacEwan and Milligan, or if Kobilka and colleagues' theory about ligand regulation at 
this receptor might be correct. In addition to using conventional methods such as pH] 
ligand binding and immunoblotting to measure receptor levels before and after drug 
treatments, it was decided that a direct visual means of detecting the receptor would be 
beneficial to the project. In the current study I used a PCR-based approach to 
construct forms of the WT- and CAM-p2 "AR that had a modified form of the 27kDa 
green fluorescent protein (GFP) derived from Aequorea victoria added in-frame to 
their C-terminal tail (detailed in methods Chapter 2, Section 2.4). Following transient 
or stable expression in cells these constructs could be directly visualised in a confocal 
microscope and changes in levels or distribution in response to various drug 
treatments provided an initial indication of ligand regulation at CAM-p2 -AR-GFP.
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Initially, transient transfection of these constructs into HEK293 cells were performed 
to confirm that expression was obtained and that the constructs could be detected by 
fluorescence microscopy. Stable cell lines were then generated and single clones 
isolated for study i.e. a WT-p2 “AR clone, a WT-P2 -AR-GFP clone and a CAM-P2 - 
AR-GFP clone. All three clones were pharmacologically characterised for their ability 
to bind various p-ligands to examine whether GFP had any effect on ligand binding at 
each receptor. Expression levels of the three receptor constructs were also determined 
along with the Kd of pH] DHA for the receptor.
Up-regulation studies were firstly performed using the inverse agonist betaxolol. 
Measurements of up-regulation were achieved by a variety of methods, including 
confocal microscopy to quickly determine events occuring in the living cell after 
treatment, binding studies on membranes and intact cells with pH] DHA and pH] 
CGP 12177, immunoblotting with antisera against the p2 ~AR and GFP, and sucrose 
density gradient experiments. A selection of p-blockers were tested. These provided 
some interesting results suggesting the basis for a potentially rapid and efficient 
screening method in finding new GPCR ligands.
3.2 Construction and expression of wild-type and constitutively active 
mutant P2 -adrenergic receptor-green fluorescent protein fusion proteins
A PCR-based strategy was used to link a cDNA encoding a modified form of the GFP 
from Aequorea victoria with enhanced autofluorescence properties (Zemicka-Goetz et 
al., 1997) with cDNAs encoding both the FLAG-tagged WT-P2 -AR and a CAM form 
of this GPCR, produced by replacement of a small segment of the distal end of the 
third intracellular loop with the equivalent segment of the hamster a  ip-AR (Samama et 
al., 1993). These fusion proteins were anticipated to encode single open reading
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frames in which the C terminus of the GPCR was linked directly to the N terminus of 
GFP (Figure 3.2a).
These fusion constructs were transiently transfected into HEK293 cells to confirm 
successful expression. Figure 3.2 illustrates confocal images obtained after 
successful expression of both WT- (b) and CAM- (c) P2 -AR-GFP fusion constructs. 
Each appeared to display a different cellular location, WT-p2 -AR-GFP being mainly 
plasma membrane located and CAM-p2 -AR-GFP being both at the plasma membrane 
but also with a large proportion of receptor expressed diffusely in intracellular 
membranes. From binding experiments using a single concentration of pH] DHA on 
membranes from four transient transfections (Figure 3.3), it was apparent that the 
CAM form of this receptor was routinely expressed at much lower levels than either 
the GFP- tagged or untagged forms of the WT receptor. However, its expression was 
slightly greater than the control experiment using empty vector pcDNA3. Previously 
CAM GPCRs have proven to be present at lower levels than their WT versions, 
possibly due to their higher instability and rapid turnover which may reflect their 
constitutive activity (Gether et al., 1997). Stable cell lines of each construct in 
HEK293 cells were then developed.
Once stable cell lines of WT-p2 -AR with and without GFP and of CAM-p2 -AR-GFP 
were established in HEK293 cells single clones of each were selected for study. A 
fluorescent microscope was utilised to directly screen for the receptor-GFP containing 
clones (Figures 3.4a,b). At least 70% of the putative WT-P2 -AR-GFP clones selected 
were positive but this was less than 40% for CAM-p2 ~AR-GFP. There were marked 
differences in location and expression levels of receptor between the two constructs. 
In clones expressing the WT-P2 -AR-GFP construct, confocal microscopy performed 
on intact cells grown on glass coverslips demonstrated substantial amounts of the 
GFP-derived autofluorescence to be plasma membrane delineated (Figure 3.4a). 
Although clear plasma membrane-localised CAM-p2 -AR-GFP could be observed in
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Figure 3.2
a) Schematic diagram of the cDNAs encoding the receptor-GFP 
fusion constructs generated for this study.
WT-P2 -AR-GFP was a kind gift from Glaxo Wellcome. CAM-P2 -AR-GFP was 
generated using a PCR based approach (see Chapter 2 Section 2.4). 
b and c) Confocal analysis to determine the cellular location of WT- 
and CAM- p2 -AR-GFP following transient transfection in HEK 293 
cells.
Following transient transfection of HEK293 cells on glass cover slips with WT- 
and CAM- P2 -AR-GFP cDNAs, cells were fixed, mounted on a microscope slide 
as described in Section 2.8a and then imaged by confocal microscopy, b) WT-p2 - 
AR-GFPandc) CAM-p2 -AR-GFP.
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Figure 3.3
The WT-p2 -AR and WT-P2 "AR-GFP constructs are transiently 
expressed at higher levels than the CAM-p2 -AR-GFP construct.
Membranes (20 p,g) prepared from HEK293 cells transiently expressing either the 
WT-P2 -AR, WT-p2 "AR-GFF or the CAM-P2 -AR-GFP constructs were analysed 
for their ability to bind a single, near saturating concentration of pH] DHA (2 nM). 
Both wild type receptor constructs were expressed at much higher levels than the 
CAM construct. Results are from one experiment performed in triplicate ± S.D. 
Similar results were obtained from two further experiments.
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Figure 3.4
a) WT-p2 “AR-GFP stable cell clones.
The WT~P2 “AR-GFP construct was expressed stably in HEK293 cells and 
individual clones were identified by live cell confocal microscopy. All positive 
clones were similar to the three clones (7,13,14) imaged with a largely plasma- 
membrane delineated autofluorescence.
b) CAM-p2 “AR-GFP stable cell clones.
The CAM”P2 "AR-GFP construct was expressed stably in HEK293 cells and 
individual clones were identified by live cell confocal microscopy. All positive 
clones were similar to the two clones (2 ,1 2 ) imaged with some autofluorescence at 
the plasma membrane but a large proportion of receptor being distributed diffusely 
in intracellular membranes.
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Figure 3.4
a) WT -P2 -AR-GFP clones
''V
 ^ V,.
b) CAM-P2 -AR-GFP clones
stably expressing clones, there was a greater fraction of the GFP autofluorescence 
located intracellularly than for WT-P2 -AR-GFP (Figure 3.4b). These clones routinely 
had much less intense autofluorescence patterns than the WT-p%-AR-GFP clones, a 
factor contributing to possibly why less CAM clones were detected. The non GFP- 
tagged WT-p2 “AR clones were initially screened by intact cell adenylyl cyclase 
assays. Figure 3.5 demonstrates -1/3 of the WT-p2 ~AR clones which were screened 
of which only 1 0 - 2 0  % were found to produce no significant response to isoprenaline. 
WT-P2 -AR clone #27 was selected for its ability to grow strongly and maintain a good 
level of receptor expression. WT-p2 -AR-GFP clone #13 was chosen for study based 
on clear plasma membrane delineated fluorescence and marked time-dependent 
receptor internalisation into discrete, punctate intracellular vesicles upon addition of 
the p-AR agonist isoprenaline (Figure 3.6). CAM-p2 -AR-GFP clone #2 
demonstrated clear and easily detectible receptor compared to other clones isolated and 
for this reason was also chosen. Figure 3.7 gives an approximate indication of 
expression levels of each of these clones from using a single concentration of pHJ 
DHA in binding studies. However, it was neccessary to carry out more detailed 
analysis to pharmacologically characterise these constructs.
3.3 Pharmacological characterisation
To determine more accuarately the receptor expression level of each clone saturation 
binding experiments with pH] DHA, an antagonist at the P2 -AR were carried out 
(Figures 3.8a, 3.9a and 3.10a). In agreement with the lower levels of 
autofluorescence in the CAM-P2 “AR-GFP-expressing clone compared to the WT-p2 - 
AR-GFP clone lower levels of pH] DHA-specific binding to membrane fractions 
isolated from the CAM-P2 -AR-GFP-expressing cells were measured (Table 3.1, 
Bmax values). Higher expression of the GFP-tagged WT receptor was obtained than 
for the non-tagged receptor, a feature also exhibited by the pi-AR (see Chapter 4).
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Figure 3,5
Screening of WT-P2 -AR stable cell clones by intact cell adenylyl 
cyclase assays.
The WT-p2 -AR construct was expressed stably in HEK293 cells and individual 
positive clones were detected by intact cell adenylyl cyclase assays (Chapter 2 , 
Section 2.7d). 5xl0"5 M forskolin was used as a positive control for adenylyl 
cyclase activation and clones were selected on their ability to be stimulated by 
isoprenaline (10-^ M, 30 min). Data are means ± S.D. from a single experiment 
performed in triplicate.
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Figure 3.6
Internalisation of WT-P2 "AR-GFP by agonist stimulation.
A patch of WT-P2 -AR-GFP clone #13 cells were imaged in the confocal 
microscope in the absence of agonist (a) and following addition of 10'^ M 
isoprenaline for 10 (b), 15 (c), 20 (d), 30 (e) and 40 (f) minutes. This is 
representative of three separate experiments.
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Figure 3,7
Estimation of receptor levels o f P2  AR clones from membrane 
binding studies with a single concentration of [^H] DHA.
20p,g of a membrane preparation from each cell line was used to estimate the 
approximate receptor level (fmol/mg). A close to saturating conentration of pH] 
DHA (2 nM) was used to determine total binding with lO'  ^ M propranolol as 
competing ligand to determine non-specific binding. Specific binding was used to 
estimate the receptor expression in each clone (fmol/mg). Data are presented as 
means ± S.E.M. n=3.
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Table 3.1
Ligand-binding characteristics of wild-type and CAM P2-AR-GFP constructs.
Clone Kd (nM) Bmax (pmol/mg)
WT-Pz-AR 0.62 ± 0.26 4.1 ± 0 .9
WT-p2-AR-GFP 0.75 ± 0 .17 8.7 ± 0 ,7
CAM-p2-AR-GFP 0.36 ±0.13 1.0 ± 0.2
Data represent means ± S. D. from three independent experiments using [^H] 
DHA as radioligand.
Table 3.2
Competition binding experiments at wild-type and CAM p2“AR-GFP constructs.
Clone Kjfor
isoprenaline
(nM)
K ifor
betaxolol
(nM)
Ki for 
alprenolol 
(nM)
WT-p2-AR 363 ± 82 (2) 344 ± 24(2) 1.13 ± 0 .2  (2)
WT-Pz AR GFP 7 8 2 ± 160 (3) 478 ± 16 (2) 2.50 ± 0.7 (2)
CAM-pz AR GFP 24.2 ± 2.6 (3) 249 ± 14 (3) 0.72 ± 0.02 (3)
Data represent means ± S.E.M. from two or three independent experiments using 
[^H] DHA as radioligand. The number of experiments are indicated in brackets.
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The non-specific binding of pH] DHA at these receptor constructs, as determined by 
using a saturating concentration of propranolol (a p-AR blocker), was very low in this 
study (Figure 3.8a(ii), 3.9a(ii) and 3.10a(ii)). Saturation binding curves were 
converted into Scatchard plots for each receptor construct and results from these 
experiments indicated that the CAM-P2 -AR-GFP construct bound this ligand with an 
affinity similar to the wild-type P2 -AR-GFP (Table 3.1, K j values and Figures 3.8b, 
3.9b and 3.10b).
Competition for the specific binding of pH] DHA to membranes expressing WT-P2 - 
AR, WT-p2 -AR"GFP or CAM-P2 -AR-GFP with either betaxolol (an inverse agonist), 
alprenolol (an antagonist) or isoprenaline (an agonist) were perfonned to demonstrate 
that adding GFP to the C terminus of the receptor had little effect on basic receptor 
pharmacology (Table 3.2). When isoprenaline was used as the competing drug results 
indicated that this agonist had substantially higher affinity for CAM-P2 -AR-GFP (Ki 
= 24.2 ± 2.6 nM) than for WT-p2 -AR-GFP (Ki = 363 ± 82 nM) (Figure 3.11). As 
such, the previously noted high affinity of this agonist for the CAM-P2 -AR compared 
with WT-p2 ~AR (Samama et al., 1993) was preserved following addition of GFP to 
the C-terminal tail of both of these GPCR variants. High affinity of the antagonist 
alprenolol and low affinity of the inverse agonist betaxolol for CAM-P2 -AR was also 
retained after addition of GFP as measured by the competition for the specific binding 
of pH] DHA by alprenolol or betaxolol at CAM-P2 -AR-GFP (Figure 3.12 and Table 
3.2).
3.4 Ligand regulation of CAM-p2 "AR“GFP compared to the wild-type 
receptor constructs
From previous investigations long term treatment (>24 h) of the CAM-P2 -AR causes 
an increase in expression levels of the receptor (Pei et al., 1994; MacEwan and
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Figure 3.8
P2 -AR binding characteristics in WT-p2 -AR-expressing cells.
ai) A saturation binding study using increasing concentrations of pH] DHA was 
performed to measure specific binding (pmol/mg) in membranes from WT-P2-AR 
cells.
aii) The same saturation binding study as in (ai) but showing total, specific and 
non-specific binding (d.p.m.).
b) Transformation of the specific binding data to generate a Scatchard plot. In the 
example displayed Bmax was 3.31 pmol/mg and the Kd for pH] DHA was 0.36 
nM.
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Figure 3.9
P2 "AR binding characteristics in WT-p2 “AR-GFP-expressing cells.
ai) A saturation binding study using increasing concentrations of pH] DHA was 
performed to measure specific binding (pmol/mg) in membranes from WT-P2 -AR- 
GFP cells.
aii) The same saturation binding study as in (ai) but showing total, specific and 
non-specific binding (d.p.m,).
b) Transformation of the specific binding data to generate a Scatchard plot. In the 
example displayed Bmax was 9.24 pmol/mg and the Kd for pH] DHA was 0.87 
nM.
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Figure 3.10
p2 “AR binding characteristics in CAM-P2 “A.R-GFP-expressing cells.
ai) A saturation binding study using increasing concentrations of DHA was 
performed to measure specific binding (pmol/mg) in membranes from CAM-p2“ 
AR-GFP cells.
aii) The same saturation binding study as in (ai) but showing total, specific and 
non-specific binding (d.p.m.).
b) Transformation of the specific binding data to generate a Scatchard plot. In the 
example displayed Bmax was 0.74 pmol/mg and the K j for pH] DHA was 0.23 
nM.
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Figure 3.11
High affinity of Isoprenaline for the CAM-pi-AR is retained after 
addition of GFP.
Competition between pH] DHA (0.34 nM) and varying concentrations of 
isoprenaline for specific binding to membranes expressing either WT-P2 -AR-GFP 
(triangles) or CAM-p2 -AR-GFP (squares) was assesed. Results are from one 
experiment performed in triplicate ± S.D. Similar results were obtained from two 
further experiments.
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Figure 3.12
High affinity of alprenolol compared to betaxolol at CAM-p^-AR.
Competition between pH] DHA (0.65nM) and varying concentrations of alprenolol 
(triangles) or betaxolol (circles) for specific binding to membranes expressing 
CAM-P2 -AR-GFP was assessed. Results are from one experiment performed in 
triplicate ± S.D. Similar results were obtained from two further experiments.
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Milligan, 1996a,b). CAM-p2 "AR-GFP cells were treated with or without 1 0 '^ M 
betaxolol for 24 h and the effects monitored firstly by confocal microscopy (Figure 
3 .13a,b) where a marked increase in both plasma membrane-delineated and diffuse 
intracellular fluorescence was observed (Figure 3.13b). Washing of the cells 
followed by an intact cell ligand binding experiment with pH] DBA indicated a 2.75 
± 0.28 fold up-regulation of CAM-p2 -AR-GFP in response to betaxolol (Figure 
3.13c). Similar results were obtained when the same experiment was performed on 
membrane preparations from the same cells (Figure 3.14). This figure also 
demonstrated that sustained treatment of cells expressing WT-p2 ~AR or WT-P2 ~AR- 
GFP with betaxolol failed to result in a significant up-regulation of the construct. That 
the increased GFP autofluorescence in response to treatment with betaxolol in cells 
expressing CAM-P2 -AR-GFP represented up-regulation of the GPCR-GFP fusion 
protein was further confirmed by immunoblotting studies on membranes of untreated 
and betaxolol-treated cells (Figure 3 .15a, lanes 1 and 2, and Figure 3 .15b, lanes 1 and 
2). Antibodies against both the P2 -AR and against GFP indicated that betaxolol 
treatment substantially increased levels of a family of poorly resolved polypeptides 
that are likely to represent differentially glycosylated forms of the receptor (Figure 
3.15), although the current studies cannot exclude that a degree of proteolytic 
degradation had occurred to produce this pattern. Little or no effect of betaxolol at the 
WT-p2 "AR (Figure 3.15b, lanes 3 and 4) or WT-p2 -AR-GFP (Figure 3.15a, lanes 3 
and 4, and Figure 3.15b lanes 5 and 6 ) was detected by immunoblotting.
Up-regulation of GFP-autofluorescence was also observed by treatment of the CAM- 
p2 -AR-GFP-expressing cells with a range of other ^-blockers including DBA, 
labetolol, and ICI 118551 (24 h, each at a saturating dose of 10"  ^M) (Figure 3.16). 
Pharmacological selectivity of this effect was apparent because it was not produced by 
treatment with the ai-A R antagonist prazosin or the « 2-AR antagonist yohimbine (24 
h, each at 10'^ M) (Figure 3.17). Although each of the (3-blockers described above 
resulted in greater levels of autofluorescent signal, the pattern of distribution of
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Figure 3.13
Up-regulation of CAM-P2 -AR-GFP by betaxolol.
Cells of a single clone were grown on glass coverslips in the absence (a) or 
presence (b) of 10"  ^M betaxolol for 24 h. These cells were then visualised. In (c) 
the same clone was used where cells were untreated or treated with betaxolol ( 1 0 '^ 
M for 24 h). These were then washed and used to measure the specific binding of 
pH] DHA in intact cells (pH] DHA is a lipophillic antagonist that crosses the 
plasma membrane and thus provides a measure of total cell levels of P2 -AR-binding 
sites). Data are presented as means ± S.E.M., « = 3.
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Figure 3.14
Betaxolol treatment of p2 -AR clones: membrane binding studies.
Membrane fractions were prepared from cells expressing each p2 -AR construct, 
which had been maintained for 24 h in the absence or presence of betaxolol (lO^ 
M). 20 pg of each was used to measure the specific binding of pH] DHA. Data 
are represented as a % of the specific binding at untreated cells. Data are presented 
as means ± S.E.M. n=3
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Figure 3.15
Betaxolol treatment of clones: immunoblot studies.
Membrane fractions were prepared from cells expressing each p%-AR construct, 
which had been maintained for 24 h in the absence or presence of betaxolol (iO^ 
M). Each gel was loaded with 30 pg of CAM-p2 ”AR-GFP membranes, 10 pg of 
WT-P2 -AR membranes and 5 pg of WT-p2 -AR-GFP membranes in accordance 
with the differing expression level (Bmax values) for each clone.
a) The anti-GFP immunoblot shows up-regulation of CAM-P2 -AR-GFP (lane 2) 
compared to untreated cells (lane 1). WT-p2 “AR-GFP expression (lane 3) is little 
modified by betaxolol over-night treatment (lane 4).
b) The anti-p2 "AR immunoblot shows up-regulation of CAM-p2 “AR (lane 2) 
compared to untreated cells (lane 1). Betaxolol has no effect on the expression of 
WT-P2 -AR (lanes 3 and 4) and little effect on expression of WT-p2 -AR-GFP 
(lanes 5 and 6 ).
A representative experiment of three is shown.
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Figure 3.16
Up-regulation of CAM-p^-AR-GFP by other p-AR blockers.
CAM-p2 -AR-GFP-expressing cells were exposed to no ligand (a), DHA (b), 
labetolol (c), or ICI 118551 (d) (each at 10'^ M) for 24 h. The cells were then 
imaged by confocal microscopy. Results from a typical experiment are displayed.
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Figure 3.17
Pharmacological selectivity is maintained at CAM-p2 "AR-GFP.
CAM-P2 -AR-GFP-expressing cells were exposed to no ligand (a), betaxolol (b), 
prazosin (ai-AR antagonist) (c), or yohimbine (a 2 -AR antagonist) (d) for 24 h 
(each at 10-  ^M). The cells were then imaged by confocal microscopy. Results 
from a typical experiment are displayed.
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Figure 3.17
œliularCAM-p2 -AR-GFP was not identical. Both betaxolol and ICI 118551 resulted 
in a large increase in homogenous plasma membrane-delineated fluorescence (Figure 
3.16d,e). However, as with the untreated cells, a significant amount of 
predominantly diffuse, intracellular staining was observed, the level of which was 
greater than in the untreated cells (Figure3.16a,d,e). By contrast, after treatment with 
labetolol, although a substantial increase in plasma membrane CAM-P2 -AR-GFP was 
observed, there was also an increase in the intracellular signal. A significant fraction 
of this autofluorescent signal displayed a subplasma membrane, distinctly punctate 
localisation (Figure 3.16c) that appeared similar to the pattern produced by short-term 
treatment with the agonist isoprenaline (Figure 3.6). Long term treatment of this clone 
with the full agonist isoprenaline (10-^ M, 24 h) caused a large redistribution of 
receptor such that it became intracellular with a marked punctate pattern (Figure 3.18). 
To explore a possible basis for these differences, basal intact cell adenylyl cyclase 
activity and its regulation by a variety of ligands was assessed. Although basal cAMP 
level in these cells were low, both ICI 118551 and betaxolol were able to reduce them 
further, indicating that these ligands function as inverse agonists at the CAM-P2 -AR- 
GFP. By contrast, alprenolol and DHA displayed partial agonism, and, in this 
system, a maximally effective concentration of labetolol was able to elevate cAMP 
levels to the same extent as isoprenaline (Figure 3.19).
The capacity of betaxolol to alter the fluorescence intensity of CAM-p2 -AR-GFP- 
expressing cells could be detected and directly quantitated in a spectrofluorimeter after 
seeding of cells into wells of a 96-well microtiter plate (Figure 3.20, this experiment 
was carried out by Nicola Bevan, Glaxo Wellcome). This allowed concentration- 
response curves to betaxolol to be calculated conveniently. Up-regulation was 
observed with EC5 0  = 0.17 pM. This value was in good accordance with the 
measured Ki of betaxolol to bind to this GPCR-GFP construct as determined from 
competition binding experiments between pH] DHA and betaxolol (0.25 ±0.01 pM) 
(Figure 3.12). This enhanced fluorescent signal was not simply due to the addition of
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Figure 3.18
No up-regulation occurs upon treatment with agonist isoprenaline.
CAM“P2 "AR-GFP-expressing cells were exposed to no ligand, or isoprenaline 
(10~5 M) for 24 h. The cells were then imaged by confocal microscopy. Results 
from a typical experiment are displayed.
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Figure 3.19
Ligand regulation of adenylyl cyclase activity in intact cells  
expressing CAM-p2 -AR-GFP.
Basal (1) adenylyl cyclase activity and its regulation by forskolin (5x10 -5 M; 2), 
isoprenaline ( 1 0 '^ M; 3), betaxolol (4), and a range of ^-blockers used in Figure 
3.16 [labetolol (5), DHA (6 ), ICI 118551 (7)] and alprenolol (8 ; all at 10-  ^M) were 
assessed as described in Chapter 2 Section 2.7d. Data represent means ± S.D. of 
triplicate assays from a single representative experiment. Two additional assays 
produced similar results, although the extent of pH] nucleotide conversion varied 
over a 2 -fold range between experiments.
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Figure 3.20
Concentration dependence of the up-regulation of CAM-P2 -AR-GFP 
by betaxolol.
Cells expressing CAM-P2 -AR-GFP were grown in wells of a 96-well microtiter 
plate. The cells were then exposed to varying concentrations of betaxolol, and 
fluorescence was measured on a Spectrofluor Plus fluorimeter either at 0 h (circles) 
or after 22 h (triangles). Values are the mean percentages ± S.E. of basal 
fluorescence from six experiments performed in duplicate.
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the ligand, because no alteration in fluorescence intensity was recorded when 
betaxolol was added and fluorescence was measured immediately (Figure 3.20).
The betaxolol up-regulated CAM-p2 -AR-GFP was sensitive to agonist treatment. 
After the removal of betaxolol and its replacement by isoprenaline (10"^ M), lapid 
internalisation of the construct into intracellular, punctate vesicles was observed. This 
process could be visualised by confocal microscopy (Figure 3.21a-d) and was 
indistinguishable in phenotype from that recorded for WT-P2 -AR-GFP (Figure 3.6). 
pH] CGP12177 is a hydrophillic p-AR antagonist that is unable to cross the plasma 
membrane. Therefore, in intact cell-specific binding experiments, it identifies only the 
cell surface population of forms of p-ARs. Such intact cell binding studies were 
performed on naive cells expressing CAM-P2 -AR-GFP, those that had been treated 
with betaxolol (24h, lO'^ M), and such cells after replacement of betaxolol with 
isoprenaline (10"  ^M) for 30 min. Cell surface up-regulated CAM-p2 -AR-GFP was 
essentially all internalised by short-term agonist treatment (Figure 3.2le). In 
conjunction with the confocal and binding experiments Jiri Novotny performed a 
series of sucrose density gradient experiments which showed up-regulation of CAM- 
P2 -AR-GFP by betaxolol (10"  ^M, 18 h) at both the plasma membrane of these cells 
(Figure 3.22a (untreated), b (4- betaxolol), lane7) and in intracellular membranes 
(Figure 3.22a,b, lanes 3 and 4). Short term exposure of this clone to isoprenaline 
(10~  ^M, 30 min) caused a redistribution of the CAM-P2 -AR-GFP construct from lane 
7 to lanes 3,4 and 5 (Figure 3.22b,c). This can be interpreted as a movement of 
receptor from the plasma membrane to intracellular membranes (see Drmota et al., 
1999), showing that CAM-P2 -AR-GFP can still respond to agonist after up- 
regulation.
I l l
Figure 3.21
Internalisation of up-regulated CAM-P2 -AR-GFP by isoprenaline.
Confocal studies: CAM-P2-AR-GFP-expressing cells were untreated (a) or 
exposed to betaxolol (lO'^ M, 24 h; b-d). After betaxolol treatment, the cells were 
washed, and isoprenaline (10‘^  M) was added for 0 (b), 10 (c), or 30 (d) minutes. 
pH]CGP12177 binding studies: (e), cells, as above, were untreated, exposed to 
betaxolol (10'^ M, 24 h), or exposed to betaxolol followed by further exposure to 
isoprenaline (10-5 M, 30 min). Intact cells were then washed and used to measure 
the specific binding of pH]CGP12177. Data are presented as means ± S.E.M. 
11=3.
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Figure 3.22
Internalisation of up-regulated CAM-p2 “AR-GFP by isoprenaline as 
assessed by sucrose density gradient experiments.
CAM-p2“AR“GFP-expressing cells were untreated (a) or exposed to betaxolol 
(1(>5 M, 18 h; b). After betaxolol treatment, the cells were washed, and 
isoprenaline (10-^ M) was added for 30 minutes (c). The cells were fractioned on a 
sucrose density gradient and the fractions (1-8) collected. Equivalent amounts of 
fractions (1-8) for each cell sample (a, b and c) were then run on a borate based 
protein gel (Chapter 2, Section 2.6g). Once the protein was transferred to 
nitrocellulose the samples were probed with an anti-GFP antibody. A 
representative experiment is shown.
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3.5 The p2-AR antagonist alprenolol up-regulates the C AM -p^-A R -G FP  
construct in cells of th is clone
In previous studies using pH] ligand binding studies, sustained treatment of cells 
expressing the CAM“p2 "AR with alprenolol did not apparently produce an increase in 
cellular levels of the mutant protein (MacEwan and Milligan, 1996a,b). However, 
exposure of CAM-P2 "AR-GFP-expressing cells to a high concentration of alprenolol 
(24 h, 10-  ^M) caused a clear increase in cellular fluorescence (Figure 3.23a,b). It 
was noted that alprenolol treatment also resulted in a distinctly punctate appearance of 
a fraction of the intracellularly located GPCR, as observed earlier following treatment 
with labetolol. In apparent contradiction to this, when cells were washed after 
alprenolol treatment (10"  ^M, 24h) and the binding of a single concentration of pH] 
DHA assesed on intact cells, no up-regulation of the CAM-p2 -AR-GFP construct 
was detected (Figure 3.23c). To explore the basis for the apparent discrepancy of up- 
regulation of CAM-p2 "AR-GFP by alprenolol in the current studies but not CAM-p2 - 
AR in previous work, CAM-p2 -AR-GFP-expressing cells were exposed to a range of 
concentrations of alprenolol. The cellular autofluorescence pattern (Figure 3.24a) 
and, after extensive washing, the measured specific binding of pH] DHA to intact 
cells were monitored (Figure 3.24b). The pH] ligand binding studies demonstrated a 
clear increase in levels of the construct after treatment with concentrations of 
alprenolol between 10~l® M and 10^ M. This reached a plateau on treatment with 10'^ 
M alprenolol and was greatly reduced by pretreatment with 10'^ M alprenolol (Figure 
3.24b). Equivalent results were produced when using [^H] CGP12177 as radioligand 
(Figure 3.24b). This suggests that residual alprenolol interferes with the binding 
assays but not the confocal analysis.
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Figure 3.23
Up-regulation of CAM-P2 -AR-GFP by alprenolol is detected from 
confocal analysis but not by binding studies.
Confocal studies: CAM-p2 "AR-GFP-expressing cells were untreated (a) or 
exposed to alprenolol (10"5 M, 24 h; b) and then imaged on a confocal microscope. 
pH]DHA binding studies: Cells, as above, were untreated, or exposed to 
alprenolol or betaxolol (10-^ M, 24 h; c). Intact cells were then washed and used to 
measure the specific binding of pH]DHA. Data are presented as percentages of the 
untreated receptor level and are means ± S.E.M. n=3.
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Figure 3.24
Concentration-dependence of the up-regulation of CAM-P2 "AR-GFP
by alprenolol.
(a), con focal studies: CAM-P2 -AR-GFP-expressing cells were untreated or 
exposed to increasing concentrations of alprenolol; M (i), 10-  ^M (ii), 10-8 M 
(iii), 10-7 M (iv), and 10~5 M (v) for 24 h.
(b), binding studies: these cells were treated in dishes in the same way and 
subsequently washed. Intact cell-specific binding of a single concentration of either 
pH]DHA (squares) or pH]CGP12177 (triangles) was measured as described in 
Chapter 2 Section 2.7c to ascertain apparent levels of total cell receptor and cell 
surface receptor, respectively. Data represent means ± S.D. of triplicate assays 
from a single experiment that was representative of three performed.
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Figure 3.24a - Confocal microscopy
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Figure 3.25
Up-regulation of CAM-p2 "AR-GFP by the hydrophillic ligand  
CGP12177.
CAM-p2 -AR-GFP-expressing cells were untreated (a) or exposed to betaxolol (b) 
or CGP12177 (c) (lO-^ M) for 24 h and then imaged. Results from a typical 
experiment are displayed.
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3.6 The hydrophillic ligand CGP12177 up-regulates the CAM-p2 -AR- 
GFP construct
In this section I wanted to investigate whether it was essential for the agent causing 
up-regulation of the CAM-p2 '-AR~GFP to cross the cell plasma membrane in order to 
induce its effect. It is well established that CGP12177 is a hydrophillic ligand that 
does not cross the plasma membrane. pH] CGP12177 is thus used to measure 
receptors on the cell surface as explained previously. CAM-p2 “AR-GFP cells were 
plated on glass coverslips and treated with or without CGP12177 or betaxolol (10"  ^
M, 24 h). Figure 3.25 shows that both drugs up-regulate this construct to similar 
extents providing evidence that a ligand which does not permeate the cell surface can 
also elicit up-regulation.
3.7 Discussion
An area of considerable interest in GPCR biology has been the observations that many 
GPCRs are not silent in the absence of agonist ligands but display constitutive activity 
(Lefkowitz etal., 1993; Scheer and Cotecchia, 1997; Leurs et al., 1998). A range of 
mutations of GPCRs have been reported to enhance the degree of constitutive 
activity. Such modified forms of a GPCR are thus believed to offer insights into 
conformational changes which may occur upon agonist binding to a wild type GPCR 
(Javitsch et al., 1997; Gether et al., 1997b). One of the most studied constitutively 
active mutant GPCRs is a form of the human p2 ~AR in which a short segment of the 
distal region of the third intracellular loop was replaced by the equivalent section of the 
aiB“AR (Samama et al., 1993, 1994; Gether et al., 1997a; Javitsch et al., 1997). As 
well as producing considerably greater agonist-independent stimulation of adenylyl 
cyclase activity than the wild type GPCR this CAM-P2 -AR has been shown to 
denature more readily than the WT-p2 -AR when purified and potentially to have a
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markedly lower functional half-life (Gether et a l, 1997a,b). In the present study I 
constructed and stably expressed a C-terminally GFP-tagged form of this CAM-^i- 
AR to directly address such issues and to re-examine a series of reports which 
indicated that inverse agonists, but not neutral antagonists, cause up-regulation of the 
CAM-P2 -AR (MacEwan and Milligan, 1996a,b),
Although it might be anticipated that attachment of a 27kDa polypeptide to the end of a 
GPCR could significantly interfere with function, a series of reports have indicated the 
modified GPCRs to display essentially unaltered pharmacology and to interact with G 
proteins to initiate second messenger regulation (Barak et al., 1997; Kallai et al., 
1998; Drmota et al., 1998,1999; Awaji et al., 1998; Tarasova et al., 1998). Such 
GFP-tagged constructs could also be used to explore the cellular distribution of the 
CAM-p2~AR compared to the WT~p2 “AR.
MacEwan and Milligan have previously noted that prolonged treatment with either 
betaxolol or sotolol results in a substantial up-regulation of CAM-p2-AR expressed 
stably in NG108-15 cells (MacEwan and Milligan, 1996a,b). Such conclusions were 
based on detection of increased levels of specific binding of [^H]DHA following 
washing of the cells and membrane preparation. However, an equivalent up- 
regulation was not observed following pretreatment with alprenolol (MacEwan and 
Milligan, 1996). As betaxolol and sotolol both display characteristics of inverse 
agonists at the modified GPCR whilst alprenolol displays weak partial agonist 
function, an obvious conclusion was that the up-regulation reflected stabilisation of 
the CAM-GPCR in a manner dependent upon the inverse agonist characteristics of the 
ligands. However, in the current studies fluorescence analysis clearly indicated the 
CAM-P2 -AR-GFP construct to be up-regulated by alprenolol (Figure 3.23a,b and 
Figure 3.24) as well as by betaxolol (Figure 3.13) and a range of other “p-blockers” 
(Figure 3.16). The most likely explanation for this discrepancy is that the current 
fluorescence studies provide a direct monitor of the effect of the added ligands. By
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contrast, the previous work required removal of the ligand, membrane preparation
and subsequent [^H]ligand binding studies. Betaxolol, as a Pi-AR-selective ligand
has relatively low affinity for the CAM-P2 -AR whereas alprenolol has high affinity
(Table 3.2). It could thus be anticipated that betaxolol would be effectively removed
in washing regimens whereas this would be more difficult to achieve with a high
affinity ligand. As such, it was possible that residual alprenolol would compete with
[^H]DHA in the subsequent binding experiments thus reducing the measured binding
of a single concentration of [^H]DHA. To approach this directly CAM-P2 -AR-GFP-
expressing cells were treated for 24h with differing concentrations of alprenolol,
subsequently washed and the specific binding of [ H]DHA measured. Clear
concentration-dependent up-regulation of [ H]DHA binding was observed by prior
treatment of the cells with concentrations of alprenolol up to 10 M. This plateaued at 
7  510" M but at 10" M was essentially non-existent (Figure 3.24b). Such results would 
indeed be consistent with the competition model outlined above. Furthermore, 
equivalent results were obtained when the specific binding of a single concentration of 
the membrane impermeant antagonist [ HJCGP12177 was measured following 
cellular pretreatment with varying concentrations of alprenolol (Figure 3.24b). 
Ligand-induced up-regulation of fluorescence associated with the CAM-P2 -AR-GFP 
retained pharmacological specificity. Levels of the GPCR construct were unaltered by 
sustained treatment of the cells with either the ai-AR antagonist/inverse agonist 
prazosin or the 0 2 -AR antagonist/inverse agonist yohimbine. Morello et al., (2000), 
have suggested that V2 vasopressin receptor (V2R) mutants (shown to be associated 
with nephrogenic diabetes insipidus) do not fold properly and are located inside of the 
cell. Small cell-permeant V2R antagonists, but not impermeable antagonists were able 
to stabilise mutant V2Rs and allowed their maturation to the cell surface. This was not 
the case for the CAM-p2 -AR-GFP construct. The hydrophillic |3-ligand, CGP12177, 
also produced an increase in receptor density suggesting that a stabilisation of an 
inherently unstable protein on the cell surface is occuring. This agrees with MacEwan 
and Milligan’s findings that betaxolol treatment of NG108-15 cells stably expressing
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the CAM-p2 -AR had no effect on the levels of mRNA encoding this receptor, 
indicating that betaxolol may be binding to the receptor and reducing the rate of 
receptor degradation. Contradictory to studies reporting that this receptor is also up- 
regulated by isoprenaline (10“^  M, 48h) (Gether et al., 1997), this was not found to be 
the case for the CAM-P2 -AR-GFP construct. However, this study used a 10 fold and 
sometimes a 1 0 0  fold smaller concentration of isoprenaline than used in the cited piece 
of work. Sf9 insect cells were also used whereas I used HEK293 cells, a mammalian 
cell expression system. These may be plausable explanations for the discrapancy.
Levels of the WT-p2 "AR-GFP construct were little affected by sustained treatment 
with p-blockers but as previously reported by others (Barak et al., 1997, Kallal et al., 
1998) the agonist isoprenaline caused rapid internalisation of the construct into 
punctate vesicles and recycling of this construct to the plasma membrane could be 
achieved in rapid order by removal of the agonist and replacement with alprenolol (see 
Chapter 4, Section 4.5). It is well established that the CAM-P2 -AR does not function 
in an entirely agonist-independent manner (Samama et al., 1993, 1994; Stevens and 
Milligan, 1998), thus following betaxolol-mediated up-regulation of the CAM-P2 -AR- 
GFP, isoprenaline was also able to cause rapid internalisation of the construct into 
punctate vesicles in a manner similar to the WT-p2 -AR-GFP (Figures 3.21a-d). The 
sucrose density gradient experiment performed also provides a clear indication of this 
internalisation process (Figure 3.22).
Treatment of CAM-P2 -AR-GFP-expressing cells with a range of “p-blockers” 
resulted in increased brightness of the cells as monitored in the confocal microscope. 
However, careful examination of the cells demonstrated differences in the distribution 
pattern of the up-regulated GPCR (Figures 3.16,3.23a,b and 3.24a), Treatment with 
both betaxolol and ICI 118551 resulted in an essentially uniform pattern of plasma 
membrane-delineated GPCR fluorescence. In contrast, alprenolol, to some degree, 
and more markedly labetolol, produced a pattern in which a fraction of the GPCR
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signal was present with a punctate intracellular location, somewhat akin to the pattern 
observed after short term treatment with the agonist isoprenaline. It is known that 
compared to full agonists such as adrenaline or isoprenaline the relative intrinsic 
activity of partial agonists is more pronounced at the p2-AR as expression levels are 
increased (MacEwan et al., 1995) and for the CAM-P2 -AR compared to the WT-p2 " 
AR at equal levels of expression (Samama et al., 1993). Relatively few ligands 
traditionally described as “antagonists” appear to be purely neutral in effect following 
binding within the crevice formed from the topological architecture of the seven 
transmembrane domains of GPCRs for catecholamines (Milligan etal., 1995; Milligan 
and Bond, 1997). Indeed, ligand stabilisation of particular conformations of a GPCR 
may be considered in a similar manner to the induced-fit models of enzyme-substrate 
interactions. Therefore, the bulk of “antagonists” will favour production of 
conformations less or more similar to agonist-induced conformations than the mean 
spectrum of populations present in the absence of ligand. They will, therefore, 
behave as either inverse agonists or partial agonists. If partial agonists, however, it 
might be expected that they would display poor intrinsic activity relative to classical 
agonists for that GPCR, or they would previously have been characterised as agonists 
rather than antagonists. Therefore, the capacity of the “P-blockers” employed in this 
study to regulate cAMP levels in intact cells expressing CAM-P2 -AR-GFP (Figure 
3.19) was measured. Although the basal level of cAMP was relatively low in these 
cells both betaxolol and ICI 118551 reduced this level further, a property consistent 
with their classification as inverse agonists. However, alprenolol displayed a clear 
ability to increase cAMP levels in intact CAM-P2 -AR-GFP-expressing cells, acting as 
a partial agonist when compared to isoprenaline. Perhaps surprisingly, labetolol was 
as effective as isoprenaline in stimulating intact cell adenylyl cyclase activity in these 
cells (Figure 3.19). This property of labetolol has been reported previously from 
experiments in whole cells (Samama et al., 1993; Chidac et al., 1994) dispite being 
inhibitory in membranes (Murray and Keenan, 1989). It thus appears that visual 
examination of the distribution of up-regulated CAM-p2 -AR following sustained
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exposure to a selection of “p-blockers” can provide a useful indication of their 
functional pharmacological properties in whole cells.
Visual examination of the fluorescence of cells grown on individual coverslips with 
and without sustained treatment with the p-AR ligands was appropriate when 
examining a single concentration of ligand but not very suitable to attempt to generate 
quantitative concentration-response curves. However, the increase in cellular 
fluorescence of CAM-p2 -AR-GFP-expressing cells in response to treatment with 
betaxolol could also be monitored in a spectrofluorimeter. As such, cells grown in a 
96 well microtitre plate could be used to generate EC50 values for the effect of 
betaxolol (Figure 3.20). The values obtained were in good accord with previous 
estimates for the up-regulation of non GFP-tagged CAM-P2 -AR and inhibition of 
basal adenylyl cyclase activity in membranes expressing the CAM-P2 -AR (MacEwan 
and Milligan 1996a) and with the K; of betaxolol estimated from ligand binding 
experiments in these cells. Importantly, the increase in cellular fluorescence was not 
observed by simply adding betaxolol to the cells and immediately monitoring 
fluorescence intensity. As such it requires the time-dependent up-regulation of CAM- 
P2-AR-GFP levels.
This study has demonstrated that the fluorescence methods utilised here are extremely 
advantageous over other methods, as ligand regulation can be easily detected or 
visualised without further manipulation of the cells. The quantitative feature of this 
fluorescence study in 96 well plates has now prompted the possibility of developing a 
rapid screening assay to identify new GPCRs and their regulatory ligands. To 
determine whether ligand regulation can be monitored by these techniques in other 
GPCR systems, studies are currently underway in our lab investigating ligand effects 
on the constitutively active aiB-AR and a CAM-Pi-AR, both tagged with GFP. The 
advantages of GFP-tagging have been presented here but there are limitations in the 
sensitivity of the experimiment. However, this has led to extending the study on
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CAM-p2 'AR to the use of other fluorescent tags such as Renilla luciferase and 
Photinus luciferase to develop a more sensitive GPCR and GPCR ligand screening 
assay.
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Chapter 4
The Use of GFP Tagging to Compare 
Internalisation, Trafficking and Ligand 
Regulation of the WT-Pi-AR versus the WT-Pz'
AR
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Chapter 4
4.1 Introduction
The sub-family of p-adrenergic receptors (p-AR) are seven transmembrane spanning 
serpentine-like receptors regulated by transducer-like molecules called G proteins. 
These receptors therefore, belong to the super-family of signalling receptors termed G 
protein coupled receptors (GPCRs). In the case of the pi- and p2 - AR sub-types of 
p-AR, upon agonist binding to receptor and subsequent receptor activation, these 
stimulate the effector molecule adenylyl cyclase (AC) through the stimulatory G 
protein a  sub-unit (Gsa) to increase intracellular levels of cAMP. p-ARs are activated 
by catecholamines and related molecules. Both Pi- and P2 - ARs mediate responses to 
noradrenaline released from sympathetic nerve terminals and to circulating adrenaline. 
Table 4.1 summarises some of the characteristics of these 2 sub-types of p-AR.
To elicit an effector output agonist ligand must bind to the receptor binding site. Tota 
and Strader (1990) have indicated that it is the seven transmembrane (TM) spanning 
regions of the p-AR which are arranged to form a binding pocket buried within the 
membrane bilayer. Further studies using deletion and mutagenesis approaches have 
identified key residues within Pi- and p2 - ARs important not only for binding agonist 
ligands but also neutral antagonists. For the P2 -AR, AspU3 located in TM3 is vital 
for both agonist and antagonist binding, whereas, key residues Ser^04 and Ser^O  ^in 
TM5 interact with two hydroxyl groups of the catechol ring of agonists (Strader et al., 
1988, 1989). Wieland et al., (1996) and Zuurmond et a l, (1999) have identified and 
studied respectively the responsibility of Asn^^ in TM6 of the P2 -AR for 
stereoselectivity of catecholamines by virtue of its interaction with the p-OH in the 
aliphatic side chain. Work of the same nature has also been carried out on the Pi-AR 
reporting TM4 to be largely responsible for the 10 fold higher affinity of 
noradrenaline at this receptor compared to the P2 -AR (Frielle et al., 1988 and Dixon et
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al., 1989). A recent study by Isogaya et al., (1999) used a similar approach to look at 
agonist binding as Marullo et al., (1990) who reported that no TM region in the p-AR 
is responsible for selectivity of antagonists. From generating pi/p^-chimeric 
receptors TM2 and TM7 of the p2 -AR were found to be important for binding to p2 - 
AR selective agonists, Tyr^^S of TM7 being particularly important. This residue is a 
Phe in the Pi-AR and agonist binding at this receptor is only determined by TM2; 
LeullO, T hrill and Val^^^ being the key residues involved (Isogaya et al., 1998, 
Isogaya etal., 1999).
Sustained exposure of Pi- and p2- ARs to agonist ligands frequently results in a 
waning of response to the ligand, an effect termed desensitisation. This is a multi-step 
phenomenon designed to prevent hormonal overload, and has been well studied for 
the P2 -AR/Gs/AC system. First, uncoupling of the receptor from the G protein occurs 
causing receptor function to be attenuated. Sequestration of the receptor into an 
intracellular compartment then occurs followed by down-regulation, if the stimulation 
is chronically persistent.
Short-term desensitisation occurs within seconds to minutes and involves 
phosphorylation of the receptor by two classes of Ser/Thr kinases, cAMP dependent 
protein kinase A (PKA) and p-AR kinases (pARKs) also known as G protein coupled 
receptor kinases (GRKs), to uncouple the receptor from the stimulatory G protein, Gg 
(Lohse, 1993; Benovic et al., 1988 and Hausdorff et al., 1990). For the P2 -AR all of 
the 11 GRK phosphorylation sites have been proposed to reside in the distal portion 
of the C-terminal tail, whereas one PKA site located in the 3rd cytoplasmic loop and a 
second less characterised site in the proximal portion of the C terminal tail have been 
identified. There are 10 proposed GRK sites in the p i-AR C-teiminal tail and only 
one PKA site in the 3rd intracellular loop in an analogous position to the one in the P2 - 
AR (Frielle et al., 1987). Uncoupling of the receptor from Gg is assisted by binding 
of the phosphorylated receptor to inhibitory proteins called p-arresting which are
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recruited by GRK phosphorylated receptors. Zhou and Fishman, (1991) proposed 
that the p i~AR could only be desensitised through a PKA-dependent mechanism 
however, GRK2 and GRK 5 have been shown to phosphorylate this receptor. Like 
P2 -AR desensitisation, pi-AR desensitisation appears to be due to approximately 
equal contributions from GRKs and PKA (Freedman et ai., 1995).
Once phosphorylated the receptor is found to internalise by a clathrin/dynamin- 
mediated pathway assisted by p-aiTestins which are clathrin adapters (Zhang et al., 
1996, Lin et al., 1997 and outlined in Chapter 1, Section 1.6b). This process was 
found not to be involved in desensitisation but in the resensitisation and recycling of 
the receptor (Yu etal., 1993). The receptor is resensitised so it can undergo another 
round of agonist activation. Following internalisation into endosomes/vesicles 
dephosphorylation of the P2 -AR by a vesicular membrane-associated form of the 
phosphatase PP-A2 occurs. This event only occurs under acidic pH and can be 
inhibited by NH4 CI (Kreuger et al., 1997).
Elucidation of this sequence of events has resulted in an accepted model for the 
clathrin-dependent internalisation pathway exhibited by the P2 -AR (Figure 4.1). This 
is basically a receptor cycle to turn on and off the stimulus repeatedly. However, 
there is a mechanism to turn off the effect of a stimulus permanently. This is a 
process termed down-regulation, a pathway which is debated to either diverge from 
the receptor cycle (Figure 4.1, Kallal et al., 1998, Gagnon et al., 1998) or to be 
independent from receptor internalisation (Valiquette et al., 1990, Hausdorff et al., 
1991, Campbell et al., 1991, Green et al., 1994, Barak et al., 1994). Down- 
regulation is demonstrable only after a few hours and involves receptor protein 
degradation and a reduction in steady state levels of receptor mRNA (Hadcock et al., 
1988, 1989). Reports have shown that several GPCRs can be targeted to lysosomes
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Figure 4.1
Accepted model of agonist stimulated GPCR sequestration and 
recycling.
Typical pathway for a neurotransmitter receptor, exemplified by the P2-AR. 
Agonist binding which is reversible, is followed by receptor phosphorylation by 
GRKs, interaction with p-arrestins and uncoupling from G proteins, which mediate 
desensitisation. The ligand-receptor complex is internalised via clathrin into 
vesicles that soon shed their clathrin coat and become early endosomes. Ligand 
and receptor dissociate in an acidified perinuclear compartment. Endosomal 
phosphatases may dephosphorylate the receptor, allowing dissociation of 
arrestins. The ligand is degraded, whereas the receptor is recycled to the plasma 
membrane, where it can interact with ligands with high affinity. Resensitisation 
requires internalisation, processing and recycling of receptors.
From Bohm, Grady and Bunnett, Biochem. J., 1997, 322, 1-18.
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in an agonist-dependent manner (Hein et al., 1994, Petrou et a l, 1997, Tarasova et 
a l, 1997) and this has also been reported for the P2 “AR tagged with GFP (Kallal et 
a l ,  1998). Gagnon et a l, (1998) demonstrated that in HEK293 cells, receptor 
internalisation and down-regulation of the p2~AR could be inhibited by the K44A 
dominant negative mutant of dynamin, a mutant known to block the pinching off of 
endocytic vesicles. When the same experiment was performed in HeLa cells (Gagnon 
et a l, 1998) or L cells (Jockers et a l, 1999), little or no effect on down-regulation 
was measured respectively. This discrepancy may be due to a difference in cell type 
but Jockers et a l, (1999) have argued that the overexpression of K44A dynamin in 
HEK293 cells may also affect pathways other than endocytosis. They also argue that 
in L cells and A431 cells P2 -AR sites are lost after long term agonist exposure dispite 
blocking of lysosomal or proteasomal functions. They postulate that these cells may 
use an alternative mechanism for down-regulation possibly involving plasma 
membrane proteases.
In this chapter of work a comparison of ligand regulation of pi-AR versus p2 “AR was 
attempted by using stable HEK293 cell systems expressing either p i~AR or P2 -AR 
with or without GFP linked to their C-terminal tail Previous reports have shown that 
addition of the 27kDa GFP polypeptide to a range of receptors does not alter the 
receptor pharmacology or interaction of the receptor constmct with G-proteins to 
initiate a second messenger response (Barak et al., 1997; Kallal et al., 1998; Drmota et 
al., 1998,1999; Awaji et al., 1998; Tarasova et a l, 1998). As previously shown in 
Chapter 3 ligand regulation of a CAM-P2 -AR-GFP construct stably expressed in 
HEK293 cells was monitored with the added aid of confocal microscopy.
Initially, transient transfections of the pi-AR with or without linked GFP into 
HEK293 cells were performed to confirm that expression was obtained and that the 
GFP construct could be detected by fluorescence microscopy. Stable cell lines of 
HEK293 cells were then generated and single clones isolated for study i.e. a WT-Pi-
131
AR clone and a WT-Pi-AR-GFP clone. Both clones were pharmacologically 
characterised for their ability to bind the p-AR agonist isoprenaline and the Pi~AR 
selective antagonist betaxolol, to examine whether GFP had any effect on ligand 
binding at this receptor. Expression levels of the receptor constructs were also 
determined along with the Kd of pH] DHA for the receptor. Intact cell adenylyl 
cyclase assays were performed on both clones plus the two P2 -AR clones generated 
earlier in Chapter 3 to determine the EC5 0  for isoprenaline at each receptor construct.
Internalisation of the receptor-GFP constructs was determined visually and by pH] 
CGP12177 binding studies on intact cells. The rates of internalisation were 
determined and compared to wild-type receptor constructs. Confocal microscopy was 
also used to examine recycling of both WT-Pi-AR-GFP and WT-p2 -AR-GFP. 
Finally, analysis of receptor down-regulation was achieved by intact cell and 
membrane binding assays in conjunction with confocal microscopy to reveal
differences in ligand regulation of these two sub-types of p-AR.
4.2 Construction and expression of wild-type Pi-adrenergic receptor 
and a green fluorescent protein-tagged form of this receptor in HEK293 
cells.
A cDNA of the human Pi-AR was modified such that an 8 amino acid (DYKDDDDK) 
Rag™ epitope tag was added to the N terminus of the encoded protein (Rag-pj-AR). 
This construct was further modified by a PCR-based strategy to link a cDNA 
encoding a modified form of the GFP from Aequorea victoria with enhanced 
autofluorescent properties (Zemicka-Goetz et al., 1997) to its C terminus (Figure 
4.2a). This fusion protein was anticipated to encode a single open reading
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Figure 4.2
a) Schematic diagram of the cDNA encoding the WT-Pi-AR-GFP 
fusion construct generated for this study.
WT-pi-AR-GFP was generated using a PCR based approach to link GFP to the N 
terminus of the WT-Pi-AR. (see Chapter 2 Section 2.4c).
b) Confocal analysis to determine the cellular location of WT-Pi-AR- 
GFP once transiently transfected into HËK293 cells.
Following transient transfection of HEK293 cells on glass cover slips with the WT- 
pl-AR-GFP cDNA, cells were fixed, mounted on a microscope slide as described 
in Section 2.8 and then imaged by confocal microscopy.
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Figure 4.2
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frame in which the C terminus of the GPCR was linked directly to the N terminus of 
GFP (Figure 4.2a).
Both GFP-tagged and non-GFP-tagged forms of this receptor were transiently 
transfected into HEK293 cells. When WT-pi-AR-GFP transiently transfected 
HEK293 cells grown on a glass coverslip were examined in a confocal microscope, 
the cellular location of this construct was very similar to that of WT-P2 -AR-GFP 
(Figure 3.6, Section 3.2, Chapter 3), its fluorescence being distributed mainly at the 
plasma membrane of the cell (Figure 4.2b). From binding experiments using a single 
concentration of pH] DHA on membranes from HEK293 cells transiently transfected 
with pcDNA3, WT-pi-AR, WT-Pi-AR-GFP, WT-P2 -AR or WT-P2 -AR-GFP 
(Figure 4.3), it was apparent that WT-Pi-AR-GFP could be expressed at a similar 
level to both the WT-p2 -AR and WT-P2 -AR-GFP constructs. The untagged form of 
the receptor was expressed at routinely lower levels than the GFP-tagged form. 
However, its expression was significantly greater than the control experiment using 
empty vector pcDNA3. Stable cell lines of each construct in HEK293 cells were then 
developed.
Once stable cell lines of WT-Pi-AR with and without linked GFP were established in 
HEK293 cells single clones of each were selected for study. A fluorescent 
microscope was utilised to directly screen for the WT-Pi-AR-GFP containing clones. 
Figure 4.4 shows confocal images from two positive clones grown on glass 
coverslips demonstrating that the WT-pi-AR-GFP protein construct is targeted to the 
plasma membrane as substantial amounts of the GFP-derived autofluorescence is 
plasma membrane delineated. Disappointingly, only about 20% of the putative WT- 
pl-AR-GFP clones selected were positive. However, clone #9, like WT-P2 -AR-GFP 
clone #13 (Figure 3.6), exhibited a marked time-dependent receptor internalisation 
into discrete, punctate intracellular vesicles upon addition of the p-AR agonist 
isoprenaline (Figure 4.5). WT-Pi-AR-GFP exhibited a smaller degree of
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Figure 4.3
Expression levels of WT-Pi-AR and WT-pi-AR-GFP from transient 
transfections in HEK293 cells as assessed by [^H] DHA binding.
Membranes (20 pg) prepared from HEK293 cells transiently expressing either the 
WT-Pi-AR, WT-Pi-AR-GFP, WT-P2 -AR or WT-p2 -AR-GFP constructs were 
analysed for their ability to bind a single, near saturating, concentration of pH] 
DHA (2 nM). Results are from one experiment performed in triplicate ± S.D. 
Similar results were obtained form two further experiments.
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Figure 4.4
WT-Pi-AR-GFP stable cell clones.
The WT-Pi-AR-GFP construct was expressed stably in HEK293 cells and 
individual clones were identified by live cell confocal microscopy. All positive 
clones were similar to the two clones ( 6  and 9) imaged with a largely plasma- 
membrane delineated auto fluorescence.
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Figure 4.4
0g
Figure 4.5
Internalisation of WT-pi-AR-GFP by agonist stimulation.
A patch of WT-pi-AR-GFP clone #9 cells were imaged in the confocal microscope 
in the absence of agonist (a) and following addition of 10'^ M isoprenaline for 10 
(b), 20 (c), 30 (d), 40 (e) and 50 (f) minutes. This is representative of three 
separate experiments.
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internalisation than WT-p2 -AR-GFP. Both constructs internalised fairly rapidly with 
a distinct punctate pattern appearing within 10 minutes of isoprenaline addition (Figure 
3.6b and 4.5b). However, internalisation became maximal at about 30 minutes for 
WT-Pi-AR-GFP (Figure 4.5 c and d), but WT-p2 -AR-GFP internalised further with 
a 30 to 40 minute stimulation of isoprenaline. In order to make such conclusions from 
this data it was essential to investigate this more quantitatively (see Section 4.4).
The non-GFP-tagged WT-p i-AR clones were initially screened by pH] DHA binding 
studies using a single concentration of radioligand. Figure 4.6a displays a selection of 
clones examined of which 30% were found to bind substantial amounts of a single 
concentmtion of pH] DHA and therefore, were assumed to be expressing WT-pi-AR 
at reasonable levels (greater than 300 fmol/mg was determined as a reasonable level of 
pl-AR). Three of the positive clones were used to make membranes for western 
blotting with an anti-pi-AR antibody (Figure 4.6b). All three clones expressed a 
doublet of proteins with approximate molecular weights of 50 kDa and 60 kDa which 
may coiTelate with glycosylated and unglycosylated forms of the Pi-AR (Table 4.1 
indicates that the unglycosylated form of the human p i-AR is approximately 50 kDa). 
Clone #11 was selected due to strong immunodetection and a high level of pH] DHA 
binding compared to the other positive clones. Figure 4.7 gives an approximate 
indication of expression levels of clones #11 and #9 using a single concentration of 
pH] DFIA in binding studies. As with the p2 -AR clones, it was necessary to perform 
more detailed analysis to pharmacologically characterise these constructs.
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Figure 4.6
Screening of WT-Pi-AR stable cell clones
a) The WT-Pi-AR construct was expressed stably in HEK293 cells and individual 
positive clones were detected by membrane binding studies with a single 
concentration of pH] DHA (2 nM). A range of selected clones are shown. Data 
are means ± S.D. from a single experiment performed in triplicate.
b) 20 pg of membranes from clones 11(1), 22 (3) and 40 (4) were run on an SDS 
protein gel along with membranes from WT-pz-AR clone 27 (2). Nitrocellulose 
membranes were probed with anti-pi-AR antibody to detect expressed p i-AR.
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Figure 4.7
Estimation of receptor levels o f  Pi-AR clones from membrane 
binding studies using a single concentration of pH ] DHA.
2 0  pg of membrane preparation from each cell line was used to estimate the 
approximate receptor level (fmol/mg). A close to saturating dose of pH] DHA (2 
nM) was used to determine total binding with 10'^ M propranolol as competing 
ligand to determine non-specific binding. Specific binding was used to estimate the 
receptor expression in each clone (fmol/mg). Data are presented as means ± 
S.E.M. n=3.
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Table 4.2
Ligand-binding characteristics of GFP and non-GFP tagged forms of the pi~AR 
and p2“AR constructs.
Clone Kd (nM) Bmax (pmol/mg)
WT-Pi-AR 1.08 ± 0 .2 2.6 ± 0 .4
WT-Pi-AR-GFP 1.81 ± 0 .3 18.8 ±2 .5
WT-pz-AR 0.62 ± 0.26 4.1 ± 0 .9
WT-Pz-AR-GFP 0.75 ± 0 .17 8.7 ± 0 .7
Data represent means ± S.E.M. from three independent experiments using [^H] 
DHA as radioligand.
Table 4.3
Competition binding experiments at GFP and non-GFP tagged forms of the pi-AR 
construct.
Data represent means ± range, from two independent experiments using [^H] 
DHA as radioligand.
U1
Clone Ki for K ifor
isoprenaline (nM) betaxoiol (nM)
WT-Pi-AR 127 ± 1 0 16 ± 0 .4
WT-Pi-AR-GFP 289 ± 64 25 ± 12 \-U-
4.3 Pharmacological characterisation
Expression levels of WT-pj-AR and WT-pi-AR-GFP clones were determined more 
accurately by saturation binding experiments with pH] DHA (also an antagonist at the 
pl-AR). WT-pi~AR-GFP (Figure 4.9a(i)) was found to be expressed at much higher 
levels than WT-Pi-AR (Figure 4.8a(i)) (Table 4.2 B^ax values). The ability of the 
GFP fusion construct to be expressed at higher levels than its non-GFP-tagged form 
was also apparent for the WT-Pa-AR. As for the WT-p%-AR, the non-specific 
binding at both pi-AR constructs was very low (Figures 4.8a(ii) and 4.9a(ii)). 
Saturation binding curves were converted into Scatchard plots for each receptor 
construct and results from these experiments indicated that both constructs bound the 
ligand pH] DHA with similar affinity (Table 4.2 and Figures 4.8b and 4.9b).
Competition for the specific binding of pH] DHA to membranes expressing WT-pi- 
AR or WT-p i-AR-GFT* with either betaxoiol (a p i-AR antagonist) or isoprenaline (an 
agonist) were performed to demonstrate that adding GFP to the C terminus of the 
receptor had little effect on basic receptor pharmacology (Table 4.3). When betaxoiol 
was used as a competing drug results indicated that both pi-AR constructs bound this 
ligand with high affinity (Figure 4.10 a and b, and Table 4.3). Betaxoiol is a p i-AR 
selective antagonist and proved to bind to the pi-AR constructs with 10-20 times 
higher affinity than the P2 -AR constructs (compare Tables 3.2 and 4.3). As such, the 
previously noted high affinity of the antagonist betaxoiol for the pi-AR was preserved 
following addition of GFP to the C-terminal tail. Isoprenaline was found to have 
approximately 3 fold higher affinity for the pi-AR constructs compared to the P2-AR 
constructs (compare Table 3.2 and 4.3), but little difference in the Ki for isoprenaline 
was detected between the two pi-AR constructs (Figure 4.11 a, b).
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Figure 4.8
Pl-AR binding characteristics in WT-Pi-AR-expressing cells.
a i) A saturation binding study using increasing concentrations of pH] DHA was 
performed to measure specific binding (pmol/mg) in membranes from WT-Pi-AR 
cells.
a ii) The same saturation binding study as in (a i) but showing total, specific and 
non-specific binding (d.p.m.).
b) Transformation of the specific binding data to generate a Scatchard plot. In the 
example displayed Bmax was 3.21 pmol/mg and the Kd fpr pH] DHA was 1.35 
nM.
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Figure 4,9
Pl-AR binding characteristics in WT-pi-AR-GFP-expressing cells.
ai) A saturation binding study using increasing concentrations of pH] DHA was 
performed to measure specific binding (pmol/mg) in membranes from WT-pi-AR- 
GFP cells.
a ii) The same saturation binding study as in (a i) but showing total, specific and 
non-specific binding (d.p.m.).
b) Transformation of the specific binding data to generate a Scatchard plot. In the 
example displayed Bmax was 16.91 pmol/mg and the Kafor pH] DHA was 1.24 
nM.
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Figure 4.10
High affinity of the Pi-AR antagonist betaxoiol for the WT-Pi-AR is 
retained after addition of GFP.
Competition between pH] DHA (1.2 nM (a) and 1.0 nM (b)) and varying 
concentrations of betaxoiol for specific binding to membranes expressing either 
WT-pi-AR, Hill coefficient = 0.9 (a); or WT-Pi-AR-GFP, Hill coefficient = 0.9 
(b) was assessed. Similar results were obtained from one further experiment 
(Table 4.3).
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Figure 4.11
GFP has little effect on the affinity of isoprenaline for the WT-pi- 
AR.
Competition between pH] DHA (1.0 nM (a) and 1.6 nM (b)) and varying 
concentrations of isoprenaline for specific binding to membranes expressing either 
WT-Pi-AR, Hill coefficient = 0.8 (a); or WT-pi-AR-GFP, Hill coefficient = 0.6 
(b) was assessed. Similar results were obtained from one further experiment 
(Table 4.3).
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4.4 Internalisation studies
In Chapter 3 and in Section 4.2 internalisation of WT-P2 -AR-GFP and WT-pi-AR- 
GFP were shown respectively. It is impossible to determine accurately the time- 
course of internalisation from confocal images as this relies on judgement by eye. 
Therefore, intact cell binding studies were employed to quantitate more fully the time- 
course of internalisation of the two receptor-GFP constructs. This also allowed a 
comparison with the non-GFP-tagged receptors to be achieved. As internalisation of a 
cell surface receptor was to be measured, pH] DHA was not an appropriate 
radioligand for this assay as it is hydrophobic and can cross the plasma membrane. 
Therefore, any internalised receptor would still bind pH] DHA. pH] CGP121777 
was an ideal choice for such studies as it is hydrophilic, so cannot cross plasma 
membranes, and is an antagonist at both the pi-AR and the p%-AR.
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To compare the functionality of WT-p2 “AR-GFP and WT-p2 -AR the two clones were 
labelled with pH] adenine (1 pCi/ml, 24 h) and the capacity of isoprenaline to 
stimulate the generation of pH] cAMP measured. Both constructs allowed 
stimulation of pH] cAMP production with isoprenaline displaying a similar potency at 
WT-P2 -AR-GFP (EC5 0  = 1.43 ± 0.2 X 10 -9 M) compared to WT-P2-AR (EC5 0  = 
3.82 ± 0.5 X 10'^ M), However in these selected clones, WT-P2-AR-GFP gave a 
lower maximal isoprenaline stimulation than WT-P2 -AR (Figure 4.12a). A 
concentration-effect curve for isoprenaline was also generated for WT-pi-AR and 
WT-Pi-AR"GFP expressing clones. Isoprenaline had a 10 times higher potency at the 
WT-pi-AR-GFPconstruct (EC5 0  = 6.7 ± 0.2 x lO'^ M) compared to the WT-pi-AR 
construct (EC5 0  = 7,1 ± 0.4 x 1 0 "^  M) and a similar potency to the p2“AR constructs 
examined above (Figure 4 .12b).
Figure 4.12
Isoprenaline stimulated regulation of adenylyl cyclase activity in 
intact cells expressing various p-AR constructs.
a) Basal adenylyl cyclase activity and its regulation by increasing concentrations of 
isoprenaline M to 10'^ M) in WT-P2 ~AR and WT-P2 -AR-GFP expressing 
cells was assessed as detailed in Chapter 2 Section 2.7d. Data represent means ± 
S.D. of triplicate assays from a single representative experiment. Two additional 
assays produced similar results. The average EC5 0  of isoprenaline ± S.E.M was 
calculated for both constructs. Isoprenaline stimulation gave an EC5 0  = 3.8 ± 0.9 x 
10-9 M at WT-P2 -AR. mean ± S.D., /i = 3; and EC5 0  = 1 4  ± 0.3 x 10-9 m  at WT- 
P2 -AR-GFP, mean ± S.D., w = 4.
b) A similar dose-response to isoprenaline on WT-pj-AR and WT-Pi-AR-GFP 
expressing cells. Results are from a single representative experiment performed in 
triplicate.
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Confocal experiments involved treatment of cells grown in a monolayer on a glass 
coverslip. The intact cell binding experiments with pH] CGP12177 employed in 
Chapter 3 involved binding of the radioligand to cells in suspension (Gagnon et al.,
1998; Orsini et al., 1998). As this is inconsistent with the confocal approach this 
binding assay was modified slightly to accommodate this discrepancy. Cells of each 
clone (WT-pi-AR, WT-^i-AR-GFP, WT-p2 -AR and WT-P2 -AR-GFP) were seeded 
into 24 well plates and were allowed to attach for 24 h. Time courses to monitor the 
rate of binding of pH] CGP12177 at 4°C were performed. A temperature of 4°C was 
used to prevent recycling of any internalised receptor. All four constructs bound pH]
CGP12177 with similar rates (Figure 4.13a-d), maximal binding being achieved at 
approximately 60 minutes. It was decided that all pH] CGP12177 intact cell binding 
assays would be incubated for 90 minutes to insure that maximal binding was being 
achieved.
A second factor to consider was to ensure that all isoprenaline was efficiently washed 
away after treatment. Two experiments were performed on the (3 2 "AR-expressing 
cells to determine this (Figure 4.14 a and b). WT-P2 -AR and WT-p2 -AR-GFP cells 
were untreated or treated in 24 well plates with lO'-^  M isoprenaline for 30 minutes at 
4°C to achieve association of ligand with cell surface receptor but to induce no 
receptor internalisation. Cells were then washed 0 , 1 , 2, 3, or 4 times and 
subsequently incubated at4°C with pH] CGP12177 for 90 minutes (Figure 4.14a).
It was apparent that binding of the agonist had occuixed as unwashed cells exhibited a 
reduced binding of pH] CGP12177 indicating that residual isoprenaline was 
competing for binding and interfering with the assay (Figure 4.14a), One wash with 
buffer seemed to sufficiently wash away competing isoprenaline but it was decided 
that two washes would ensure all contaminating ligand was washed away. Providing 
all isoprenaline is washed away efficiently the hydrophobic ligand pH] DHA should 
be able to bind to any internalised receptor. Again WT-p2 -AR and WT-p2 -AR-GFP- 
expressing cells were treated for zero or 30 minutes with 10"  ^ M
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Figure 4.13
Time-course of pH ] CGP12177 binding to Pi- and p%- adrenergic 
receptor expressing clones.
Cells of each clone were seeded into 24 well plates and the rate of binding of pH] 
CGP12177 (10 nM) to the WT-P2 -AR (a), WT-P2 -AR-GFP (b), WT-Pi-AR, (c) 
or WT-p i-AR-GFP (d) was measured at 4°C.
Results are from a representative experiment performed in triplicate ± S.D.
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Figure 4.14
Optimisation of pH ] CGP12177 binding assays.
a) To show that isoprenaline could efficiently be washed away, WT-P2 -AR, and 
\VT-P2 -AR-GFP-expressing cells were untreated or treated in 24 well plates with 
lO -^M isoprenaline for 30 minutes at 4 °C. After washing the cells for 0, 1, 2, 3, 
or 4 times intact cell bindings were performed with 10 nM pH] CGP12177 at 4 °C 
for 90 minutes.
b) To show that internalised P2 -AR could still be measured, WT-p2 -AR, and WT- 
P2 -AR-GFP-expressing cells were untreated or treated in 24 well plates with 10^ 
M isoprenaline for 30 minutes at 37 °C. After two washes cells were incubated 
with pH] DHA for 45 minutes at 30 or pH] CGP12177 for 90 minutes at 4 ®C. 
Results are from a representative experiment performed in triplicate ± S.D,
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isoprenaline at 37°C to induce agonist-stimulated internalisation of the receptor 
constructs. Following two washes with ice cold buffer, intact cell bindings were 
performed for 90 minutes at 4°C with pH] CGP12177, and for 45 minutes at 30°C 
with pH] DHA (Figure 4.14b). A time-dependent internalisation of both receptor 
constructs occurred, as measured by loss of pH] CGP12177 binding, whereas total 
levels (cell surface and internalised) of the receptor were unchanged as monitored by 
the binding of pH] DHA (Figure 4 .14b).
Time-dependent receptor internalisation in response to the agonist isoprenaline was 
now determined for the four clones. WT-p2~AR-GFP produced little or no detectable 
internalisation 5 minute post-stimulation but internalised linearly up to 40 minutes, 
slightly plateauing off to 60 minutes (Figure 4.15). The WT-p2 -AR construct 
internalised more rapidly than WT-P2 -AR-GFP, its internalisation becoming maximal 
at 20 to 30 minutes of isoprenaline stimulation (Figure 4.14). Therefore, GFP 
appears to slow the ability of the p2 ~AR receptor to internalise in response to agonist 
stimulation. This was also true for the Pi-AR constructs. WT-Pi-AR-GFP 
internalisation is maximal only at 40 minutes whereas the non-tagged construct only 
takes about 10 to 20 minutes to become maximally internalised (Figure 4.16). In 
agreement with the confocal data from Section 4.2 (Figures 3.6 and 4.6), the WT-pi- 
AR internalised to a lesser extent (40 % internalised) than the WT-p2 ~AR (70 % 
internalised) (Figure 4.17). These figures are also true for the GFP-tagged versions 
of these receptors except that only approximately 60 % of WT-P2 -AR-GFP was 
internalised at 60 minutes (Figure 4.18).
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Figure 4.15
Isoprenaline-stimulated internalisation of WT-p2 “AR versus WT-P2“ 
AR-GFP .
WT-P2 -AR, and WT-P2 -AR-GFP-expressing cells were untreated or treated in 24 
well plates with 10'^ M isoprenaline for various time intervals. pH] CGP12177 
binding was then performed to measure the rate of agonist stimulated internalisation 
of the two constructs with respect to each other. Results are represented as means 
± S.E.M., n = 5 for WT-p2 “AR (diamonds) and « = 4 for WT-p2 -AR-GFP 
(squares).
153
Figure 4.15
1
ièu
F
uigu
%
120
100
80
60
40
20
-10
i
♦  WT-B2-AR 
□ WT-B2-AR-GFP
10 20 30 40 50 60 70
Time (min)
Figure 4.16
Isoprenaline-stimulated internalisation of WT-pi-AR versus WT-Pi- 
AR-GFP.
WT-Pi-AR, and WT-p i-AR-GFP-expressing cells were untreated or treated in 24 
well plates with 10’^  M isoprenaline for various time intervals. pH] CGP12177 
binding was then performed to measure the rate of agonist stimulated internalisation 
of the two constructs with respect to each other. Results are represented as means 
± S.E.M., n = 3 for WT-pi-AR (diamonds) and « = 5 for WT-Pi-AR-GFP 
(squares).
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Figure 4.17
Isoprenaline-stimulated internalisation of WT-Pi-AR versus WT-Pi- 
AR.
WT-Pi-AR, and WT-p2 "AR-expressing cells were untreated or treated in 24 well 
plates with 10"  ^ M isoprenaline for various time intervals. pH] CGP12177 
binding was then performed to measure the rate of agonist stimulated internalisation 
of the two constructs with respect to each other. Results are represented as means 
± S.E.M., « = 3 for WT-Pi-AR (diamonds) and w = 5 for WT-P2 -AR (squares).
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Figure 4.18
Isoprenaline-stimulated internalisation of WT-Pi-AR-GFP versus 
WT-Pi-AR-GFP .
WT-pi-AR-GFP, and WT-P2 -AR-GFP-expressing cells were untreated or treated 
in 24 well plates with lO^ M isoprenaline for various time intervals. pH] 
CGP 12177 binding was then performed to measure the rate of agonist stimulated 
internalisation of the two constructs with respect to each other. Results are 
represented as means ± S.E.M., w = 5 for WT-pi-AR-GFP (diamonds) and « = 4 
for WT-P2 -AR-GFP (squares).
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4.5 Recycling of p-AR constructs
Internalisation of GPCRs occurs after the receptor becomes desensitised and can no 
longer respond to the stimulus. Internalisation is a prerequisite to resensitisation of 
the receptor which occurs in an intracellular compartment before returning to the cell 
surface to undergo another round of agonist stimulation. Tagging p-ARs with GFP 
was extremely useful when monitoring the recycling of these receptors. Firstly WT- 
P2-AR-GFP-expressing cells were untreated or pretreated with 10"  ^M isoprenaline 
for 30 minutes (Figure 4.19 a and b). The agonist was then removed by washing, 
and the p2 -AR selective antagonist alprenolol added at IQ-  ^ M to prevent further 
internalisation of any recycled P2 -AR. After a 30 minute exposure to alprenolol a 
large proportion of the receptor had recycled back to the plasma membrane (Figure 
4.19 c). This was more pronounced at 40 minutes (Figure 4,19d). Recycling of 
internalised WT-pi-AR-GFP was also examined on cells pretreated with 10"^  M 
isoprenaline for 30 minutes (Figure 4.20 a and b). After a 10 minute exposure to 
betaxolol distinct recycling of receptor was noted (Figure 4.20c) which was even 
more pronounced at 30 minutes (Figure 4.20d).
4.6 Long term treatments with agonist isoprenaline
It has previously been documented that long term treatment (> 24 h) of cells 
expressing the P2 -AR with agonists such as isoprenaline can cause a substantial 
down-regulation of the receptor. The receptor is internalised and instead of being 
resensitised and recycled back to the plasma membrane the protein is trafficked to 
lysosomes where it is degraded. It seemed appropriate to determine that the GFP- 
tagged WT-P2 -AR, like the untagged form, could be down-regulated.
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Figure 4.19
Recycling of WT-P2  AR-GFP fo llow ing isoprenaline-stimulated 
internalisation.
WT-P2 -AR-GFP-expressing cells were untreated (a) or pretreated with 10'^ M 
isoprenaline for 30 minutes (b-d). Following washing with 10"  ^ M alprenolol, 
receptor recycling was monitored at the indicated time points. 10“^  M alprenolol for 
30 minutes (c) and 10'^ M alprenolol for 40 minutes (d).
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Figure 4.19
Figure 4.20
Recycling of W T-pi-AR-GFP fo llow ing isoprenaline-stimulated 
internalisation.
WT-Pi-AR-GFP-expressing cells were untreated (a) or pretreated with 10"  ^ M 
isoprenaline for 30 minutes (b-d). Following washing with 10"  ^ M betaxolol, 
receptor recycling was monitored at the indicated time points. 10"^  M betaxolol for 
10 minutes (c) and 10"^  M betaxolol for 30 minutes (d).
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Figure 4.20
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WT-p2 -AR and WT-p2 -AR-GFP expressing ceils were untreated or exposed to 10'^ 
M isoprenaline for 24 hours. After thoroughly washing the cells, intact cell binding 
was performed using a single concentration of pH] CGP12177 to measure cell 
surface receptor and pH] DHA to measure the extent of total receptor loss. As 
expected the WT-p2 -AR-expressing clone exhibited a large loss of receptor from the 
cell surface with a 40 ± 3 % (mean ± S.D) loss in total cell receptor (Figure 4.21a). 
Perhaps surprisingly, although the WT - P2 -AR-GFP-expressing clone displayed a 
massive loss of cell surface receptor 81 ± 9 % of total receptor was still detected from 
binding studies after agonist treatment (Figure 4.21a), pH] DHA binding on 
membranes from cells treated in the same way indicate that approximately 60 % of 
total WT-P2 -AR is lost but no loss of WT-P2 -AR-GFP occurs (Figure 4.21b). Due to 
this discrepancy confocal analysis of living WT~p2 -AR-GFP cells before and after 
treatment with isoprenaline was required. Following a 24 h treatment with 10"  ^ M 
isoprenaline the cells imaged demonstrated that WT-P2 -AR-GFP was certainly being 
lost from the cell surface but had associated into a massive aggregation within an 
intracellular compartment with very little or no protein degradation (Figure 4.21c).
Long term treatment with 10'^ M isoprenaline was also performed on the WT-pi-AR- 
GFP clone (Figure 4.22). An 8  h treatment produced a marked punctate pattern of 
fluorescence within the cells with receptor still remaining at the cell surface (Figure 
4.22b). This punctate pattern was also apparent at 24, 48, and 72 h of isoprenaline 
stimulation with a possible loss of receptor from the cell surface (Figure 4.22 d, e and 
f, respectively). Figures 4.22 a and c are images of these cells in the basal state. To 
attempt to clarify the results obtained here, ligand binding experiments on intact cells 
were performed on WT-^i-AR-GFP and WT-^i-AR using a single concentration of 
pH] radioligand (pH] DHA or pH] CGP 12177) (Figure 4.23). Following treatment 
of WT“Pi-AR-GFP cells with 10'^ M isoprenaline for 24, 48 or 72 h, binding 
experiments with pH] DHA indicated that a slight up-regulation of the receptor 
construct had occurred at 24 h but essentially the levels of receptor remained near to
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Figure 4.21
Down-regulatlon of p2 -AR-expressing clones
WT-P2 -AR and WT-p2 “AR-GFP-expressing cells were untreated or treated with 
10'^ M isoprenaline for 24 h.
a) Cells were washed thoroughly and subsequently incubated with pH] DHA for 
45 minutes at 30 °C or pH] CGP12177 for 90 minutes at 4 °C to determine the 
ratio of total receptor and cell surface receptor respectively. Results are represented 
as means ± S.E.M., n = 3 for WT-p2 -AR and n = 3 for WT-P2 ~AR-GFP.
b) Cells were treated as stated and membranes prepared. pH] DHA binding 
experiments were performed on 2 0  pg of each membrane preparation and the 
expression level of each construct after treatment determined (fmol/mg). A 
representative experiment performed in triplicate is shown.
c) Untreated and treated WT-P2 -AR-GFP cells were imaged in a confocal 
microscope to show the location of the receptor-GFP construct before and after 
treatment.
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Figure 4.22
Fluorescence studies of WT-pi-AR-GFP-expressing cells after long 
term treatments with isoprenline.
WT-Pi-AR-GFP expressing cells were plated onto glass cover slips and untreated 
(a,c) or treated with 10'^ M isoprenaline for 8 h (b), 24 h (d), 48 h (e) and 72 h (0- 
The cells were then imaged in a confocal microscope.
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Figure 4.23
[^H] ligand binding studies on WT-Pi-AR and W T-pi-AR-GFP- 
expressing cells after long term treatments with isoprenaline.
WT-pi-AR and WT-Pi-AR-GFP-expressing cells were untreated or treated in 24  
well plates with 10*^  M isoprenaline for 24, 48 and 72 hours. After washing, the 
cells were incubated with pH] DBA for 45 minutes at 30 or pH] CGP12177 
for 90 minutes at 4  to determine the ratio o f total receptor and cell surface 
receptor respectively. Results are represented as means ± range, w = 2.
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basal levels . From pH] CGP12177 binding an internalisation of WT-pi-AR-GFP 
was measured correlating with the punctate pattern seen in Figure 4.22 d, e and f.
WT-p i-AR was up-regulated at 24 h but at 48 and 72 h again the receptor level stayed 
near the basal level of receptor. The pH] CGP12177 binding experiment predicts a 
slight internalisation of WT-Pi-AR (Figure 4.23). This is different to the WT-P2 -AR 
which undergoes a 40 % down-regulation. As seen previously, the WT-P2 -AR-GFP 
construct undergoes little down-regulation at 24 h but after 48 to 72 h isoprenaline 
stimulation at least 40 to 50 % of the receptor is destroyed in agreement with the data 
from the WT-P2 -AR. Essentially long term treatment of both Pi-AR constructs 
caused a slight redistribution of receptor from the plasma membrane but little change ^
in total receptor level.
4.7 D iscussion
Detailed studies have been performed on p2 “AR-expressing cell systems to 
characterise the P2 -AR/Gs/AC signaling pathway in response to agonist stimulation. 
Figure 4.1 and Section 4.1 present a generally accepted model of this process 
including subsequent receptor desensitisation, sequestration and resensitisation. Far 
fewer studies have examined the Pi-AR but as it shares 54 % amino acid homology 
with the P2 “AR, it might be expected to share regulatory mechanisms with the P2 -AR.
Previously, addition of the 27kDa GFP polypeptide has been utilised to present a 
clearer picture of not only P2 -AR regulation (Barak et al., 1997; Kallal et al., 1998) 
but also of the TRH receptor, the cxib- A R  and the cholecystokinin receptor (Drmota 
et ai., 1998,1999; Awaji et al., 1998; Tarasova et al., 1998). All have indicated that 
the modified GPCRs display essentially unaltered pharmacology and are able to 
interact with their cognate G protein to initiate second messenger regulation. Barak et 
al., (1997) first used a GFP-tagged form of the P2 -AR to directly visualise the 
receptor and measure agonist and antagonist binding, agonist-stimulated adenylyl
’
cyclase activity, receptor phosphorylation and receptor internalisation compared to the 
WT“|32“AR transiently expressed in HEK293 cells. Kallal et al., (1998) extended 
these studies using HeLa cells stably expressing either WT-p2~AR or WT-p2-AR- 
GFP. Both stressed the usefulness o f GFP to monitor real time trafficking of the p2- 
AR in response to agonist stimulation. As the use of GFP has been well established 
and is a popular technique to study the aforementioned GPCRs it was decided this 
approach should be applied to compare Pi-AR signaling with the already investigated 
P2-AR system.
In Chapter 3, Section 3.3 it was shown that saturation binding studies with pH] DBA  
on the P2"AR stably expressed in HEK293 cells confirmed previous data that the 
binding characteristics of antagonists at the GFP-tagged construct is not different from 
the untagged form of this receptor. This was also apparent from saturation binding 
experiments on GFP-tagged and untagged forms of the Pi-AR (Table 4.2). From 
competition binding experiments with betaxolol or isoprenaline, both Pi-AR 
constructs were shown to have similar affinities for each drug (Table 4.3 and Figures 
4 .10 and 4.11). This was previously found for the P2-AR in Chapter 3 (Table 3.2 
and Figures 3.11 and 3.12).
Both Pi- and P2- AR constructs were functionally characterised using isoprenaline- 
stimulated intact cell adenylyl cyclase assays. From studies on the P2-AR, over the 
past decade it is evident that the number of p2-ARs expressed can have a dramatic 
effect on the kinetic parameters of adenylyl cyclase activation. Whaley et a l,  (1993) 
generated a series of L cell clones stably expressing the hamster and human P2-AR 
over a 2000-fold range of receptor level (5 to 10000 fmol/mg of membrane protein). 
An increase in expression level of the P2-AR was found to correlate with a decrease in 
EC50 for isoprenaline and with a slight increase in intrinsic activity (Vmax or maximal 
output) for adenylyl cyclase activation. This work developed a mathematical 
prediction to analyse alterations in p-AR full agonist EC50 values with changes in
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receptor number and has been extended by MacEwan and Milligan, (1995) to the 
study of partial agonist potency at the p2"AR. Bouvier et al., (1988) have also 
observed similar results to Whaley et al., for the human p2-AR expressed in Chinese 
hamster fibroblast cells (CHW). However, the intrinsic activity was reduced 
markedly in cells expressing very high levels of receptor. Likewise, in a more recent 
study, when P2-AR levels were increased in an inducible expression system of rat 
glioma cells stably expressing this receptor, the maximal cyclase output was decreased 
with a small shift in the dose-effect curve to the left (ie a reduction in EC50) (Zhong et 
al., 1996). The mechanisms for this are not yet clear. In this present study 
isoprenaline exhibited a similar potency at the WT-P2-AR to the WT-P2-AR-GFP, in 
agreement with Kallal et al., (1998). However, the more highly expressed GFP 
construct gave a lower maximal response (20 to 30 % lower than that of the WT-P2- 
AR). This is consistent with the above data from Bouvier et al., (1988) and Zohng et 
al., (1996).
In systems in which the effector species is quantitatively the limiting component of a 
signal transduction cascade, it is often observed that elevations in receptor number 
result in a leftward shift in the dose-effect curve (ie a reduction in EC50 value), 
consistant with the notion of a receptor population reserve. Isoprenaline was found to 
have a 10 times lower potency at the WT-pi-AR than at the much more highly 
expressed WT-Pi-AR-GFP. The maximal cyclase activities for both constructs are 
similar but the 10 fold shift in EC50 would indicate a pi-AR reserve. Zhong et al., 
(1996) show this for stably expressed Pi-AR in the inducible rat €5  glioma cell 
exppression system. The EC50 for isoprenaline decreased with little effect on the 
maximal cylcase ouput when the receptor number was increased.
Alternatively, these results could be attributed to the addition of GFP to the C terminus 
of this receptor which may be interfering with activation of adenylyl cyclase. An 
additional factor to consider is that GFP has been engineered to be extremely stable in
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mammalian cells and may stabilise the protein it is attached to, therefore, increasing 
expression levels of the receptor. In reality GFP may be a culprit here, causing 
stabilisation and increased expression of receptor, indirectly resulting in a variation of 
agonist potency.
Internalisation studies provided more evidence that the use of GFP has to be treated 
with caution. From the earliest study on WT-P2-AR-GFP, Barak et al., (1997) used 
flow cytometry to measure a 57 ± 5 % decrease in cell surface WT-p2-AR after 30 
minutes of isoprenaline exposure. WT-p2“AR-GFP similarly exhibited a 62 ± 11 % 
loss from the cell surface. However, only one time point was investigated. Kallal et 
al., (1998) confirmed WT-p2-AR-GFP internalisation by pH] CGP12177 binding in 
a HeLa cell line. A time-course of internalisation was performed in response to 
isoprenaline stimulation but not in parallel with WT-fÎ2-AR-expressing cells. The data 
in this present study clearly indicates that addition of GFP to WT-p2-AR slows the 
internalisation of this receptor. Addition of GFP to WT-Pi-AR produced similar 
results (Figures 4 .15 and 4.16). To estimate the ti/2 of receptor internalisation for 
each receptor constuct it was neccessary to recalculate the raw data as the number of 
receptors gained within the cell at time x as a percentage of total receptor gained at 60 
minutes. The natural log (In) of each percentage value was then plotted against time 
and the ti/2 at 50 % receptor internalisation was calculated from the equation of each 
line fit. Figure 4 .24 and Table 4.4 demonstrates that WT-p2-AR (a) internalises 
extremely rapidly with a calculated t i /2 = 0 .5 minutes and WT-P2-AR-GFP (b) 
internalises much more slowly with a calculated ti/2 = 25 minutes. W T-pi-AR (c) 
internalises with a t i /2 too rapid to be calculated with this data. A more detailed time 
course of internalisation is required with a large range of time points under 5 minutes. 
WT-pi-AR-GFP (d) internalises more slowly than its untagged version but at a 
quicker rate than WT-P2-AR-GFP with a calculated ti/2 = 15 minutes. This, 
therefore, indicates that GFP is exerting an effect on receptor internalisation.
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Figure 4.24
Estimation of intracellular receptor gain following isoprenaline 
stimulation of p-AR clones.
Raw data from the linear part of the curves in Figures 4.15, 4.16, 4.17 and 4.18 
was used to calculate the number of receptors internalised as a percentage of total 
receptors internalised at 60 minutes isoprenaline stimulation. The natural logs of 
these values were then replotted against time. The equation of each line fit was 
used to estimate the ti /2  of receptor internalisation for; a) WT-p2 -AR and WT-p2 - 
AR-GFP, b) WT-pi-ARand WT-Pi-AR-GFP, w = 3 (Table 4.4).
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Table 4.4
Rate of isoprenaline stimulated internalisation as X\a values and % of receptor 
internalisation for the denoted constructs.
Clone ti/2 of internalisation 
(minutes)
Maximal receptor 
internalisation (%)
W T-PrAR *N.D. 30
WT-pi-AR-GFP 15 30
WT-p2“AR 0.5 50
WT»p2-AR-GFP
................................................. ....... .... _
25 40
Values of were calculated for 50 % receptor internalisation from the equation 
of the line fits in Figure 4.24.
N.D. = Not defined.
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To attempt to understand how GFP may be achieving this, work by Jockers et al., 
(1996) may help form an explanation. The p3 -AR does not readily undergo rapid 
agonist-promoted desensitisation and internalisation (Ligget et al., 1993; Mantel et al., 
1993; Chaudhry et al., 1994). It also has high sequence homology with the p2 -AR. 
Jockers et al., constructed a series of 15 P3 /P2 -ARchimeras to identify which regions 
of the P2 -AR are important in uncoupling and sequestration. It was revealed that the 
C-terminal tail, intracellular loop 3 and intracellular loop 2 of the P2 -AR added 
individually into the P3 -AR all partially restored the uncoupling phenotype and that 
their effects were additive to produce a desensitisation profile similar to that of the P2 - 
AR. The C-terminal tail, intracellular loop 2 and intracellular loop 1 all play additive 
roles in receptor sequestration, but not to restore it completely, whereas, intracellular 
loop 3 has a dominant negative effect. It may be that GFP interferes with the C- 
terminal tail and, therefore, slows internalisation. It is apparent however, that other 
regions in the P2 -AR must be involved for full sequestration of this receptor. It is 
evident that the pi-AR internalises more rapidly and to a lesser degree than the P2 -AR 
(Figures 4.17 and 4.18). However, the latter observation is only apparent for the 
GFP-tagged constructs at later time points of 30 minutes or greater.
GFP’s ability to slow down regulatory processes of receptors to which it is linked is 
again apparent when investigating long term treatment of receptor expressing HEK293 
cells to the agonist isoprenaline. Gagnon et al., (1998) have previously reported that 
40 to 50 % of the P2 -AR is lost from intact cells when stably expressed in HeLa cells 
(at 3-5 pmol/mg) and exposed to isoprenaline for 24 h. The present study shows that 
similar experiments on HEK293 cells stably expressing WT-p2 "AR produces results 
in accordance with Gagnon et al (Figure 4.21a). However, when WT-p2 -AR-GFP- 
expressing HEK293 cells are treated in exactly the same way, there is only a 10 to 30 
% reduction in total receptor in whole cells. This is more pronounced in membrane 
binding assays (Figure 4.21b) where WT-p2 "AR-GFP was only reduced by about 10 
%. Confocal analysis clearly indicates that the GFP-tagged receptor is held within an
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intracellular compartment (probably the lysosomes) following a 24 h treatment with 
isoprenaline (Figure 4.21c). These results are contradictory to Kallal et al., (1998) 
who demonstrated a down-regulation profile for WT-p2-AR-GFP in HeLa cells, 
similar to that reported by Gagnon et al., (1998) for the WT-p2-AR also expressed in 
HeLa cells. The expression level of the GFP-tagged receptor in Kallal's study was 
substantially lower, only 200 fmol/mg. WT-P2-AR-GFP is expressed at 
approximately 9 pmol/mg in the present study. This high expression level may be a 
determining factor in the extent of down-regulation of the receptor. When WT-P2- 
AR-GFP-expressing cells are treated with agonist for 48 and 72 h, levels of P2-AR 
antagonist binding sites do decrease to similar levels as WT-p2~AR antagonist binding 
sites after 24 h of isoprenaline treatment (Figure 4.23). The data again demonstrate 
GFP’s ability to compromise regulatory processes of the P2-AR.
Previous reports on agonist regulation of Pi- and p%- ARs have indicated significant 
differences in their uncoupling, sequestration and down-regulation patterns (Rousseau 
et al., 1996; Suzuki et al., 1992; Zhou et al., 1995). The P3-AR undergoes very little 
desensitisation and down-regulation and it has been generally accepted that agonist 
stimulation of the p^-AR leads to a desensitisation and down-regulation profile which 
is intermediary between the P2- and P3- ARs. From Figure 4 .23 long term 
isoprenaline treatment produced a different profile of regulation for both GFP-tagged 
and non-GFP-tagged receptors. For WT-Pi-AR, the total receptor level appeared to 
increase initially and then decrease slightly but stayed above untreated levels of 
receptor. The GFP-tagged WT-Pi-AR, on the other hand, remained at similar levels 
of expression throughout treatment. In binding studies with pH] CGP12177 both 
constructs were lost from the cell surface at 48 and 72 h agonist treatment. The 
confocal images of WT-Pi-AR-GFP confirm this loss of receptor from the plasma 
membrane (Figure 4.22). Therefore, in this cell system it appears that the pi~AR does 
not undergo agonist induced down-regulation.
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The results of this chapter do demonstrate that GFP can be utilised as a helpful tool in 
monitoring the trafficking of GPCRs in response to agonist stimulation. It must be 
stressed that there are limitations, as with any method, in what can be interpreted from 
the results obtained. Highly expressing receptor systems are advantageous when 
trying to use a method with low sensitivity but the generated data should always be 
treated with caution. From using a range of methods in conjunction with one another 
a clearer picture of cellular receptor processing can be generated.
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Chapter 5
Pharmacological Characterisation and Signalling 
of a C-terminally Mutated P2 -AR Tagged With
GFP
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Chapter 5
5.1 Introduction
For regulation of a cell's biological processes the phosphorylation and 
dephosphorylation of proteins or enzymes is a fundamental and extiemely important 
mechanism. In mammalian cells these processes include, 1) metabolic pathways such 
as glycolysis, gluconeogenesis, glycogen synthesis/breakdown, fatty acid 
synthesis/breakdown etc., 2) cellulai' signaling pathways through GPCRs or tyrosine 
kinase receptors leading to activation of effectors such as adenylyl cyclase, PKA, 
PKC, MAPK etc., 3) phosphorylation of transcription factors, eg. c-jun, c-fos or 
CREB to induce effects on gene expression.
Chapter 4 presented a selection of the evidence surrounding the elucidation of an 
accepted model for receptor activation, desensitisation, internalisation and recycling or 
down-regulation of the P2 -AR sub-type of GPCR in response to agonist stimulation 
(Figure 4.1, Bohm at al., 1997). The processes of phosphorylation and 
dephosphorylation act as key molecular switches at various points in this cycle of 
events. In the process of receptor desensitisation, where a decreased responsiveness 
of receptor to agonist occurs, two distinct classes of kinases - second-messenger 
dependent kinases (PKA and PKC) and receptor specific protein kinases (GRKs) are 
involved. Phosphorylation of the P2 -AR by cAMP dependent protein kinase (PKA) 
has been pin-pointed at serines 261 and 262 in the third intracellular loop PKA 
consensus site (Clark et al., 1989; Yuan et al., 1994; Hausdorff et al., 1989) and at a 
second site at serines 345 and 346 in the C-terminal tail. 11 potential GRK 
phosphorylation sites at serine/threonine residues in the C-terminal tail of the P2 -AR 
have been identified by mutagenesis studies (Hausdorff et al., 1989; Bouvier et al., 
1988). Currently 6 GRKs have been identified, all containing an N-terminal domain 
(residues 1-184), a catalytic domain (residues 185-456), a conserved C-terminal
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autophosphorylation region (457-522) and a variable C-terminal region giving the 
GRK sub-type specificity (reviewed by Krupnick and Benovic, 1998; Bohm et al., 
1997). In GRK2 (P-AR kinase-1 (PARK 1)) or GRK3 (PARK 2), the C-terminal 
variable region contains a pleckstrin homology (PH) domain, conferring binding 
specificity to Gpy proteins, assisting recruitment of the protein to the plasma 
membrane. Fushman et al., (1998) have presented the solution structure and 
dynamics of the PH domain of GRK2 (pARK 1) to show that it is capable of 
protein/protein interactions with Gpy sub-units. GRK5 has also been found to 
phosphorylate the p2 -AR, but does not contain a Gpy binding domain. Instead it is 
thought to associate with certain phospholipids in the plasma membrane to carry out 
its function (Kunapuli et al., 1993; Premont et al., 1994; Premont et al., 1995).
GRK phosphorylation is not sufficient to induce full desensitisation and uncoupling of 
receptor from activated G-protein. This is assisted by bifunctional, soluble proteins 
called arrestins. In the case of the P2 -AR, p-arresting 1 or 2 are involved. The 
primary function of these proteins is to destroy the interaction of ligand bound 
receptor which has been phosphorylated by a GRK, with the heterotrimeric G protein 
ot sub-unit to attenuate agonist activation (Lohse et al., 1990; Pippig et al., 1993). p- 
arrestins also regulate sequestration (internalisation) of several GPCRs including the 
P2 -AR by acting as clathrin adapters, the main component of clathrin coated pits of the 
endocytic receptor pathway (Figure 4.1). p-arrestin/arrestin chimeras defective in 
either receptor or clathrin binding do not support agonist-dependent internalisation of 
the p2 -AR (Goodman et al., 1996; Krupnick et al., 1997; Goodman et al., 1997). In 
the basal state p-arrestin 1 is a phospho-protein but is dephosphorylated on binding 
receptor and acting as a clathrin adapter (Lin et al., 1997). However, it is not clear 
whether p-arrestin 1 dephosphorylation precedes or follows receptor binding. Studies 
on GPCR internalisation regulated by p-arrestin 2 have revealed that p-arrestins 
dissociate from the P2 -AR following the redistribution of p-arrestins to coated pits 
(Zhang et al., 1999). This dissociation is proposed to facilitate dephosphorylation of
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the P2 -AR by phosphatases in early endosomes so the receptor can be recycled back to 
the plasma membrane for another round of agonist stimulation (Krueger et al., 1997).
It appears that p-arrestin-mediated internalisation may be linked to downstream 
mitogenic signaling pathways. Lin et al., (1999) have demonstrated that p-arrestin 1 
function is regulated by a negative feedback loop involving extracellular signal- 
regulated kinases (ERKs) through a protein termed MEKl. This was shown by using 
a dominant negative K97A mutant of MEKl which increased p-arrestin 1-mediated 
sequestration. The same group have also demonstrated p-arrestin-dependent 
formation of p2 -AR-Src protein kinase complexes to generate a second wave of signal 
transduction in which the desensitised receptor functions as a critical structural 
component of a mitogenic signaling complex (Luttrell et al., 1999).
Of interest to this study are the sites of GRK phosphorylation and their role in P2 -AR 
internalisation. Fredericks et al. (1996), demonstrated in vitro phosphorylation of the 
P2 -AR by GRKs following reconstitution of recombinant P2-AR into liposomes. 
Serines 396, 401 and 407, and threonine 384 in the C terminus of the p2~AR were 
identified as the sites of GRK2 (pARK 1) phosphorylation whereas GRK5 also 
phosphorylated these residues in addition to threonine 398 and serine 411. It was 
hypothesised that these were also the sites of GRK phosphorylation in intact cells 
since the phosphorylation sites in the rhodopsin receptor identified in vitro were the 
same sites phosphorylated by rhodopsin kinase (RK or GRKl) in vivo (Palczewski, 
et al., 1995; Ohguro et al., 1995; Papac et al., 1993; McDowell et al., 1993). These 
findings also agreed with a previous study on the P2 -AR (Hausdorff et al., 1989). 
However, considerable debate has arisen surrounding the importance of these residues 
in receptor desensitisation and internalisation. Seibold et al., (1998) investigated 
desensitisation and internalisation of a range of P2 -AR constructs with mutations at the 
proposed GRK phosphorylation sites and PKA phosphorylation sites. Three mutant 
constructs of the P2 -AR were studied, PKA" with mutations at the 2 PKA consensus
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sites (S261A, S262A, S345A, S346A), GRK2"constmctedfrom the PKA" construct 
with additional mutations (T384A, S396A, S401A, S407A) and GRK5" constructed 
from GRK2" with additional mutations (T393A, S41 lA). All three mutants appeared 
to be rapidly phosphorylated and underwent a similar degree of agonist-induced 
desensitisation and internalisation compared to the wild-type p2 "AR. It was, 
therefore, proposed that the GRK site(s) that mediate the desensitisation and 
subsequent internalisation of the P2 -AR do not involve the sites identified by in vitro 
phosphorylation and that unidentified sites of phosphorylation are yet to be found. 
Indeed, Jockers et al., (1996) have implicated serines 137 and 143 in the intracellular 
loop 2  of the p2 "AR as potential phosphorylation sites of a different kinase such as 
cdc2 kinase. Serine 137 is contained within a potential cdc2 kinase phosphorylation 
consensus site S/TPXK/R. It was found that when the second intracellular loop of the 
p2"AR was substituted into the P3 -AR, this markedly increased the ability of the 
receptor to undergo agonist-induced internalisation. Therefore, there may be a link 
with these potential phosphorylation sites and internalisation of the p2 "AR.
Available for study was a mutant P2 -AR in which all the 11 potential C-terminal GRK 
phosphorylation sites had been mutated to alanine or glycine (BARK"-p2 -AR). This 
receptor construct was C-terminally tagged with GFP (BARK"-p2 -AR-GFP) and 
stably expressed in HEK293 cells, the same cell expression system used by Seibold et 
al., (1998). The trafficking of this receptor in response to agonist stimulation was 
monitored to try and shed some light on the discrepancies reported above. Firstly, the 
construct was pharmacologically characterised for its ability to bind the p-AR agonist 
isoprenaline, the inverse agonist betaxolol and the antagonist alprenolol to determine 
any effect of the mutations on ligand binding. The expression level of BARK"-p2 - 
AR-GFP was determined along with the K^of pH] DHA for the receptor.
The internalisation profile of BARK"-P2 -AR-GFP was compared to that of the WT- 
P2-AR-GFP construct as measured by confocal microscopy and pH] CGP12177
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binding studies on intact ceils. Due to disagreement on the importance of PKA in p2- 
AR desensitisation (Benovic et al., 1985 versus Seibold et al., 1998), the role of PKA 
in receptor internalisation was investigated by the use of two PKA activators, 
dibutyryl cAMP and 8-bromo cAMP and two PKA inhibitors H89 and Rp cAMP. 
The role of MEKl in the regulation of P2 -AR endocytosis was also studied. Intact 
cell adenylyl cyclase assays were also performed to determine if this construct could 
generate a second messenger output and if so, to measure the EC5 0  for isoprenaline at 
this receptor construct.
5.2 Construction and expression of a green fluorescent protein-tagged 
form of the mutant BARK"-p2 "AR in HEK293 cells.
A cDNA of the human P2 -AR containing glycine amino acid substitutions at all of its 
11 potential GRK C-terminal ser/thr phosphorylation sites (BARK“-p2 "AR in Figure 
5.1), was modified such that an 8 amino acid (DYKDDDDK) Flag ™ epitope tag was 
added to the N terminus of the encoded protein (Hag-BARK"-P2 "AR). This constinct 
was further modified by a PCR-based strategy to link a cDNA encoding a modified 
form of the GFP from Aequorea victoria with enhanced autofluorescent properties 
(Zermicka-Goetz et al., 1997) to its C terminus (Figure 5.2a). This fusion protein 
(BARK“-P2 "AR-GFP) was anticipated to encode a single open reading frame in which 
the C terminus of the GPCR was linked directly to the N terminus of GFP (Figure 
5.2a).
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Figure 5,1
Structural model of the WT-p2 -AR .
The seven transmembrane P2 -AR containing the 11 putative GRK (PARK) 
phosphorylation sites (black), the two identified PKA phosphorylation sites (grey) and 
the one identified palmitoylation site (light grey). The labeled GRK sites are those 
identified/« viTro by Fredericks et al., (1996) to be phosphorylated by GRK2 and 
GRK5. All the potential GRK Ser/Thr phosphorylation sites in the C-terminal tail of 
the p2 "AR were mutated to glycines or alanines to produce a BARK“-p2 -AR cDNA 
construct.
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a) Schematic diagram of the cDNA encoding the BARK-p^-AR-GFP  
fusion construct generated for this study.
BARK-P2 -AR-GFP was generated using a PCR based approach to link GFP to the C 
terminus of a BARK-P2 -AR construct (Chapter 2, Section2.4d).
b) Confocal analysis of the cellular location of BARK-P 2 -AR-GFP 
transiently transfected in HEK293 cells.
Following transient transfection of HEK293 cells on a glass coverslip with the 
BARK‘-p2 -AR“GFP cDNA, cells were fixed 48 h later, mounted on a microscope 
slide as described in Section 2.8 and then imaged by confocal microscopy.
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One concern was that such a highly mutated form of the p2-AR with GFP added onto 
its C terminus would have such structural alterations within the protein that it might 
not be targeted coiTectly to the plasma membrane. However, this was not the case. 
Transient transfection of the BARK"-P2"AR-GFP construct into HEK293 cells grown 
on a glass coverslip was followed by imaging in a confocal microscope. The cellular 
location of the construct was very similar to that of WT-p2“AR“GFP (Figure 3.2b) 
and WT"Pi-AR-GFP (Figure 4.2b), its fluorescence being distributed mainly at the 
plasma membrane of the cell (Figure 5.2b). From binding experiments using a single 
concentration of pH] DHA on membranes from HEK293 cells transiently expressing 
empty vector pcDNA3, WT-P2-AR, WT-p2“AR-GFP or BARK“-P2-AR-GFP 
(Figure 5.3), it was apparent that the mutant receptor was routinely expressed at 
substantially lower levels than either of the non-mutated P2-AR constructs. However, 
BARK“-p2-AR-GFP was expressed at levels to provide a significantly greater number 
of pH] DHA binding sites than the control experiment using empty vector pcDNAS. 
Stable cell lines of this mutant construct in HEK293 cells were then developed for 
comparison with the WT- P2-AR-GFP stable cell clone already studied.
Once stable cell lines expressing BARIO-P2-AR-GFP were established in HEK293 
cells single clones were selected for study. A fluorescent microscope was utilised to 
directly screen for positive clones. Only 2 out of 50 clones screened were positive 
indicating the difficulty in expressing this mutant construct. Clones #46 and #47 are 
shown in Figure 5.4a demonstrating that in these selected clones, the BARK"-p2-AR- 
GFP construct is targeted to the plasma membrane as a substantial amount of the 
GFP-derived autofluorescence is plasma membrane delineated. Clone #47 
membranes were also subjected to western blot analysis using an anti-P2~AR antibody 
directed to an amino acid sequence mapping to the C-terminal tail of the human p2" 
AR. The blot in Figure 5.4b indicates that BARK"-P2-AR-GFP was detected by this 
antibody as a range of bands between 65 and 80 kDa even though it has a substantially 
altered C terminus. As with the p2‘AR constructs analysed in Chapter 3 and in Figure
Figure 5.3
Levels of BARK-P 2 -AR-GFP compared to WT-p2 “AR and WT-p2 "AR- 
GFP following transient expression In HEK293 cells.
Membranes (20 pg) prepared from HEK293 cells transiently expressing either the 
WT-p2 -AR, WT-p2 -AR-GFP or BARK"-p2 -AR-GFP constructs were analysed for 
their ability to bind a single concentration of pH] DHA (2 nM). Results are from one 
experiment performed in triplicate and are presented as means ± S.D. Similar results 
were obtained from two further experiments.
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Figure 5.4
Cell clones stably expressing BARK-p^-AR-GFP .
a) The BARK"-p2-AR-GFP construct was expressed stably in HEK293 cells and 
individual clones identified by live cell confocal microscopy. The two positive clones 
(#46 and #47) are imaged herein, with largely plasma membrane delineated 
autofi uorescence.
b) 15 pg of membrane preparations were loaded onto an SDS-PAGE protein gel. 
After transfer of the protein to a nitrocellulose membrane, the membrane was probed 
with an anti-p2-AR antibody to show that all the P2-AR constructs used in this study 
could be detected by this antibody, 1) CAM-p2-AR-GFP, 2) WT-P2-AR, 3) WT-P2- 
AR-GFP and 4) BARK'-Pa-AR-GFP.
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5.4b, CAM-p2 "AR-GFP (1), WT-P2 -AR (2) and WT-P2  AR-GFP (3), the range of 
bands for BARK"-P2 -AR-GFP (4) probably correspond to differential glycosylation 
states of the protein, although protein degradation cannot be excluded. Figure 5.5 
gives an approximate indication of expression levels of clone #47 compared to WT- 
P2 -AR-GFP clone #13 and WT-P2 -AR clone #27 using a single concentration of pH] 
DHA in membrane binding studies. It was now necessary to perform more detailed 
analysis to pharmacologically characterise this BARK~-p2 -AR“GFP construct in 
comparison to WT-j32"AR-GFP.
5.3 Pharm acological characterisation
Expression levels of BARK-P2 -AR-GFP clone #47 were determined more accurately 
by a saturation binding experiment with pH] DHA (Figure 5.6a(i)). BARK"-p2-AR- 
GFP was stably expressed at comparable levels to both WT-P2 -AR and WT-P2 -AR- 
GFP (Table 5.1, Bmax values). As for all the previous constructs examined 
throughout this study, the non-specific binding of pH] DHA at BARK-p2 -AR-GFP 
using 10'^ M propranolol to compete for p2 -AR binding sites was very low (Figure 
5.6a(ii)). The saturation binding curve was converted into a Scatchard plot and the K^ 
value calculated from the slope of the line indicated that this construct bound the ligand 
pH] DHA with similar affinity to both WT-P2 -AR constructs (Table 5.1 and Figure 
5.6b).
Competition for the specific binding of pH] DHA to membranes expressing BARK"- 
P2 -AR-GFP with either isoprenaline (an agonist), alprenolol (an antagonist) or 
betaxolol (an inverse agonist) were performed to determine whether the mutations 
introduced in the C teiminus of the p%-AR construct or addition of GFP had induced 
any alterations in basic receptor pharmacology (Table 5.2 and Figures 5.7, 5.8, and 
5.9). High affinity for the antagonist alprenolol at this particular P2 -AR construct was
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Figure 5.5
Estimation of receptor level in BARK“-p2 “AR-GFP clone #47 from  
membrane binding studies using a single concentration of pH ] DHA.
20  pg of membrane preparation from each of the denoted cell lines was used to 
estimate approximate receptor levels. A close to saturating concentration of pH] DHA 
(2 nM) was used to determine total binding with 10'^ M propranolol as competing 
ligand to determine non-specific binding. Specific binding was used to estimate the 
receptor expression in each clone (fmol/mg). Data are presented as means ± S.E.M., 
n = 3.
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Figure 5.6
Binding characteristics of BARK - AR-GFP-expressing cells.
a i) A saturation binding study using increasing concentrations of pH] DHA was 
performed to measure specific binding (pmol/mg) in membranes from BARK“-p2-AR- 
GFP cells.
a ii) The same saturation binding study as in (a i) but showing total, specific and non­
specific binding (d.p.m.).
b) Transformation of the specific binding data to generate a Scatchard plot. In the 
example displayed the estimated Bmax was 8 .4 pmol/mg and the Kd for pH] DHA 
was 0.81 nM.
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Table 5.1
Ligand binding charactheristics of GFP and non-GFP-tagged foi*ms of WT-p2-AR and 
ofBARK‘-P2"AR-GFP.
Clone Kd(nM) B m a x  (pmol/mg)
WT-p2-AR 0.62 ± 0.26 4.1 ±0.9
WT-p2-AR-GFP 0.75 ± 0 .17 8.7 ± 0 .7
BARK-p2-AR-GFP 0.60 ±0 .25 6.7 ± 1 .5
Data represent means ± .S.D. from three independent experiments using [^H] DHA as 
radioligand.
Table 5.2
Competition binding experiments at GFP and non-GFP-tagged foims of WT-p2~AR and 
atBARK’-p2“AR-GFP.
Clone Ki for 
Isoprenline (nM)
K ifor  
Betaxolol (nM)
Ki for 
Alprenolol (nM)
WT-P2-AR 363 ± 156 (2) 344 ± 3 4  (2) 1.1 ± 0 .3  (2)
WT P2-AR-GFP 782 ± 277 (3) 478 ± 23 (2) 2.5 ± 1.0(2)
BARK P2-AR-GFP 345 ± 22 (3) 345 ±64 (3) 1.1 ± 0 .2  (3)
Data represent means ± S.D. from two or three independent experiments using [^H] 
DHA as radioligand. The number of experiments are indicated in brackets.
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maintained (Figure 5 .7). The inverse agonist betaxolol displayed an affinity 
approximately 300 times lower than alprenolol at BARK"-p2"AR-GFP (Figure 5.8), 
which is consistent with the data obtained from competition binding studies on WT- 
P2-AR-GFP (Table 5.2). A 2.3 fold higher affinity of isoprenaline at BARK"-p2-AR- 
GFP versus WT-P2-AR-GFP was measured (Figure 5.9 and Table 5.2).
5 .4  Internalisation  studies
As BARK"-P2-AR-GFP is a modified version of the P2-AR containing none of the 
known GRK/pARK phosphorylation sites it was postulated that this construct might 
undergo none or very little internalisation. It should be noted that the construct still 
contains the two identified PKA phosphorylation sites, one in the 3rd intracellular 
loop and one in the C terminus. Isoprenaline-induced internalisation studies were 
performed on BARK"-P2-AR-GFP-expressing cells in parallel with the same 
experiment on WT-p2-AR-GFP-expressing cells. Confocal microscopy promptly 
indicated that the mutant BARK"-P2-AR-GFP construct did indeed internalise when a 
10""5 M concentration of isoprenaline was added to the cells (Figure 5.10). In fact, the 
profile of internalisation looked substantially more rapid than that of the WT-P2-AR- 
GFP construct (Figure 3.6). A distinct punctate pattern of fluorescence was seen 
inside the cell after 5 minutes of isoprenaline stimulation (Figure 5 .10b). This became 
more pronounced at later times up to 30 minutes (figure 5.10 c to e). In Chapter 3, 
Figure 3.6, WT-p2-AR-GFP only started to produce a detectable punctate pattern of 
internalisation at 10 minutes of isoprenaline stimulation. To accurately determine the 
differences in internalisation patterns between the two P2-AR constructs it was 
necessary to perform pH] CGP12177 binding studies on intact cells of both clones.
Similar internalisation experiments to those detailed in Chapter 4, Section 4 .4  were 
performed on BARK"-p2-AR-GFP-expressing cells. For a time-course o f 0 to 60
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Figure 5.7
Mutations within B A R K -P2 -AR and addition of GFP to its C terminus 
does not alter the high aKinity of the P2 -AR antagonist alprenolol.
Competition between pH] DHA (0.8 nM) and varying concentrations of alprenolol for 
specific binding to membranes expressing BARK“-P2 -AR-GFP, Hill coefficient = 
0.8. Similar results were obtained from two further experiments (Table 5.2).
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Figure 5.8
Betaxolol has a similar affinity at the BARK-p^-AR-GFP construct as 
at the WT-p2 -AR-GFP construct.
Competition between pH] DHA (0.8 nM) and varying concentrations of betaxolol for 
specific binding to membranes expressing either BARK-P2-AR-GFP, Hill coefficient 
= 0.9 or WT-P2 -AR-GFP, Hill coefficient = 0.8. Similar results were obtained from 
two further experiments (Table 5.2).
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Figure 5.9
Affinity for isoprenaline at the mutant BARK-P2 -AR-GFP construct.
Competition between pH] DHA (0.8 nM) and varying concentrations of isoprenaline 
for specific binding to membranes expressing BARK"-p2 -AR-GFP, Hill coefficient = 
0.7. Similar results were obtained from two further experiments (Table 5.2).
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Figure 5.10
Internalisation of BARK"-p2 -AR-GFP by agonist stimulation.
A patch of BARK“-P2 -AR-GFP clone #47 cells were imaged in the confocal 
microscope in the absence of agonist (a) and following addition of 10'^ M isoprenaline 
for 5 (b), 10 (c), 20 (d) and 30 (e) minutes. This is representative of two separate 
experiments.
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minutes cells were treated with 10'^ M isoprenaline at 37^0, followed by a binding 
study with either pH] CGP12177 to measure plasma membrane receptors, or pH] 
DHA to measure total receptor (plasma membrane and internal receptor). Confirming 
the confocal data, BARK“-p2-AR-GFP underwent marked internalisation which was 
more rapid than WT-P2-AR-GFP (Figure 5.11a). Conversion of the internalisation 
data to natural log plots indicated that isoprenaline-stimulated BARK -P2-AR-GFP 
internalised with a t i /2 ~  10 minutes (Figure 5.11b). WT-p2"AR-GFP had a 
substantially higher t i /2 = 25 minutes (Table 4.4, Chapter 4). It is well known that 
the p2"AR internalises through a clathrin-mediated pathway in HEK293 cells. To 
determine if BARK"-p2-AR-GFP also internalised through this pathway, 0 .4 M 
sucrose was used to inhibit clathrin cage formation around internalisation vesicles and 
therefore, to impede receptor internalisation. As predicted, sucrose inhibited 
isoprenaline-stimulated internalisation of the WT-P2-AR and WT-p2"AR-GFP 
construets (Figure 5.12). This was also apparent for BARK -P2-AR-GFP indicating 
that this construct internalises through a clathrin-mediated pathway (Figure 5.12).
It has recently been reported that the function of p-arrestin 1 to facilitate clathrin- 
mediated endocytosis of the P2-AR and to promote agonist-induced activation of 
extracellular signal-related kinases (ERK) is regulated by its phosphorylation/ 
dephosphorylation at Ser412 (Lin et al., 1999). ERK is regulated by a protein called 
MEKl to negatively regulate receptor internalisation. This was demonstrated by using 
a dominant-negative K97A mutant of MEKl which subsequently caused an increase 
in isoprenaline-stimulated P2-AR internalisation in HEK293 cells. To further 
investigate this the present study used a MEK inhibitor, PD98059, to attempt to block 
the effect of MEK l on ERK and therefore, induce further i soprenaline-i nduced 
internalisation of WT-P2-AR, WT-P2-AR-GFP and BARK--P2-AR-GFP (Figure
5.13). However, no effect of the MEKl inhibitor was seen in the denoted stable cell 
lines studied.
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Figure 5.11
Isoprenaline-stimuiated internalisation of BARK"-P2 "AR-GFP versus 
W T-Pi-AR-GFP .
a) WT-p2 -AR-GFP, and BARK'-P2 -AR-GFP-expressing ceils were untreated or 
treated in 24 well plates at 37°C with 10"5 M isoprenaline for various time intervals. 
pH] CGP12177 binding was then performed for 90 minutes at 4°C to measure the 
rate of agonist-stimulated internalisation of the two constructs. Results are represented 
as means ± S.E.M., n =4 for WT-P2 -AR-GFP (squares) and « = 4 for BARK-P2 - 
AR-GFP (diamonds).
b) The internalisation data from the linear part of the curve for BARK-P2 -AR-GFP 
was converted to a natural log plot. The equation of the line fit was used to calculate 
the time at which 50 % of cell surface receptors were internalised. The calculated ti/2= 
10 minutes, n = 4.
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Figure 5.12
0.4 M sucrose inhibits isoprenaline-induced internalisation of the 
denoted constructs.
The denoted cell clones were seeded into 24 well plates and were untreated or treated 
with 10-5 M isoprenaline, 0.4 M sucrose or 10-5 M isoprenaline + 0.4 M sucrose for 
30 minutes at 37°C. After washing, the cells were incubated with 10 nM pH] 
CGP12177 for 90 minutes at 4®C to measure the effect of each treatment on the level 
of cell surface receptor. Results are from one experiment performed in triplicate ± 
S.D.
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Figure 5.13
MEK inhibitor PD98059 has no effect on isoprenaline-induced  
internalisation of the p2 “AR .
The denoted cell clones were seeded into 24 well plates and were pre-incubated with 
or without PD98059 (50 pM) for 10 minutes. The cells were then incubated with 10'^ 
M isoprenaline for 15 or 30 minutes at 37°C. After washing, the cells were incubated 
with 10 nM pH] CGP12177 for 90 minutes at 4®C to measure the level of cell surface 
receptor following the various treatments. Results are means ± range., « = 2.
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5.5 How significant a role does PKA play in internalisation of the 
AR ?
The BARK“-P2 "AR-GFP construct does not contain the 11 potential GRK 
phosphorylation sites but does contain the two identified PKA phosphorylation sites. 
It may be reasonable to predict that these sites of phosphorylation could be responsible 
for the agonist-induced internalisation exhibited by BARK"-p2 -AR-GFP, and that a 
loss of regulation may have occuiTed by removing the GRK phosphorylation sites to 
cause an increase in the rate of agonist-induced internalisation. Dibutyryl cAMP and 
8-bromo-cAMP are cAMP analogues which can directly bind to and activate PKA. 
These reagents were used on WT-p2 -AR, WT-p2-AR-GFP and BARK -P2 -AR-GFP 
expressing cells to attempt to induce agonist-independent receptor internalisation 
through phosphorylation by directly activated PKA (Figure 5.14). After a 60 minute 
incubation with either of these PKA activators, no receptor internalisation was 
detected by pH] CGP12177 intact cell binding in either clone. Incubation with 10 
M isoprenaline for 60 minutes induced 60 to 70 % receptor internalisation (Figure
5.14). However, this may indicate that only PKA activated through agonist bound 
receptor may be able to phosphorylate and internalise receptors. Therefore the 
problem was approached from a different angle using PKA inhibitors.
The PKA inhibitor H89 has been used routinely (Chijiwa et al., 1990). BARIC-P2 - 
AR-GFP-expressing cells were untreated or pretreated with H89 (15 minutes) to allow 
the inhibitor to enter into the cells and bind to PKA. A time-course of isoprenaline- 
stimuiated internalisation for 0 to 60 minutes was then performed. As H89 is 
dissolved in DMSO a control experiment using DMSO in the incubation buffer was 
performed showing that this agent had no effect on the ability of isoprenaline to induce 
internalisation of the receptor construct (Figure 5.15). H89 appeared to substantially 
impede agonist-induced receptor internalisation (Figure 5.15). Contrary to this result, 
when a second inhibitor called Rp cAMP, was used, no inhibition of agonist-induced
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Figure 5,14
Direct activation of PKA does not induce Internalisation of p2 "AR 
constructs.
The denoted cell clones were seeded into 24 well plates and were untreated or treated 
with 10“^  M isoprenaline, 1 mM di-butyryl cAMP or 1 mM 8-bromo cAMP for 60 
minutes at 37^C. After washing, the cells were incubated with 10 nM pH] 
CGP12177 for 90 minutes at 4°C to measure the effect of each treatment on the level 
of cell surface receptor. Results are from one experiment performed in triplicate ± 
S.D.
198
Figure 5.14
a)
1&Oûc1
PM
O.üu
l
WT-B2-AR 
WT-B2-AR-GFP
BARK-B2-AR-GFP
100 -
untreated isoprenaline DB cAMP 8-Br-cAMP
Figure 5.15
PKA inhibitor H89 appears to markedly reduce isoprenaline-induced 
internalisation of BARK-P 2 -AR-GFP .
BARK--P2 -AR-GFP cells were seeded into 24 well plates and were pre-incubated 
with or without the PKA inhibitor H89 (10 pM) for 15 minutes. The cells were then 
incubated with 10“^  M isoprenaline at 37°C for a time course of 0 to 60 minutes. After 
washing, agonist-induced internalisation was measured by an intact cell binding study 
with 10 nM pH] CGP12177 at 4°C for 90 minutes. Results are from one experiment 
performed in triplicate ± S.D.
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receptor internalisation was measured for either WT-p2 "AR, WT-p2 -AR"GFP or 
BARK""p2 ”AR-GFP. Rp cAMP alone had no effect on the cells (Figure 5.16a). As 
PKA is an agonist-independent protein kinase, (GRK activation requires agonist 
bound to receptor) its effects may be more pronounced at low concentrations of 
agonist. The previous experiments used a high, saturating isoprenaline concentration 
(10"^ M). A second experiment was performed where WT-p2 “AR-expressing cells 
were untreated or treated with 10'^, 10"'^  or 10"  ^ M isoprenaline for 30 minutes. 
Approximately 50 % of receptor was internalised with 10~^  and 10-  ^M isoprenaline 
but this could not be detected by treatment with 10'^ M isoprenaline (Figure 5.16b). 
When cells were pre-incubated with Rp cAMP for 15 minutes and then stimulated in 
the same way, again Rp cAMP had no effect on isoprenaline-induced internalisation at 
the higher concentration of 10"  ^ M or even at a 100 fold lower concentration of 
isoprenaline.
The ambiguity in the results using the two different PKA inhibitors was recently 
explained by Penn et al., (1999). It was shown in this study that H89 acts as an 
antagonist at both the pi-AR and P2 -AR. Competition binding of iodopindoiol 
established Kj values of -180 nM and 350 nM for H89 antagonism of the pi-AR and 
P2 -AR, respectively. Penn et al., (1999) demonstrated that a 10'^ M concentration of 
H89 can markedly reduce the number of iodopindoiol binding sites in BEAS- 
2B cells stably expressing the P2 -AR. As H89 was routinely used at a concentration 
of 3 X 10'5 M (100 fold higher than the Ki at the P2 -AR), in the present study, it is not 
surprising that it appeared to impede agonist-induced internalisation when in fact, it 
was competing for binding of isoprenaline. To show H89s ability to act as an 
antagonist at the P2 -AR a binding study with pH] DHA on WT-p2 -AR and BARIC- 
P2 -AR-GFP expressing cell membranes was performed which indicated that H89 
bound to the P2 -AR in a concentration-dependent manner. Although 10'^ M H89 was 
shown to reduce [l^^I] iodopindoiol binding sites, it only blocked 70 to 80% of p2- 
AR sites when using pH] DHA as the competing ligand (Figure 5.17). 3 x 10"  ^M
2 0 0
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Figure 5.16
PKÂ inhibitor Rp cAMP bas no effect on isoprenaline-induced  
internalisation of the denoted P2 -AR constructs.
The denoted cell clones were pre-incubated for 15 minutes with or without the PKA 
inhibitor Rp cAMP (100 pM). The cells were then treated with agonist as indicated.
a) The denoted cell clones were treated or untreated with 10~5 M isopreanline for 30 
minutes at37°C.
b) WT“-p2 -AR cells were untreated or treated with 10'^, lO-'^  or 10'^ M isoprenaline 
for 30 minutes at 37°C.
After washing, the cells were incubated with 10 nM pH] CGP12177 for 90 minutes at 
4°C to measure the level of cell surface receptor following each treatment.
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Figure 5.17
The PKA inhibitor, H89, binds to WT-P2 -AR and BARK" Pi-AR-GFP  
in a concentration-dependent manner.
20 pg of WT-P2 -AR or BARK‘-p2 -AR-GFP membranes were used in a pH] DHA 
binding study to demonstrate competition binding of 10-5 or 3 x 10-5 M H89 
compared to the P2 -AR selective antagonist alprenolol (10-5 M). Results are from 
experiments performed in triplicate and are represented as means ± range., w = 1 for 
BARK--P2 -AR-GFP, « = 2 for WT-P2 -AR.
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H89 was still not as effective an antagonist as 10-5 alprenolol but did block up to 
90% of pH] DHA binding sites (Figure 5.17). A second experiment with CAM-j32- 
AR-GFP-expressing cells (developed in Chapter 3) was performed (Figure 5.18). 
These cells were untreated (a) or treated with 10-5 y[ ygç (b), 3 x 10-5 H89 (c), or
10-4 M Rp cAMP (d) for 24 h. The cells were then imaged in a confocal microscope. 
An up-regulation of CAM-p2"AR-GFP was detected with H89 (Figure 5.18 b and c) 
similar to the up-regulation observed when using 10-5 ]y[ betaxolol (e). However, Rp 
cAMP induced no up-regulation of CAM-^a-AR-GFP (d) indicating that it is the 
antagonistic effect of H89 and not its inhibition of PKA which caused receptor up- 
regulation. From an intact cell binding study on CAM-P2 -AR-GFP-expressing cells 
(Figure 5 .18f) treated in the same way as previously, 10-5 M H89 induced up- 
regulation of the receptor to the same extent as 10-5 M betaxolol. 3 x 10-5 H89 also
up-regulated the receptor but to a lesser extent. This may be due to insufficient 
washing away of a higher concentration of H89 (Figure 5.18f).
As both PKA activators and PKA inhibitors had negative effects in the above 
experiments, no positive control was present to determine if these reagents were 
functioning properly in these cells. Some PKA inhibitors can be cell specific. It was 
attempted to monitor down-stream of PKA and examine phosphorylation of one of its 
target proteins, CREB using the Phospho Plus CREB (Serl33) antibody kit. A 
phospho-CREB antibody directed to Serl33 of CREB was used to detect changes in 
the levels of phospho-CREB following various drug treatments (Figure 5.19). 
However, little could be taken from the data (Figure 5.19a). The basal level of CREB 
phosphorylation was very high in untreated WT-p2 “AR-expressing cell lysates 
(Figures 5.19 a and b lane 1) compared to the provided negative control of SK-N-MC 
cells (Figure 5.19b, lane 3). Even the levels of phosphorylated CREB in cell extracts 
from SK-N-MC cells treated with the adenylyl cyclase activator forskolin (Figure 
5.19b, lane 4) appeared lower than the levels of phosphorylated CREB from untreated 
WT-p2 “AR-expressing HEK293 cell extracts (Figure 5.19b, lane 1).
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Figure 5.18
The PKA inhibitor H89 up-regulates the CAM-p^-AR-GFP construct.
CAM-p2 "AR-GFP-expressing cells were plated onto glass coverslips and were 
untreated (a) or treated with 10-5 M H89 (b), 3 x 10-5 ^  H89 (c), 104 M Rp cAMP 
(d) or 10-5 M betaxolol (e) for 24 h at 37®C. the cells were then imaged on a confocal 
microscope.
f) Cells of the same clone were seeded into a 24 well plate and treated as above. After 
washing the cells, pH] DHA binding was performed at 30°C for 45 minutes to 
measure the level of CAM-p2 “AR-GFP expression following treatment. Results are 
from a single experiment performed in duplicate and are represented as means ± range.
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Figure 5.19
Phosphorylation of CREB at serine 133 in WT-P2 "AR-expressing cells.
Confluent WT-p2 -AR-expressing cells in 6 cm dishes were pretreated with or without 
100 |xM Rp cAMP for 15 minutes, then with the denoted stimulant applied for 30 
minutes. 15 pi of cell lysates prepared from these cells were loaded onto a 10% SDS- 
PAGE gel. Following transfer of protein to nitrocellulose membrane, the membrane 
was probed with a phospho-CREB antibody to indirectly determine the level of PKA 
activity by phosphorylation of serine 133; a) untreated (1), 1 mM dibutyryl cAMP (2), 
100 pM Rp cAMP + dibutyryl cAMP (3), 10-5 isoprenaline (4), 10^ M 
isoprenaline (5), Rp cAMP + 10-5 ^  isoprenaline (6), Rp cAMP (7); b) untreated (1), 
dibutyryl cAMP (2), 10 pi untreated SK-N-MC cell lysate (3), forskolin treated SK- 
N-MC cell lysate (4).
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5.6 Activation of adenylyl cyclase by agonist-stim ulated BARK -P2 
AR-GFP
Internalisation of BARK"-(32-AR-GFP indicated that this receptor may be able to 
produce a second messenger output. As no effect of PKA was detected in the 
previous set of experiments it was anticipated that BARK"-|32-AR-GFP would not 
produce cAMP as a second messenger through adenylyl cyclase activation. However, 
when intact BARK"-P2-AR-GFP-expressing cells were labelled with pH] adenine 
and isoprenaline-stimuiated production of pH] cAMP measured, isoprenaline induced 
a concentration-dependent increase in levels of cAMP with an EC50 = 6.9 ± 1.3 x 10"^  
M (mean ± S.D., n = 2) (Figure 5.20). This is 10 fold higher than the EC50 for 
isoprenaline at WT-p2-AR-GFP (Chapter 4, Section 4.3).
5.7 Sustained treatm ent of BARK -Pz-A R-G FP-expressing cells w ith 
isoprenaline.
To assess if BARK"-p2-AR-GFP underwent agonist-mediated down-regulation. 
BARK"-P2-AR-GFP cells were untreated or treated with 10"-^  M isoprenaline for 24 h 
washed, and membranes prepared. From membrane binding studies using a single 
concentration of pH] DHA, BARK"-P2-AR-GFP appeared to undergo substantially 
less down-regulation than WT-P2-AR but may have down-regulated to a greater extent 
than WT-p2-AR-GFP (Figure 5.21a). BARK~-P2-AR-GFP cells treated as above 
were imaged in a confocal microscope (Figure 5.21b). An aggregation of BARK"-p2- 
AR-GFP was detected after isoprenaline treatment. This aggregation did not appear to 
be so pronounced as the aggregation of WT-p2-AR-GFP after 24 h isoprenaline 
treatment (Figure 4.20).
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Figure 5.20
Isoprenaline-stimuiated regulation of adenylyl cyclase activity in intact 
cells expressing the BARK"-p2 -AR-GFP construct.
Basal adenylyl cyclase activity and its regulation by increasing concentrations of 
isoprenaline in BARK"-p2 -AR-GFP-expressing cells was assessed as detailed in 
Chapter 2 Section 2.7d. Data represent means ± S.D, of triplicate assays from a 
single representative experiment. One additional assay produced similar results. The 
average EC5 0  of isoprenaline was calculated for BARK"-p2 -AR-GFP as EC5 0  = 6.9 ± 
0.9 X 10^ M, mean ± range, n = 2.
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Figure 5.21
Overnight treatment of BARK“-P2 -AR-GFP with isoprenaline.
a) BARK“-p2 “AR-GFP"expressing cells were treated with or without 10'^ M 
isoprenaline for 24 h and membranes prepared. 20 pg of each membrane preparation 
was used in binding studies with a single concentration of pH] DHA (2 nM) to assess 
the levels of B ARK“-p2 -AR-GFP in each sample.
b) Cells of the same clone were plated onto glass coverslips and treated as above. 
The cells were then viewed on a confocal microscope and imaged to assess the 
distribution of BARK--P2 -AR-GFP.
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5.8 Discussion
For over a decade the processes of GPCR agonist activation, desensitisation, 
internalisation and recycling or down-regulation have attracted the attention of many 
research groups. The most studied receptor has been the P2 -AR and as yet the full 
details of the above receptor cycle (Figure 4.1) have not been fully elucidated. It is 
generally accepted that upon agonist activation of the p2 "AR, phosphorylation of its 
C-terminal tail occurs by GRK 2,3 or 5 and second-messenger activated kinase PKA 
to uncouple the receptor from G protein and initiate its desensitisation.
There has been debate as to which residues of the P2 -AR are actually phosphorylated 
by GRKs in vivo. The sites found in vitro by Fredericks et al., (1996) to be 
phosphorylated in the P2 -AR by GRK2 and GRK5 (Ser 396, 401, 407, 411 and Thr 
384, 398) were found not to be the sites phosphorylated in vivo by Seibold et al. 
(1998). A mutant construct with both PKA consensus sites and all the GRIC2 and 
GRK5 serine/threonine phosphorylation sites mutated to alanine, was still found to be 
phosphorylated, undergo desensitisation and agonist-induced internalisation. The 
authors postulated that other sites within the P2 -AR C-terminal tail could be in vivo 
sites of GRIC phosphorylation (Ser 355, 356, 364 and Thr 360) as Fredericks et al., 
only analysed residues 374-413 of the P2 -AR which contained only 7 potential GRK 
phosphorylation sites. All 11 of the serine/threonine residues found in the P2 -AR C- 
terminal tail , from amino acid 355 to 413, have been implicated as possible sites of 
GRK phosphorylation. Decreased desensitisation and phosphorylation has been 
reported for a mutant p2“AR containing substitutions at all 11 C-terminal 
serine/threonine sites stably expressed in Chinese hamster fibroblast (CHW) cells 
(Hausdorff et al., 1989; Bouvier et al., 1988). Hausdoff et al., (1991) also studied a 
P2-AR construct with only serines 355, 356, and 364 and threonine 360 substituted 
for either glycine or alanine and indicated that the in vivo sites of phosphorylation 
could be among these.
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To investigate these discrepancies a mutant p%-AR with the 11 potential GRK C- 
terminal phosphorylation sites mutated to alanine or glycine was utilised. To aid 
investigations the mutant receptor was C-terminally tagged with the 27 kDa GFP 
polypeptide so that confocal analysis of the protein could be achieved to visually 
monitor the receptor. The GFP-tagged mutant P2~AR (BARK“-p2"AR*-GFP) was 
stably transfected into HEK 293 cells and pharmacologically characterised to 
determine if mutations in the C-terminal tail of the P2-AR or addition of GFP caused 
any effect on basic receptor pharmacology. Although expressed at relatively low 
levels in transient transfections, clones stably expressing this form of the p2~AR at 
levels comparable to the WT-p2“AR-GFP construct were isolated. The Kd for pH] 
DHA at the mutant receptor was similar to WT P2-AR-GFP (Table 5.1). Affinity for 
the agonist isoprenaline, inverse agonist betaxolol or antagonist alprenolol did not 
dramatically change (Table 5.2). Therefore, addition of GFP or the mutations 
introduced in the C-terminal tail of the receptor did not alter the basic receptor 
pharmacology of the receptor.
Analysis by confocal microscopy of BARK"-P2~AR-GFP in response to agonist 
stimulation indicated that this receptor construct rapidly internalised following addition 
of 10"^  M isoprenaline (Figure 5.10). This confirmed findings by Hausdorff et al., 
(1989) that a similar construct also internalised in CHW cells. However, the 
internalisation profile of BARK“-p2-AR-GFP (ti/2 = 10 minutes) was faster than that 
of WT-p2“AR-GFP (ti/2 = 25 minutes) as assessed in pH] CGP12177 intact cell 
binding studies (Figure 5.1 la  and Table 4.4). A distinct punctate pattern of B A R K - 
P2-AR-GFP receptor internalisation was detected at 5 minutes whereas internalised 
WT-P2-AR-GFP was only detectable at 10 minutes in the confocal microscope 
(Figure 5 .10b and 4.6b respectively). A factor to consider here is that the BARK"-p2- 
AR-GFP construct may not be able to recycle as efficiently as the WT construct. 
Inhibitors of the recycling machinery were not used in the internalisation studies above
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and therefore, a faster rate of internalisation detected for the BARK"-P2~AR-GFP
construct could be an effect of inefficient recycling of this construct. It appears, 
however, that BARK -Pz-AR-GFP also internalises by a clathiin-dependent 
mechanism since 0.4 M sucrose inhibited agonist-stimulated internalisation of this 
construct (Figure 5.12).
As the BARK"-P2"AR-GFP construct still internalised in response to isoprenaline 
stimulation a potential role for PKA was investigated. The importance of PKA in the 
process of p2 -AR desensitisation and internalisation has been hotly debated, some 
groups agreeing with its role in receptor desensitisation (Post et al., 1996; Lohse et 
al., 1990; Benovic et al., 1985; Hausdorff et al., 1989; Moffet et al., 1996) and others 
finding little effect of PKA phosphorylation on P2 -AR desensitisation and 
internalisation (Seibold et al., 1998; Green et a l, 1981). The use of the direct PKA 
activators, dibutyryl cAMP and 8-bromo cAMP, to attempt to induce internalisation of 
WT-p2 -AR, WT-P2 -AR-GFP or BARK"-P2 “AR-GFP in the absence of agonist 
demonstrated that either PKA phosphorylation of the receptor had no effect on 
receptor internalisation, or that only PKA activated through agonist bound receptor 
may be able to internalise receptors (Figure 5.14).
When the previously described PKA inhibitor H89 was used to treat BARIC-P2 -AR- 
GFP-expressing cells internalisation of the construct in response to agonist 
isoprenaline was inhibited by approximately 40% (Figure 5.15). However, this was 
found not to be due to inhibition of PKA, but by the antagonistic properties of H89 at 
the P2-AR (Penn et al., 1999). H89 has a measured Ki ~ 350 nM for the P2 -AR 
stably expressed in BEAS-2B cells. This is comparable to the binding affinities of 
betaxolol and isoprenaline at the WT-P2 -AR (Table 5.2). As BARK"-p2 "AR-GFP- 
expressing cells were pre-incubated with H89 at a concentration 100 times greater than 
its Ki, it is not surprising that it was able to compete for binding of isoprenaline and 
thus impede agonist-induced receptor internalisation. H89 was demonstrated directly 
to be a ligand at the WT-P2 -AR construct when included in a pH] DHA binding
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study. 10'^ and 3 x 10'^ M H89 reduced binding of pH] DHA at the WT-P2 -AR by 
80 and 90% respectively and at the BARK“-P2 -AR-GFP by 70 and 90% respectively 
(Figure 5.17). Moreover H89, unlike Rp cAMP, induced up-regulation of CAM-p2- 
AR-GFP following a 24 h treatment, an effect anticipated for p-blockers from the data 
of Chapter 3.
A second inhibitor, Rp cAMP, had no effect on agonist-induced receptor 
internalisation of the P2 -AR (Figure 5.16a) which could indicate that PKA has no role 
in internalisation of the P2 -AR or that this inhibitor is cell specific and does not 
function in HEK293 cells. Hausdorff et al., (1989) found that mutating the two PKA 
consensus sites in the P2 -AR to glycine residues produced a receptor which still 
underwent agonist-promoted internalisation, but exhibited decreased phosphorylation 
at low concentrations of isoprenaline (10 nM) and reduced desensitisation at low and 
high (2 pM) concentrations of isoprenaline. This would indicate that internalisation 
of GPCRs can still occur when phosphorylation and desensitisation of the receptor are 
impeded. The data presented in this study using Rp cAMP as an inhibitor of PKA 
would indicate this to be the case as receptor internalisation still occured in the 
presence of this inhibitor, even at low concentrations of isoprenaline (Figure 5.16 a 
and b). Seibold et al., (1998) also measured agonist-induced internalisation by
adrenaline of a PKA" mutant of the P2 -AR, however no effect on desensitisation of 
the receptor was measured. Rapid phosphorylation of this construct was also detected 
after 1 minute of adrenaline treatment, however GRKs could have phosphorylated the 
receptor since a high concentration of agonist was used. Interestingly, a P2 -AR 
mutant lacking the in vitro phosphoiylation sites (Fredericks et al., 1996) and both 
PKA consensus sites was still phosphorylated upon agonist stimulation. This would 
indicate new sites of in vivo phosphorylation present at other regions of the P2-AR. 
In fact, additional sites of phosphorylation in intracellular loop 2 of the P2 -AR have 
been postulated from a study by Jockers et al., (1996). This study investigated the 
differences between the desensitisation and sequestration patterns of the p2 "AR
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compared to the pg-AR. The P3-AR undergoes very little desensitisation and 
sequestration in response to agonist stimulation whereas the P2-AR is well known to 
undergo rapid desensitisation and internalisation. This group wanted to find the 
components of the P2-AR responsible for these processes. They constructed a series 
of 15 P3/P2-AR chimeras to identify which regions of the P2-AR are important for 
uncoupling and sequestration. It was revealed that the C-terminal tail, intracellular 
loop 3 and intracellular loop 2 of the P2-AR added individually into the P3-AR all 
partially restored the uncoupling phenotype and that their effects were additive to 
produce a desensitisation profile similar to that of the P2-AR. The C-terminal tail, 
intracellular loop 2  and intracellular loop 1 all played additive roles in receptor 
sequestration, but did not restore it eompletely, whereas, intracellular loop 3 had a 
dominant negative effect. They identified two potential sites of phosphorylation at 
serines 137 and 143 in intracellular loop 2 of the P2-AR. Serine 137 is contained in 
the potential phosphorylation consensus site S/TPKK/R, which has been shown to be 
the preferred site for cdc2 kinase. It may be interesting to investigate mutation of 
these two sites to glycine or alanine within the BARK“-p2-AR-GFP construct to find 
if this abolishes agonist-induced desensitisation and sequestration.
As the BARK““P2-AR-GFP construct underwent agonist-stimulated internalisation, 
experiments were performed to detennine if the construct could generate a second 
messenger output. cAMP was generated in a concentration-dependent manner upon 
addition of isoprenaline (Figure 5.20). The EC50 was 10 times higher than at the WT- 
P2-AR-GFP construct indicating that isoprenaline has a lower potency at the B A R K - 
p2"AR-GFP construct. This result was rather surprising as previous experiments in 
this study indicated no role for PKA in receptor internalisation of the P2-AR. A 
possible explanation for this is that Rp cAMP does not function in these cells, a factor 
which was not determined from the phospho-CREB experiments performed (Figure 
5.19). Conversely, PKA phosphorylation may not be a functional aspect of P2 AR 
internalisation and may only be involved in the uncoupling and desensitisaiton of the
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receptor since mutation of PKA consensus sites within the P2 -AR has produced a 
receptor construct that still internalises but exhibits reduced desensitisation (Hausdorff 
et ah, 1989). However this was not found by Seibold et al., (1998). When down- 
regulation of the BARK“-p2 -AR-GFP construct was analysed, a 24 h treatment with 
isoprenaline (10"  ^ M) appeared to cause a slight decrease in total receptor levels 
compared to WT-p2 -AR-GFP (Figure 5.21).
Despite the reported role of ERK regulation of j3-arrestin 1 through MEKl (Lin et ah, 
1999), and feedback inhibition of GRK2 activity by ERKs (Pitcher et ak, 1999) an 
inhibitor of MEKl (PD98059), had no effect on agonist-induced internalisation of 
WT-p2 “AR-GFP (Figure 5.13). The inhibitor was expected to promote further 
internalisation of the P2 -AR. This result therefore, is not consistent with the reported 
findings.
It is apparent from this chapter of work that there is still controversy surrounding (32- 
AR phosphorylation mechanisms which induce receptor uncoupling, desensitisation 
and sequestration in response to agonist stimulation. The results herein have not 
reached definite conclusions about these processes but they have presented suggested 
avenues for further investigation. As the BARIC"-P2 -AR-GFP construct was shown 
to internalise through the clathrin-mediated pathway (Figure 5.14) it should be further 
investigated if p-arrestins can colocalise with this receptor using confocal microscopy 
(Groarke et al., 1999; Vrecl et al., 1998; Zhang et al., 1999; Milligan, 1999). The 
sites of phosphorylation on the p2 "AR need to be investigated further to fully 
determine which residues and which protein kinases are regulating desensitisation and 
sequestration. There may be distinct residues for distinct processes since mutation of 
certain residues in the C terminus of the P2 -AR has appeared to have an effect on 
phosphorylation and desensitisation of the receptor but no effect on sequestration. 
The potential role of serines 137 and 143 in intracellular loop 2 of the P2 -AR could
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hint at new mechanisms of regulation of this receptor and should be further 
investigated.
215
Chapter 6
Final Discussion
216
Over the past few decades an understanding of cellular signalling processes has been 
formulated but attempts are still being made to characterise these events more fully. A 
variety of stimuli including hormones, neurotransmitters, ions, odourants and photons 
of light are able to activate receptors expressed on the surface of a cell. Detection of 
these signals by cell surface receptors initiates a series of events within the cell to 
produce ultimate effects on cell growth, differentiation and division.
One of the largest families of cell surface expressed receptors are the GPCRs. Over 
two hundred of these receptors have been identified and all have the same basic 
hydrophobicity profile of 7 a  helices to form 7 transmembrane spanning regions 
linked by 3 extracellular and 3 intracellular loops. The extracellular N terminus 
contains sites for glycosylation. The 7 transmembrane regions are important for 
recognition and binding of ligands. Coupling to intracellular signalling processes is in 
part achieved by the intracellular loops, mainly intracellular loop 3, and also by the C- 
terminal tail.
In order to produce effector activation ligand bound receptor requires a G protein 
which is a heterotrimer of a , p and y subunits. In the resting state receptor is coupled 
to GDP-bound G protein and agonist binding and activation induces a conformational 
change in the G protein to exchange GDP for GTP and promote dissociation of the py 
dimer from the active GTP-bound a  subunit/receptor complex. Once the a  subunit 
interacts and activates effector, GTP is hydrolysed to GDP promoting reformation of 
the heterotrimeric G protein complex (Gilman, 1984; Gilman, 1987). Several a , p 
and y variants have been identified conferring different functional roles of G proteins. 
Both the GTP-bound a  subunit and the Py complex can influence the activity of 
cellular effector systems including adenylyl cyclase, phospholipase isoforms, various 
ion channels and MAP kinase activity, differentially or in combination.
This study has concentrated on two sub-types of the p-AR sub-family of GPCRs, 
these being the pi- and p%- ARs which couple through the stimulatory G protein G^a
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to activate adenylyl cyclase and formation of the second messenger cAMP. Some 
receptors display the ability to activate effector independent of agonist stimulation. 
These are termed constitutively active receptors and can frequently be produced from 
mutations in their amino acid sequence. A selection of these receptors include a CAM 
form of the p2 ~AR (Samama et al., 1993, 1994), the ajp-AR (Cotecchia et al., 1990; 
Kjelsberg et al., 1992), the thyrotropin receptor (Parma et al, 1993), the leuteinizing 
hormone receptor (Shenker et al., 1993), the dopamine Di and D5  receptors (Tiberi 
and Caron, 1994) and 5HTiDa, 5 H T a n d  5HT2C receptors (Barker et al., 1994; 
Thomas et al., 1994).
In Chapter 3 a CAM form of the P2 -AR (CAM~p2 "AR) was examined in a HEK293 
cell system to investigate its potential use for drug screening. MacEwan and Milligan 
(1996a,b) had previously demonstrated that this CAM-p2 -AR expressed stably in 
NG108-15 cells became up-regulated when exposed to saturating doses of the P2 -AR 
inverse agonists sotalol and betaxolol for 24 h. This characteristic was not exhibited 
by agonist or antagonist treatment and this was therefore, proposed as a potential drug 
screen for inverse agonists at this receptor. However, other studies have indicated 
that any p-ligand whether agonist, antagonist or inverse agonist can stabilise the 
CAM-P2 -AR and thus up-regulate it (Gether et al., 1997a,b). It was the aim of this 
study to develop the basis of a rapid drug screening assay with some degree of 
accuracy and efficiency. As it is now possible and extremely popular to tag GPCRs 
with GFP this approach was implemented in the study and proved advantageous for a 
drug screen over other methods. Stable expression of a CAM-p2 -AR-GFP construct 
in HEK293 cells and overnight treatment with several p-blockers indicated that not 
only inverse agonists but antagonists also induced up-regulation of the receptor. The 
different ratios of internal to plasma membrane up-regulated receptor demonstrated the 
differential regulation by these selected p-blockers. These patterns of up-regulation 
appeared to correlate with the ability of the drug to stimulate adenylyl cyclase activity 
through the receptor. Inverse agonists such as betaxolol and ICI 118551, which did
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not stimulate adenylyl cyclase, resulted in an increase in homogenous plasma 
membrane-delineated fluorescence with diffuse, intracellular staining as in untreated 
CAM-P2 "AR-GFP~expressing cells. In contrast, although labetolol produced a 
substantial increase in plasma membrane CAM-p2 -AR-GFP there was also an increase 
in intracellular signal with a marked punctate pattern, similar to the pattern produced in 
WT-p2 -AR-GFP-expressing cells exposed to agonist isoprenaline for a short period 
of time. Labetolol was able to elevate cAMP levels to the same extent as isoprenaline. 
However, isoprenaline did not up-regulate the CAM-P2 -AR-GFP construct.
In contrast to MacEwan and Milligan (1996a,b), alprenolol caused up-regulation of 
CAM-p2"AR-GFP. Inefficient washing away of this high affinity ligand meant that 
residual alprenolol was able to compete for radioligand binding to the receptor, 
reducing the level of detectable receptor in MacEwan and Milligan's study. 
Monitoring fluorescence of a GFP-tagged GPCR is one way of overcoming the 
problem of using high concentrations of ligands. Therefore, effects of ligands can be 
directly screened without such complications. It may be argued that western blotting 
of the protein is just as an efficient way to look at ligand regulation. However, this 
method gives no indication of the cellular location of the protein. Cell fractions need 
to be ran on sucrose density gradients and then probed with antibody to determine 
protein location within the cell. This method is extremely time consuming so the 
prospect of being able to rapidly and directly visualise the level and location of 
receptor within the cell is understandably advantageous.
As initial fluorescence studies on the confocal microscope were not quantitative this 
prompted development of an assay to measure the extent of up-regulation using a 
spectrofluorimeter in 96 well format, which would produce numerical data for 
analysis of levels of up-regulation. From preliminary data, the EC5 0  for up-regulation 
of the CAM-P2 -AR-GFP construct by betaxolol was calculated to be in close 
agreement with the Ki of this drug at this receptor. However, the output of
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fluorescence in this assay is quite limited and now constructs of the CAM-j3 2 -AR have 
been made with more suitable tags such as Renilla and Photinus luciferase to produce 
a better signal output (Ramsay and Milligan, unpublished results).
GFP tagging also proved useful in Chapter 4 when assessing the effect of short-term 
agonist stimulation at both the j3i- and p2 - ARs. Successful GFP-tagging has been 
exhibited for a number of receptors; eg, the p2 "AR (Barak et al., 1997; Kallal et al., 
1998; McLean and Milligan, 1999) and a CAM-p2~AR (McLean et al, 1999), the 
cholecystokinin type A receptor (Tarasova et al., 1997), the thyrotropin releasing 
hormone receptor (TRHR-1) (Milligan, 1998; Drmota et al., 1998, 1999), the « ia -  
AR (Hirasawa et al., 1997), the ajp-AR (Hirisawaet al., 1997; Awaji et al., 1998), 
the vasopressin V2 receptor (Schulein et al., 1998), the parathyroid hormone receptor 
(Conway et al., 1999), the CXCR-1 chemokine receptor (Barlic et al., 1999) and the 
Ca^+-sensing receptor (Gama and Breitwieser, 1998).
Optical time imaging of agonist-stimulated receptor internalisation was achieved 
directly on the confocal microscope for the pi- and P2 - ARs, however, limitations to 
the method were apparent. A quantitative measurement of receptor internalisation was 
achieved by pH] ligand binding studies. By using the hydrophillic ligand pH] 
CGP12177 a loss of cell surface receptor following agonist stimulation was 
measured. On comparing time-courses of internalisation between the GFP and non- 
GFP-tagged constructs for both pi- and p2 - AR constructs, GFP substantially 
impeded the ability of the receptor to internalise. Overall the GFP-tagged receptors 
exhibited a similar pharmacological profile to their non-tagged versions and WT-pi- 
AR-GFP like WT-pi-AR internalised to a lesser extent than WT-p2 -AR-GFP and 
WT-P2 -AR respectively. The differences of Pi- versus p2 - AR internalisation may be 
attributed to a different process of internalisation (Tang et al., 1999). However, the 
kinetic properties of this internalisation process was the feature altered by GFP a 
finding not previously reported from studies using GFP-tagged receptors. Secondly,
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down-regulation of the p2 -AR in response to a 24 h treatment with agonist 
isoprenaline was impared by the presence of GFP at the C terminus of the construct. 
This chapter of work, therefore pointed out the limitations of using GFP as a tool 
when analysing functional and kinetic parameters of GPCRs, in this case the Pi- and 
p2 - ARs.
In my final chapter the issue of p2 -AR sequestration in response to agonist stimulation 
was addressed. As yet the exact events of the desensitisation and sequestration of the 
p2 -AR following agonist stimulation are still to be resolved. Debate centres around 
several issues. What residues of the receptor are responsible for desensitisation and 
sequestration, and are the same or unique residues involved in each of these 
processes? Jockers et al., (1996) demonstrated that intracellular loop 3 of the P2 -AR 
is partly responsible for desensitisation of the receptor but has a dominant negative 
effect on sequestration and therefore, the 2  events are not related. This would indicate 
that one particular region of the P2-AR may not be involved in both processes of 
desensitisation and sequestration. A GFP-tagged form of the P2 -AR with all the 11 
potential GRK phosphorylation sites mutated from ser/thr to gly/ala underwent a 
marked time-dependent internalisation in response to isoprenaline stimulation. The 
rate of internalisation was faster for the BARK“-P2 -AR-GFP construct than for the 
unmodified form of the receptor. If phosphorylation is critical for receptor 
internalisation in this case then either PKA is responsible or the receptor contains 
unidentified phosphorylation sites. The PKA inhibitor Rp cAMP had no effect on 
isoprenaline-induced BARK"-P2“AR-GFP internalisation, which may indicate, that 
other sites of phosphorylation are present in the receptor construct. Jockers et al.,
(1996) identified two potential phosphorylation sites at ser 137 and 143 in intracellular 
loop 2 of the P2 -AR. The role of PKA in P2 -AR desensitisation and sequestration has 
also been hotly debated. Seibold et al., (1998) have found no role of this kinase in 
desensitisation or sequestration which is contradictory to Hausdorff et al., (1989) who 
demonstrated that a P2 -AR lacking a PKA consensus site exhibited reduced
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desensitisation but still internalised in response to agonist stimulation. Other groups 
(Post et al., 1996; Lohse et al., 1990; Benovic et al., 1995; Moffet et al., 1996) also 
agree with Hausdorff. Although the BARK“-P2 -AR-GFP construct does indeed 
internalise, the rapidity of internalisation may bean indication of impeded recycling of 
the receptor. If this receptor construct cannot recycle efficiently, internalised receptor 
may aggregate in intracellular membrane compartments and, therefore, it may look as 
if more of the BARK“-p2 -AR-GFP construct has internalised at earlier time points 
compared to the WT~j3 2 “AR-GFP construct which can efficiently recycle. As 
recycling of BARIC"-p2 -AR~GFP was not investigated by removal of agonist or 
addition of antagonist in this study, the recycling capacity of this mutant receptor in 
contrast to the WT construct should be investigated. Secondly, the sites of in vivo 
phosphorylation need to be further assessed and related to their role in desensitisation 
and sequestration. Another issue to consider is whether this construct still internalises 
through the clathrin/dynamin-mediated pathway. However, experiments with sucrose 
did indicate that this construct internalised through a clathrin-mediated pathway in 
response to agonist stimulation.
This study has highlighted the advantages of using GFP-tagging but like any method 
it should not be used in isolation. It is clearly apparent that GFP can affect the 
functioning of the receptor and in this study has provided no direct answers to the 
questions surrounding p2 ~ versus pi- AR sequestration processes. However, in the 
area of drug screening, GFP, its variants and other fluorescent tags (luciferases) look 
to be a new and efficient way of analysing drug effects at different GPCRs. To 
conclude, GFP is not a be all and end all but is a helpful tool for investigating protein 
mobilisation and signalling.
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